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Cancer is the leading cause of the burden of disease and injury in Australia, accounting for 
approximately 19 percent of the total disease burden. In 2010, the risk of developing cancer 
before the age of 85 years was 1 in 2 in men and 1 in 3 in women and as such, its burden on 
society as a whole is immense. In recent years, considerable advances have been made in 
developing new therapeutics for cancer, particularly therapies targeted to specific molecular 
subtypes, which have resulted in significantly improved patient survival. However, for some 
types of solid cancers there have been no significant recent improvements in patient survival or 
development of targeted therapies. Examples are the triple negative (estrogen and 
progesterone receptor, and human epidermal growth factor receptor 2 negative) subgroup of 
breast carcinomas and Ewing sarcomas. Herein, we explore two biological pathways that are 
frequently dysregulated in these cancers and thus provide opportunity for therapeutic 
intervention.  
 
Section I of this thesis explores the proteasome as a therapeutic target and the potential use of 
proteasome inhibitors in the treatment of solid cancers and in particular triple negative breast 
cancers. In general, cancer is associated with increased proteasome activity, and is therefore an 
attractive target for therapy. Bortezomib, carfilzomib and ixazomib are proteasome inhibitors 
with FDA approval, but their current use is limited to multiple myeloma and mantle cell 
lymphoma. Chapter 1 summarizes our current understanding of the structure and function of 
proteasome variants, their dysregulation in solid cancers, as well as the rationale for 
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proteasome inhibitor based therapy. Chapter 2 assesses the potential for the use of 
proteasome inhibitors for the treatment of breast cancers. Initially, the proteasome of breast 
cancer subgroups was characterized in detail by analysis of the The Cancer Genome Atlas breast 
cancer RNA-sequencing database. Analysis of these data revealed biologically meaningful 
insights which were subsequently confirmed by experiments in breast cancer cell lines. These 
results revealed that patients with basal-like and HER2+ breast cancer subgroups express 
significantly higher levels of the immuno-proteasome variant compared to luminal subgroups. 
Based on the presented data, it was concluded that this subgroup of breast cancers are likely to 
respond to proteasome inhibitor based therapy.  
 
Proteasome inhibitors in clinical use have several shortcomings including side-effects and lack 
of efficacy for treatment of solid cancers. In chapter 3, 4 and 5, by exploiting a cross-disciplinary 
collaboration with Chemistry, we explore the efficacy of new synthesized compounds which can 
inhibit the proteasome and novel strategies to improve efficacy and/or decrease side effects 
associated with the current clinical used FDA approved proteasome inhibitors.  
 
Section II of this thesis explores the potential of new therapeutic approaches for the treatment 
of Ewing sarcoma. Chapter 6 evaluates the potential of exploiting the p53 pathway as a 
targeted therapy for Ewing sarcoma. p53 is a critical tumour suppressor that is involved in a 
multitude of cellular processes including cell cycle regulation and apoptosis. It is frequently 
deactivated in the majority of cancers by either direct mutation or by up-regulation of its 
negative regulators MDM2 and MDM4. Ewing sarcoma is atypical among cancer types as the 
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more than 90% of cases retain a wild-type p53 with functionally intact downstream pathways. 
Chapter 7 and 8 assess two drugs that engage p53 signaling to elicit their anti-tumourigenic 
effects. Chapter 7 explores whether the RNA polymerase I inhibitor, CX-5461, has potential for 
treatment of Ewing sarcoma. RNA Polymerase I is a cellular enzyme that regulates ribosomal 
synthesis and thus controls the rate of cellular growth and proliferation. To attain accelerated 
growth, cancer cells up-regulate RNA Polymerase I activity and therefore it is an attractive 
therapeutic target. It has previously been shown that inhibition of RNA Polymerase I by CX-
5461 causes cell death or cell cycle arrest in a variety of cancers both in vitro and in vivo in a 
p53-dependent manner. Our results reveal that Ewing sarcoma cell lines are acutely sensitive 
to RNA Polymerase I inhibition by CX-5461, with cell lines with wild-type p53 exhibiting 
cytotoxic LD50 values in low nanomolar figures (<3nM). This study provides encouraging pre-
clinical results for the application of CX-5461 for Ewing sarcoma treatment and warrants 
further in vivo evaluation. Chapter 8 assesses the potential of XI-006, a pharmacological 
inhibitor of MDM2, a p53 antagonist, for the treatment of Ewing sarcoma. While results were 
not consistent with targeting the activity of p53, XI-006 was found to be a potent inducer of 





















This chapter discusses the diverse functions of the proteasome that have been characterized 





Protein degradation by the ubiquitin-proteasome system is a highly selective and efficient 
process. For a protein to be recognized by the proteasome, a small peptide (ubiquitin) must 
first be attached to the target protein. This process is controlled by a group of enzymes (E1, E2 
and E3) collectively referred to as ubiquitin ligases. E1 activates ubiquitin and transfers it to the 
carrier protein E2. E2 presents ubiquitin to E3. E3 recognizes and binds the target protein and 
interacts with E2 to covalently attach ubiquitin to the target protein (Figure 1). This process is 
reiterated a number of times to create a polyubiquitin chain that can be subsequently 
recognized by the proteasome. To date, there is only one known E1, 50 E2 and over 500 E3 
ubiquitin ligases (reviewed in [1, 2] ) providing a highly protein specific and controlled process 




Figure 1. The Ubiquitin-Proteasome System. In step 1, ubiquitin is activated by an ubiquitin 
activating enzyme, E1. In step 2, activated ubiquitin is transferred to an ubiquitin conjugating 
enzyme, E2. In step 3, ubiquitin is subsequently conjugated to target proteins in a process 
mediated by an E3 ubiquitin ligase. In step 4, the polyubiquitinated substrate protein is 
degraded by the 26S proteasome.  
 
26S Proteasome Structure 
 
 
The constitutive proteasome (c-proteasome), generally referred to as 26S, is composed of a 20S 
catalytic core (~700kDa) capped with 19S regulatory structures at one or both ends (Figure 2). 
The 20S core is made up of four stacked rings, creating a central chamber where proteolysis 
occurs. The outer two rings, which are predominantly structural, each contain seven α subunits. 
Two inner rings each consist of seven β subunits. The proteolytic sites of the proteasome are 
located on three of the β-subunits on each of the two of inner rings, in the central cavity, 
resulting in a total of six proteolytic sites (reviewed in [3]). Catalytic activities of the proteasome 
are based upon preference to cleave a peptide bond after a particular amino acid residue. 
These activities are referred to as chymotrypsin-like (CT-L) activity, that cleaves after 
hydrophobic residues; trypsin-like (T-L) activity, that cleaves after basic residues; and caspase-
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like (C-L) activity, that cleaves after acidic residues [4, 5]. The CT-L, T-L and C-L activities are 
associated with the β5, β2 and β1 subunits respectively [6]. 
 
Entry into the proteolytic chamber is controlled by binding to the 19S ATP-dependent 
regulatory particle. Polyubiquitin-tagged proteins are recognized by the 19S particle, the 
ubiquitin molecules are cleaved, the target protein is unfolded, and then can enter the 20S 
central catalytic chamber to be cleaved into short polypeptide fragments [5].  
 
Figure 2.The Structure of the 26S Proteasome. The proteasome is a 26S enzyme complex that 
is comprised of a core 20S catalytic complex and a 19S regulatory complex. The 20S proteasome 
core has chymotrypsin-like, trypsin-like, and caspase-like activities that are associated with 
three distinct units: β5, β2, β1, respectively. Chymotrypsin-like activity at proteasome β5 
subunit is associated with the rate-limiting step of proteolysis. 
 
There are two other known variants of the 20S in eukaryotes. In cells of the immune system, 
the β1i, β2i and β5i subunits replace the corresponding constitutive subunits β1, β2 and β5 to 
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form an alternative 20Si core [7, 8]. The resulting proteasome is referred to as the immuno-
proteasome (i-proteasome). Upon exposure to inflammatory cytokines (e.g. interferon-γ), many 
solid tissues and cancers are also capable of expressing the i-proteasome variant. In the context 
of catalytic activities, β5i has CT-L activity, equivalent to β5, and β2i has T-L activity, equivalent 
to β2. However, β1i displays CT-L activity rather than the β1-associated C-L activity (Figure 3). 
The i-proteasome variant also contains a different regulatory subunit PA28 (also known as 11S 
cap). 
 
There is a third proteasome variant expressed by the cortical thymic epithelium in which the 
β5t replaces β5i in i-proteasomes to form the thymo-proteasome [7]. In addition to the variants 
described above, cells are also capable of expressing mixed proteasomes that contain varying 
combinations of thymo-, immuno- and constitutive- subunits [9]. Theoretically, combination of 
these different catalytic subunits can generate up to 36 different 20S core complexes that differ 
in their proteolytic specificity, although only a small subset have been demonstrated in vivo. 
The complexity of proteasome subtypes is further enhanced by association with different 
regulatory caps that can associate with 20S cores on one or both ends to form PA700 or PA28 







The nomenclature of the various proteasome subunits used in this thesis is quite confusing due 
in part to the multitude of subunits, often with multiple symbols for the same subunit and 
proteasome variants. In addition, the same gene is referred to by different symbols in humans 
and mice. For ease of reading, Table 1 provides a list of names for the different catalytic 
subunits in humans and mice. The remainder of this chapter focuses on the critical differences 
between the functions of the c- and i-proteasome with emphasis on the roles of i-proteasome. 
 
 
Figure 3. Subunit composition of the active sites of the constitutive, immuno- and thymo- 
proteasomes. The proteolytic subunits of the 20S constitutive, immuno- and thymo- 
proteasomes. Compared with the c-proteasome, the i-proteasome has a strongly decreased 
caspase-like activity and an increased chymotrypsin-like activity, whereas the 






Table 1. Nomenclature of proteasomes. 
Protein subunit Homo sapiens gene symbol Mus musculus gene symbol 
β1 PSMB6 - 
β2 PSMB7 - 
β5 PSMB5 - 
β1i PSMB9 Lmp2 
β2i PSMB10 Mecl1 




Immuno-proteasome in antigen presentation 
 
The majority of proteasome generated peptide fragments from intracellular proteins are 
further degraded into shorter amino acid sequences and recycled for the synthesis of new 
proteins. However, a very small fraction of the cleaved peptides are delivered by the 
Transporter associated with antigen processing proteins (TAPs) to the endoplasmic reticulum, 
where these peptides act as ligands to nascent MHC class I molecules [10]. These MHC I bound 
peptides egress to the surface of the cell and can be recognized by naive CD8 T cells for routine 
immune surveillance. In addition, proteasomes also generate peptides for MHC I presentation 
from exogenous proteins that are internalised by endocytosis and or phagocytosis, a 




As mentioned previously, c-proteasome and i-proteasome possess different catalytic subunits. 
Compared to the c-proteasomes, i-proteasomes cleave more rapidly after hydrophobic and 
basic amino acid residues and less rapidly after acidic ones. As substrates with hydrophobic and 
basic C-termini are favored for uptake by TAP transporters [12] and are essential for tight 
binding to MHC class I molecules [13], it has long been suggested that i-proteasomes have a 
specialized role in creating peptides that are antigenic. Initial in vivo studies used single gene 
knockouts of the immuno-subunits to analyse phenotypic and CD8 T cell cytotoxic responses. 
Mecl-1-deficient mice infected with lymphocytic chromiomeningitis virus (LCMV) had a slightly 
reduced number of CD8 T cells, and a decreased response to LCMV GP276 and NP205, but 
normal responses to NP396, GP33 and several other LCMV epitopes [14]. Mice lacking the Lmp2 
subunit of the i-proteasome generate normal cytotoxic responses to Sendai virus and LCMV but 
show reduced capacity to generate CD8 T cells against the nucleoprotein epitope of influenza A 
[15]. Knockdown of Mecl1 or Lmp2 does not alter the cell surface expression of the class MHC I 
molecules in the above singly-deficient mice. In contrast, Fehling et al. observed that 
splenocytes from mice lacking Lmp7 subunit (β5i) had a modest (~50%) reduction in MHC class I 
cell surface expression as well as decreased number of CD8 T cells specific to the male minor 
antigen HY [16]. Contrary to this study, Basler et al. did not observe any difference in the 
clearance of LCMV virus epitopes in Lmp7 deficient and wild-type mice. Overall, these studies 
suggest that mice lacking one i-proteasome subunit can substantially alter the production of 
some epitopes. However, these studies have only examined the presentation of a selective 




To rule out the possibility that functional overlap in peptide generation by the three i-
proteasome subunits could compensate for the loss of one subunit, Kinciad et al. generated 
triple knockout-mice that were deficient in all three i-proteasome subunits [17]. Kinciad et al. 
showed that class I MHC antigenic presentation in these triple deficient mice was both 
qualitatively and quantitatively different from that of single knockout mice. In their analysis of 
11 MHC class I antigens expressed on dendritic cells, expression of 8 antigens was significantly 
reduced. For Smyc antigen, compared to single-deficient mice that expressed this antigen 
without any defects, expression was substantially reduced in triple-deficient dendritic cells. 
Similarly, there were substantial defects in the expression of LCMV antigens GP33 and GP118, 
influenza antigen NP366-374 and antigen OVA257–264 presentation not seen in single-deficient 
mice in previous studies. This study substantiates that the i-proteasome is a major contributor 
to the MHC class I antigen presentation.  
 
However, it should be noted that that while many antigens are efficiently produced by the i-
proteasome, some are preferentially generated by the c-proteasome and their generation by 
the i-proteasome is highly inefficient. For example, the HLA-A2-binding antigenic peptide [18] 
ITDQVPFSV (gp100 209-217) derived from melanocytic protein gp100PMEL17, and the peptide 
YMDGTMSQV from melanocytic protein tyrosinase, are produced by the c-proteasome, but not 
by the i-proteasome. As a consequence, cells exclusively expressing c-proteasomes can 
efficiently stimulate gp100-specific and tyrosinase-specific cytotoxic T lymphocytes 
respectively. Overall, the changed subunit composition of i-proteasomes, relative to c- 
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proteasomes, contributes to altered protease activities that results in the generation of 
different antigenic peptides by these two types of proteasomes. 
 
The diversity of antigenic peptides may be further increased by the expression of intermediate 
proteasomes that contain combinations of c- and i-proteasome subunits and therefore 
differentprotease activities. The presence of proteasome complexes with different types and 
Figure 4. The role of the i-proteasome in antigen presentation. Poly-ubiquitinated 
cytoplasmic proteins are recognized and degraded by either c- or i-proteasome. 
The peptides are transported into the endoplasmic reticulum by a complex called 
TAP and attached to MHC class I molecules. Peptide-MHC complexes then egress--- 
to the cell surface where specific CD8+ T cells may recognize one of the presented 
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contributions of activating caps has the potential to further modify and alter the peptidome. 
This can influence CD8+ T cell responses by increasing the diversity of antigenic peptides 
presented on MHC class I molecules [19].  
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The role of the Immuno-proteasome in protein homeostasis 
 
 
In addition to being involved in antigen presentation, the i-proteasome has been shown to have 
roles in the cellular response to stress and injury. This idea was initially based on the 
observation that following stress, i-proteasome expression was substantially up-regulated in 
cells that do not typically present antigens [20]. For example, i-proteasome is significantly up-
regulated in immune-privileged sites like retina [21-26] and brain [21, 27] in response to acute 
injury. It is also up-regulated in cultured cells exposed to cytokines like IFNɣ and TNFα [22, 25, 
26]. Since mice deficient in subunit Lmp2 of the i-proteasome express increased levels of 
oxidized proteins [21, 28] and those double deficient in Lmp7 and Mecl1 show greater 
sensitivity to oxidative challenge [22], this suggests that the i-proteasome may provide a 
protective role against oxidative stress. 
 
Seifert et al. suggest that the primary role of the i-proteasome is to limit inflammatory damage, 
potentially by eliminating from the cell proteins damaged from inflammatory responses [29]. 
Data from Seifert and colleagues suggest that the i-proteasome is more efficient at degrading 
the “defective ribosomal products” (DRiPs), which are misfolded and /or oxidized proteins 
produced during protein synthesis. They observed that cytokine-induced oxidative stress in 
murine fibroblasts and human HeLa cells results in an initial increase in the levels of 
poly-ubiquitylated peptides, but was then followed by a decline after 24 hours, and a return to 
normal levels. The decrease observed after 24 hours coincided with induction of i-proteasomes 
and increase in proteasome CT-L activity, suggesting that i-proteasomes can function in the 
removal of poly-ubiquitinated peptides. In i-proteasome deficient cells, challenges with either 
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lipopolysaccharide or IFNɣ induced aggresome and increased levels of oxidized and 
ubiquitylated proteins by 2-fold compared to control cells. In vivo experiments supported these 
observations, with Lmp7 knockout mice exhibiting a more severe clinical score and higher levels 
of oxidized proteins and protein aggregates in the inflamed liver and brain compared to mice 
with wild-type Lmp7. Another study by Opitz et al. in a murine model of acute enterovirus 
myocarditis, showed that mice deficient in Lmp7 i-proteasome subunit exhibit severe 
myocardial destruction and large inflammatory foci in cardiac cells. These Lmp7 deficient 
cardiomyocytes also had substantially more oxidized and poly-ubiquitinylated protein 
accumulation compared to wild-type cells following exposure to IFNɣ. The authors hypothesize 
that cytokine (e.g. IFNɣ) induced inflammation significantly up-regulates protein synthesis, and 
therefore production of DRiPs leading to toxic protein aggregates, and as a consequence, the i-
proteasome is up-regulated to protect cellular homeostasis. The significance of i-proteasomes 
in protein homeostasis upon stress induction has also been observed by various other studies 
[30]. 
 
Contrary to these studies, Nathan et al. did not observe either up-regulation of poly-
ubiquitylated peptide or formation of toxic aggregates in mouse embryonic fibroblasts and B8 
fibroblasts treated with 200 U/ml of IFNɣ [31]. They also did not observe any difference in 
processing of the substrate ubiquitinated dihydrofolate reductase (Ub5DHFR) between two 
proteasome variants. Based on these results, the authors concluded that i-proteasomes are not 
more important in protein homeostasis than c-proteasomes. Discrepancies between both 
reports, however, might be explained by distinct experimental procedures [32]. 
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Proteasomes and Cancer 
 
The role of the proteasome in cancer was first considered when a number of oncogene and 
tumour suppressor gene products were found to be targets of ubiquitin and proteasome 
mediated degradation. Subsequent studies revealed that proteasome inhibitors induced 
apoptosis in leukemic cell lines and were also active in an in vivo model of Burkitt’s lymphoma 
[21, 29, 33, 34]. The proteasome controls cellular growth and division by controlling the 
degradation of all misfolded, damaged and short lived proteins, for example those involved in 
cell cycle regulation and apoptosis. Dysregulated proteolysis contributes to malignant 
transformation either by enhancing the degradation of negative cell cycle regulators or by 
causing a defect in proteolysis of positive cell cycle regulators [35]. This can occur when 
mutations in substrates result in their evasion of normal ubiquitination that controls their 
abundance, or when there are specific defects of the ubiquitin-proteasome system [36, 37]. 
 
Cancer cells are generally associated with increased proteasome activity compared to non-
malignant cells, likely due to factors including rapid cell proliferation, increased oxidative stress, 
and elevated cytokine levels [37]. With regard to i-proteasome expression levels in cancer, 
apparent differences exist across the various cancer types. For example, up-regulation of i-
proteasome has been observed in multiple myeloma, prostate cancer, and lung cancer [38, 39]. 
On the other hand, i-proteasome is reported to be down-regulated in esophageal, renal, skin, 
and head and neck cancers [40-42]. Most of these studies did not further investigate the 
functional consequences of i-proteasome down-regulation. Therefore, it remains unclear 
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whether these changes in i-proteasome expression levels have any functional significance in 
terms of cancer cell survival and proliferation. 
 
Several studies have also assessed the clinical significance of i-proteasome expression. In lung 
cancer, a study by Tripathi et al. observed that patients treated with surgery alone showed 
significantly reduced disease-free survival with low PSMB8 expressing tumours (P = 0.004) [43-
46]. PSMB8 levels also emerged as an independent significant prognostic factor for disease-free 
survival [P = 0.005; hazard ratio (HR): 2.5; 95% confidence interval (CI): 1.3–5.0]. Notably, the 
reduced i-proteasome expression led to fewer peptides presented on HLA class I molecules 
(Tripathi et al., 2016). The authors observed that in NSCLS cell lines of mesenchymal origin 
(H1299 and DFCI024) displayed a markedly reduced diversity of peptides compared to epithelial 
cell lines (DFCI032 and HCC2935). The authors predict that the due to NSCLS having high 
mutations, i-proteasomes are likely able to generate high levels and more diverse neo-epitopes, 
which can be recognized by tumour infiltrating T cells and trigger host immune responses. 
 
In breast cancer, a study reported by Rouette et al. shows that i-proteasome gene expression 
correlates with survival in breast cancer, with high i-proteasome levels associated with a 
decreased risk of death (hazard ratio = 0.53) [47]. Survival at ten years was 61.9% ± 11.7% for 
patients whose i-proteasome gene expression ranked in the top third of the cohort relative to 
36.1% ± 8.0% for those in the bottom third. Furthermore, expression of individual i-proteasome 
genes PSMB8 and PSMB10 were associated with a decreased risk of death. 
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Overall, these studies suggest that in certain cancers, i-proteasome expression is up-regulated 
and this is presumably required to facilitate increased availability of growth-promoting proteins 
to sustain accelerated cancer growth. The up-regulated i-proteasome, since they are also 
intimately connected with the MHC class I antigen-processing machinery, causes increased 
levels and diversity of antigens, their presentation and subsequent immune responses. Given 
this i-proteasome addiction for certain cancers, it is likely that disrupting proteasome function 
will have drastic effect on rapidly dividing cancer cells, which can be therapeutically exploited 
with pharmacological inhibitors. 
 
Proteasome Inhibitors in Cancer 
 
 
The first proteasome inhibitors were simple peptide aldehydes designed to study the rate of 
proteolytic activity of proteasomes in muscle atrophy. With increasing evidence for the role of 
the proteasome in cancer progression, the possibility that proteasome inhibitors may have 
potential as therapeutic agents was considered. Early studies showed that proteasome 
inhibitors displayed a broad spectrum of anti-proliferative and pro-apoptotic activity against 
hematological and solid tumours. However, these initial compounds were rudimentary and 
lacked the potency, specificity, or stability required for clinical use, which led to the design of 
new inhibitors with more potent and selective activity. Bortezomib (PS-341), a dipeptide 
boronic acid, was the first proteasome inhibitor that showed high in vitro and in vivo anti-
proliferative activity against a range of cancer types by blocking CT-L activity [48]. It was 
approved by the FDA for treatment of patients with multiple myeloma, and mantle cell 
lymphoma and is in advanced stage clinical trials for many other tumour types as a combination 
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therapy [49-51]. However, there are limitations to the use of this inhibitor, including partial to 
no response in some patients, and dose limiting toxicities, particularly peripheral neuropathy. 
Furthermore, as single agents none of these inhibitors show efficacy in solid tumours.  
 
Despite initial clinical activity in hematological malignancies, some develop resistance. In 
limited early studies of bortezomib in advanced stage solid tumours, development of resistance 
was also observed. Busse et al. demonstrated that bortezomib resistant cell-lines originating 
from refractory myeloma (U266), lymphomas (KARPAS422) and solid tumour (8505C) had 
either reduced expression, or reduced catalytic activity, of i-proteasome subunits. Given that 
bortezomib specific IC50 for c- (β5~7.5nM) or i- (β5i~3.5nM) proteasome subunits are almost 
identical, the authors suggested that sensitivity of proteasome inhibition was due to higher i-
proteasome levels. Furthermore, induction of i-proteasome assembly by IFNγ exposure 
restored (40-60%) the sensitivity of such resistant cells to bortezomib with a concomitant 
decrease in the expression of the c-proteasome, suggesting that i-proteasomes are more 
sensitive to bortezomib than c-proteasomes [52, 53]. This observation is further complemented 
by various in vitro studies that indicate that increased levels of the constitutive subunits are 
associated with decreased bortezomib sensitivity [54] . It is likely that the overall effect of 
proteasome inhibition will vary greatly between tumour types [55-58] since different organ/cell 
types can express mixed and hybrid proteasomes where individual proteasomes contain both c- 




In cancer, the functional roles of the three proteasome activities (CT-L, C-L, and T-L) and their 
relative inhibition by proteasome inhibitors have not been fully elucidated. The majority of 
proteasome inhibitors are directed against CT-L activity, traditionally considered the rate-
limiting step in protein degradation. Consequently, inhibitor potency has often only been 
measured against this activity for most proteasomes. More recently, it has been shown that all 
three catalytic activities contribute significantly to protein degradation and that their relative 
contributions are dependent on the cell type and protein substrate [30]. Furthermore, it has 
been shown that inhibition of CT-L sites alone correlates poorly with cytotoxicity and that either 
C-L or T-L sites need to be co-inhibited to achieve maximum cytotoxicity in cells [59]. 
 
These findings suggest that depending on tumour type, catalytic T-L and C-L sites become 
integral to proteasome dysfunction and need to be considered as co-targets of anticancer 
drugs. There is a paucity of data on the effect of proteasome inhibition in solid cancers, but a 
few preclinical studies reveal that bortezomib is cytotoxic to breast cancer and sarcoma-derived 
cell lines. However, these in vitro responses could not be translated into a therapeutic benefit 
in patients with breast cancer or metastatic/recurrent Ewing sarcoma [41, 60, 61]. Currently, 
there are extremely few solid tumours that respond to bortezomib in patient trials. Whether 
this poor response in solid tumours is related to their lack of i-proteasomes exemplifies the 





Most current and second generation proteasome inhibitors under development and in clinical 
trials pre-dominantly target the CT-L site and fail to account for the importance of C-L and T-L 
activities. Even though the second generation inhibitors that have now been developed (eg. 
carfilzomib and ixazomib) offer the potential for more specificity and potency, they may have 
only limited success in solid tumours that predominantly express the c-proteasomes. These 
observations highlight an urgent need to continue development of more cancer-specific 
proteasome inhibitors, as well as characterizing proteasomes in solid cancers.  
Clinical Significance 
 
Dysregulated and up-regulated activity of the proteasome is a universal feature of malignant 
cells. Up-regulated proteasome CT-L activity is characteristic in many malignancies, which 
makes this an attractive target for cancer therapy. Bortezomib and other proteasome inhibitors 
have been highly effective in liquid tumours such as multiple myeloma and refractory mantle 
cell lymphoma, which predominantly express the i-proteasome. However, these inhibitors have 
several shortcomings including toxicity and lack of efficacy in solid cancers. However, this 
maybe considered to be due to a lack of i-proteasome expression in solid cancers. Recent 
studies suggest that many solid cancers can also express the i-proteasome and therefore may 
be sensitive to proteasome inhibition. As such, further characterization of the proteasomes in 
solid cancers is crucial. In addition, the major proteasome inhibitor in current use, bortezomib, 
has limitations due to toxicity. There is scope to develop new proteasome inhibitors that can 




The following four chapters highlight the potential of using proteasome inhibitors in solid 
cancer treatment. Chapter 2 demonstrates that the i-proteasome plays a crucial role in some 
subgroups of breast cancer. Chapter 3, 4, and 5 explore novel approaches in inhibitor design 
and synthesis that may increase efficacy and reduce toxicities associated with current 
proteasome inhibitors. The studies outlined here are essential for the further development of 
these cancer- specific proteasome inhibitors, which may serve as therapeutically active agents 
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This chapter summarizes key highlights from analysis of RNA-sequencing data of breast cancers 
generated from the TCGA initiative. These analyses revealed biologically meaningful insights 
into the expression of immuno-proteasome variants in basal-like and HER2+ breast cancer 
subgroups that were confirmed by subsequent experimentation in cell line models. 
 
This research has been submitted to eLIFE journal (March, 2017) and this chapter is the 
submitted version of the manuscript.  
 
















The success of proteasome inhibitors in hematological cancers is attributed to up-regulated 
proteasome activity. Although breast cancers were resistant to this therapy in early clinical 
trials, proteasome activity was not assessed. Since patient stratification based on proteasome 
activity may provide a targeted approach, we interrogated proteasome expression in cell line 
and patient derived RNAseq breast cancer data. In basal-like and HER2+ tumours, 
immunoproteasome levels were significantly up-regulated compared to luminal A and B 
tumours. High expression of the immuno-proteasome was associated with improved patient 
survival in basal-like and HER2+ breast cancers, but not in luminal A or B. Bortezomib sensitivity 
was significantly correlated with increasing levels of immuno-proteasome expression in breast 
cancer cell lines. Bortezomib caused apoptosis in basal-like cell lines via unfolded protein 
response pathways. Overall, our findings provide an overarching hypothesis that integrates 

























The proteasome is the major recycling centre for the cell with the c-proteasome degrading 
poly-ubiquitinated proteins via an ATP-driven protein complex consisting of a 20S core and 19S 
cap (Sorokin, Kim, & Ovchinnikov, 2009). Three protein components of the 20S core provide the 
critical proteolytic activities of β1 caspase-like (encoded by the PSMB6 gene), β2 trypsin-like 
(encoded by PSMB7) and β5 chymotrypsin-like (encoded by PSMB5). In addition, there is an 
alternative form of the 20S core termed the immuno-proteasome (i-proteasome) with 
alternative active sites, β1i (encoded by PSMB9), β2i (encoded by PSMB10) and β5i (encoded by 
PSMB8), together with a specialised 11S cap. The i-proteasome degrades unfolded and oxidised 
proteins and does not require ATP-driven unfolding of proteins (Shringarpure, Grune, 
Mehlhase, & Davies, 2003). The i-proteasome is predominantly expressed in haematopoietic 
cells and drives the major histocompatibility complex (MHC) class I response. Interferon-γ is a 
major inducer of i-proteasome expression (Aki et al., 1994). 
 
Compared to normal cells, cancers are typically associated with an enhanced proteasome 
activity and this provides a potential therapeutic target (J. Adams, 2004). The proteasome 
inhibitors bortezomib, carfilzomib, and more recently ixazomib, are FDA approved and used 
clinically for treatment of multiple myeloma and mantle cell lymphoma. Disappointing results 
from early phase clinical trials using bortezomib for treatment of solid tumours such as breast 
cancer (Engel et al., 2007; Yang et al., 2006) refocused the use and development of new 
generation inhibitors primarily for multiple myeloma treatment. However, recently there has 
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been developing interest in the use of bortezomib in solid cancers in conjunction with other 
systemic treatments. 
 
Although the proteasome is a potential therapeutic target in solid cancer, there has been 
limited characterisation of the proteasome in such cancers. The availability of next generation 
RNA sequencing data from a large number of breast cancers provides the opportunity to 
investigate the expression of the proteasome and its components in detail. This analysis was 
undertaken to determine if a proteasome inhibitor based therapy could target particular 
subgroups of breast cancer. Supporting data was then determined from analysis of appropriate 

















Comparison of expression of the c-proteasome in breast cancer 
subgroups 
 
This analysis is based on the breast cancer subgroups basal-like, luminal A, luminal B and HER2+ 
 enriched as defined by PAM50, a well-characterized qRT-PCR intrinsic subtyping classifier that 
measures expression of 50 genes selected as characteristic of these five breast cancer intrinsic 
subtypes (Parker et al., 2009). The breast cancer RNAseq data is sourced from the TCGA 
initiative available from cBioPortal (Cerami et al., 2012; Gao et al., 2013). It should be noted 
that levels of message do not necessarily reflect that of protein, and the levels of individual 
proteins of the complex may not reflect a functional proteasome as this requires assembly of a 
multi-protein complex. Despite these caveats, analysis of RNAseq data reveals biologically 
meaningful insights that are then confirmed by subsequent experimentation. 
 
The level of expression of c-proteasome subunits (19S cap genes PSMC1 and PSMD1, and 
PSMB5, PSMB6 and PSMB7 encoding respectively the c-proteasome activities β5c, β1c and β2c) 
are compared across the subtypes of breast cancers (Figure 1A; Supplementary Table 1). The 
differences in expression of these subunits are similarly maintained across the different 
subtypes with HER2+ enriched tumours having an average expression 33.7% higher than luminal 
A cancers. The maintenance of these differences does suggest that these comparative gene 
expressions are representative measures of the levels of proteasome proteins. From these data 
the different subgroups of breast cancer are likely to have inherently different levels of the c-
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proteasome and this likely reflects the characteristic inherent physiological states of the 
different subtypes.  
 
It was of interest to compare expression levels of i-proteasome in the breast cancer subgroups 
as recent evidence suggests that solid tissues can express i-proteasome (Altun et al., 2005; Ho, 
Bargagna-Mohan, Wehenkel, Mohan, & Kim, 2007; Wehenkel et al., 2012). The expression of 
the i-proteasome chymotrypsin-like activity (PSMB8) was compared (Figure 1B) as this activity 
is considered to be the major activity of the proteasome (Kisselev, Callard, & Goldberg, 2006). 
The basal-like cancers had the highest proportion of tumours with high levels of the i-
proteasome (38% between 2000-4000 RSEM proteasome expression) while the luminal A 
cancers had significantly lower proportion (only 18% of cancers with greater than 2000 RSEM of 
the i-proteasome expression). It is apparent that breast cancers, in particular the basal-like 
cancers, can express levels of i-proteasome greater than that of the c-proteasome. Typically, 
the i-proteasome is highly expressed in hematopoietic cells, where it functions to generate 





Figure 1. Comparison of relative expression of proteasome across breast cancer subtypes. A. 
PSMB5, PSMB6 and PSMB7 encode the c-proteasome activities of the 20S core; PSMC1 and 
PSMD1 are constant proteins of the 19S cap. LumA: Luminal A; LumB: Luminal B. B. (left) The 
relative i-proteasome (PSMB8) expression is presented in groupings from < 2000 RSEM, 
between 2000-4000 RSEM and >4000 RSEM. B. (right) I-proteasome expression presented in 
the percentage cases in the four intrinsic breast cancer subgroups. 
 
Co-expression of genes with i-proteasome expression 
 
Co-expression, as determined by the level of correlation between the expressions of two genes, 
can provide evidence for their involvement in the same pathway. In an approach to further 
investigate the roles of the proteasome in breast cancer, genes significantly co-expressed with 
the variable genes of the 20S core were determined. All genes were analysed, irrespective of 
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their relative expression. A conservative cut-off using r=0.5 was used which was equivalent to a 
Bonferroni corrected probability of <0.001. 
  
Correlation analysis revealed that the basal-like and luminal A breast cancer subgroups had 
distinct gene signatures. There were 84 genes in luminal A breast cancers where expression was 
correlated greater than 0.5 with PSMB8, PSMB9 and PSMB10 (Figure 2A). In contrast, in the 107 
basal-like cancers there were 171 genes with correlated co-expression greater than 0.5 with 
each of PSMB8, PSMB9 and PSMB10 (Supplementary Tables 2 and 3). Notably, the basal-like 
tumours expressed higher levels of several MHC class I (TAP1, TAP2, B2M, HLA-A, -B and -C) and 
various MHC class II genes compared to luminal A tumours (Figure 2B; Supplementary Tables 3 
and 4). The two subgroups also showed difference in the expression of transcription factors and 
cytokine/chemokines. Overlapping the lists of correlated genes, we obtained a 91-gene 
signature exclusive to basal-like tumours. Pathway and GO-term enrichment analysis of this 
signature suggested that the IFNγ-mediated immune response pathways were the most 
significantly up-regulated process (Figure 2C).  
 
The genes co-expressed with the i-proteasome were divided into two groups of low and high 
average expression. Half of these co-expressed genes had an average expression in the 107 
basal-like breast cancers less than 500 RSEM and were considered as low expressing. 
Comparison of the site of expression of the two groups demonstrated that the genes with lower 
expression were typically expressed in the lymphoid lineage rather than in breast cancer (e.g. 
the basal cell line MDA-MB-468) (Supplementary Figure 1). It is speculated that these 
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transcripts originate from infiltrating lymphoid cells in the tumour tissue samples that were 
processed for RNA sequencing and this infiltration was positively correlated with the presence 
of the i-proteasome.  
 
The i-proteasome co-expressed genes with the highest expression include MHC class I and 
associated genes, such as TAP1 and TAP2, consistent with expression of i-proteasome driving 
this response. Unexpected was the high expression of the MHC class II genes that typically have 
expression in dendritic cells, mononuclear phagocytes and B cells and are induced by exposure 
to interferon gamma (Ting & Trowsdale, 2002). Possible sources of MHC class II expression are 
from breast cancer cells, stroma or from high levels of infiltrating hematopoietic cells within the 
tumour. To investigate the possible origin, MHC gene expression in breast cancer tissues was 
compared with breast cancer cell lines (Supplementary Table 4). In breast cancers, the MHC 
class I are highly expressed with the class II genes having an average expression of 23% of the 
class I. In breast cancer cell lines, although the MHC class I genes were expressed and were also 
correlated with PSMB8 expression, the expression of MHC II genes was negligible. There were 
only three of 68 breast cell lines that had showed robust expression of MHC class II genes. 
These data are consistent with the findings of Forero et al (Forero et al., 2016) where analysis 
by immunohistochemistry, and of laser-captured micro-dissected breast tumours, 
demonstrated that while the MHC II pathway was associated with B-cell and T-cell infiltration in 




Figure 2. Analysis of i-proteasome co-expressed genes. A. Venn diagram demonstrating highly 
correlated genes with PSMB8 overlapping or exclusively expressed in the basal-like or luminal A 
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tumours. B. Heat map demonstrating the relative expression of highly correlated genes with 
PSMB8 in luminal and basal-like breast tumours. C. Major biological functional classification of 
immuno-proteasome co-expressed genes exclusive to either basal-like or luminal A breast 
tumours using the FunRich analysis software (http://www.funrich.org). (Pathan et al., 2015)  
 
 The interferon-gamma mediated signaling pathway 
 
The interferon gamma mediated signaling pathway was highly represented in the i-proteasome 
co-expressed gene set (Figure 2C). Interferon-γ (IFNG) is a major inducer of the immuno-
proteasome (Aki et al., 1994). Although the relative expression of IFNG was low among the 
basal-like breast samples (median expression 6.5 RSEM) this expression was significantly 
correlated with the levels of the i-proteasome expression (correlation expression levels IFNG 
and PSMB8, r=0.62). There was no significant correlation of IFNG with the expression of the c-
proteasome (correlation of IFNG and PSMB5 expression, r=-0.08, ns). In addition, the levels of 
interferon gamma were strongly correlated with levels of TBX21 (r=0.80, median expression 
26.8 RSEM) and CIITA (r=0.69, median expression 286.2 RSEM). TBX21 protein (T-bet) is a T-cell 
(Th1)-specific transcription factor that controls the expression of the cytokine interferon-
gamma (IFNɣ) (Oh & Hwang, 2014) and CIITA is the master controller of the MHC class II 
response (Downs, Vijayan, Sidiq, & Kobayashi, 2016). These data suggest that interferon-γ 
originates from infiltrating hematopoietic cells in the breast cancers. Interferon-γ can drive the 
expression of i-proteasome via the transcription factor IRF1 resulting in expression of MHC class 
I (Namiki et al., 2005). IRF1 expression was significantly correlated with i-proteasome 
expression in basal-like breast cancers (r=0.81). We speculate that a subset of basal-like breast 
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cancers are characterized by IFN-γ secreting hematopoietic cells, which as a consequence, 
drives IRF1 expression and i-proteasome in breast cancer cells. High levels of i-proteasome are 
associated with increased expression of the MHC I pathway and also expression of the MHC II 
pathway. It is speculated that in basal-like cancers, high levels of i-proteasome will activate an 
innate immune response via MHC expression.  
 
We sought to validate this IFN-γ axis in basal and luminal cancer cell lines. As expected, 
treatment with interferon gamma significantly up-regulated mRNA expression of this axis in 
both cell lines. In MDA-MB-468, a basal cell line, both IRF1 and PSMB8 were up-regulated >10 
fold while STAT1, TAP1 and TAP2 were up-regulated >7 and >3-fold respectively. In MCF7, a 
luminal cell line, baseline transcript levels of the IFN-γ axis were significantly lower compared to 
MDA-MB-468. Upon treatment with IFN-γ, IRF1 and PSMB8 levels were up-regulated >20 and 
110> fold respectively. These up-regulated PSMB8 levels in treated MCF7 were comparable to 
that observed for MDA-MB-468 without any IFN-γ treatment. STAT1, TAP1 and TAP2 were also 
significantly up-regulated. There was no observable effect on the constitutive proteasome since 
there were only marginal changes in PSMB5 levels in both cell lines. 
 
Silencing-rescue experiments in MDA-MB-468 and MCF7 cells demonstrated that in both cell 
lines silencing the IFN-γ driven transcription factor IRF1 (>90% silencing achieved with RNAi) 
significantly down-regulated the majority of its tested targets (Figure 3). In MDA-MB-468, 
PSMB8 levels decreased over 3-fold, while there was a 50% reduction in STAT1 and TAP2 levels. 
In MCF7, the effect of IRF1 silencing was more pronounced, with over 5-fold and 14-fold 
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reduction in PSMB8 and STAT1 mRNA expression and 3-fold reduction of TAP1 and TAP2 levels. 
Together, the evidence confirms that the IFN-γ-IRF1-STAT1-PSMB8 axis is intact in breast cancer 
cell lines. 
 
Figure 3. Interferon-ɣ induced IRF1 signaling axis is intact in both A. basal-like MDA-MB-468 and 
B. luminal MCF-7 cells. RT-qPCR analysis of mRNA expression of IFN-γ induced genes in cells 
transfected with siIRF1 or mock siRNA in the presence or absence of 100U/ml IFN-γ.  
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Relationship of proteasome expression with breast cancer patient 
survival 
 
The proteasome is reported to be frequently up-regulated in cancer and therefore it was 
determined if expression of the proteasome was related to patient survival. As before, PSMB5 
and PSMB8 were used as representative of the expression of the c- and i--proteasome 
respectively as they encode the β5 chymotrypsin-like activity, considered to be the 
predominant activity of the proteasome (Kisselev et al., 2006). Kaplan Meier analyses of PSMB5 
and PSMB8 in the four intrinsic subtypes of breast cancer are summarised in Supplementary 
Table 5 (Kaplan Meir graphs in Supplementary Figure 2). Low expression of the c-proteasome in 
luminal A and B cancers was significantly associated with improved survival, while this was non-
significant or marginally significant for basal-like and HER2+cancers respectively. PSMB8 
expression was significantly associated with improved survival in basal-like cancers but was not 
significantly associated with survival in the luminal or HER2+ subgroups (although patient 
numbers in the latter were limited), Figure 4. Similar results were found for PSMB9 and 
PSMB10, the other two i-proteasome genes, and also with IRF1. This was not unexpected as 
these three genes are significantly co-expressed with PSMB8.  
 
High i-proteasome expression (greater than 1.5 times the expression of the c-proteasome, 
Supplementary Figure 3) is found in 23.1% of basal-like cancers but only 6.5% of luminal A 
cancers. It is intriguing that expression of the i-proteasome in luminal A cancers does not 
apparently influence patient survival (Supplementary Table 5). It is possible that in basal-like 
breast cancers there are specific circulating effector proteins and cytokines that allow a more 
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efficient initiation and maintenance of the innate immune response than in luminal A cancers. 
In an approach to identify such basal specific factors, genes with expression highly correlated 
with PSMB8 message were compared between those basal and luminal A cancers that 
expressed greater than 2500 RSEM of PSMB8 (Supplementary Table 3). In these high i-
proteasome expressing cancers, expression of the classical complement pathway components 
C1S, C1R, C1Q and C2, is reduced by 43% in luminal A compared with basal-like cancers and in 
luminal A cancers is not correlated with the presence of the i-proteasome (correlation of C1S 
with PSMB8 in luminal A: r=-0.16, ns; basal: r=0.57, p<0.005). The classical complement 
pathway is an effector arm of the immune system and contributes to the destruction of cancer 
cells in conjunction with antibodies produced by B-cells (Pio, Ajona, & Lambris, 2013). Notably, 
the alternative complement pathway component C3 is also reduced by 54% in the luminal A 
compared to basal-like cancers. Interestingly, of 33 breast cancer cell lines that have been 
clearly defined as basal or ductal-like (Neve et al., 2006) only the basal-like cell lines express 
high levels of C1S (Supplementary Figure 4). This is significant as several studies suggest that 
the complement system has the ability to recognise malignant cells and is activated in response 
to the expression of tumour-associated antigens, with the subsequent deposition of 
complement components on tumour tissue (Corrales et al., 2012; Gminski, Mykala-Ciesla, 





Figure 4.  Kaplan Meier survival curves of breast cancer patients are stratified by PSMB8 
expression.Survival data derived from Kaplan-Meier plotter (Gyorffy et al., 2010) using “Jetset” 
best probe set and auto-selection of best cut-off. P values are corrected for multiple testing 







Basal-like breast cancers are addicted to the immuno-proteasome 
 
High levels of the i-proteasome in basal-type breast cancers are associated with increased 
expression of HLA type I and type II genes and it is speculated that this results in increased host-
immune surveillance and consequently a better patient prognosis. WWithin a basal breast 
cancer, those cells with high levels of i-proteasome will be expected to be eliminated by 
immune surveillance, resulting in overall suppression of i-proteasome expression. The 
persistence of basal-type cancers with high levels of i-proteasome suggests that increased 
activity of i-proteasome has a function that is essential for survival of these cancer cells. It is 
suggested that basal-like cancers can become “addicted” to high levels of i-proteasome. The 
likely basis for this addiction is the role of the i-proteasome in degrading oxidised and misfolded 
proteins in an ATP independent mechanism (Sorokin et al., 2009). In rapidly dividing cancer cells 
with a general breakdown in cellular homeostasis, oxidised and misfolded proteins would be 
expected to accumulate and have the potential to trigger a persistent “unfolded protein 
response” resulting in cell apoptosis (M. Wang & R. J. Kaufman, 2014). Thus we speculate that 
basal-type breast cancers express i-proteasome genes to enable cell survival by ameliorating 
the potential to trigger an unfolded protein response. In such cancers, as a consequence of this 
i-proteasome expression, there is also triggered a host-immune surveillance resulting in 






We next set out to determine if breast cancer cell lines demonstrated i-proteasome addiction. 
The expectation would be that cancers would vary in their addiction, with the levels of 
increasing addiction reflected in higher expression of i-proteasome and increasing sensitivity to 
a proteasome inhibitor such as bortezomib. Accordingly, bortezomib LD50 was determined for 
each of the breast cancer cell lines (Figure 5A; Supplementary Table 6; Supplementary Figure 5 ) 
and the expression of PSMB5 or PSMB8 assessed from RNAseq data (Klijn et al., 2015). The 
breast cell line bortezomib LD50s were significantly negatively correlated with the expression of 
PSMB8 (r=-0.86, p<0.0014) but not with levels of PSMB5 (r=0.59, p=0.06). Basal cell lines 
together with SKBR3, an ER- PR- HER2+ cell line, were on average greater than 25 fold more 
sensitive to bortezomib compared with the cell lines classified as luminal. Western data further 
confirmed the variation in i-proteasome in these breast cancer cell lines (Supplementary Figure 
6). 
 
These findings were not the consequence of bortezomib preferentially inhibiting the i-
proteasome as native in-gel proteasome activity assay showed similar inhibition of total 
proteasome activity by 0.037µM bortezomib in MDA-MB-468 (high levels of i-proteasome and 
bortezomib LD50 of 0.037µM) and MCF-7 (low levels of i-proteasome and bortezomib LD50 of 1 
µM), Figure 5B. While this bortezomib dose was lethal for MDA-MB-468 (>90% cell death), 
there was minimal effect on MCF7 survival (Figure 5C). However, prolonged monitoring of 




and eventually increasing cell death (Supplementary Figure 7). Therefore, inhibition of the c-
proteasome causes cell cycle arrest and increasing cell death only after prolonged treatment. 
This is consistent with the major role of the c-proteasome in degradation of poly-ubiquitinated 
proteins that is required for the maintenance of cell homoeostasis, in particular, cell division 
(Julian Adams, 2004; Koepp, 2014). In breast cancer cell lines with high levels of i-proteasome, 
bortezomib treatment causes rapid cell death and this is suggested to reflect the addiction of 
such cancers to a unique function provided by the i-proteasome. 
 
To confirm that the observed sensitivity of basal breast cancer cell lines to bortezomib was due 
to direct i-proteasome inhibition and was not associated with an off-target effects of 
bortezomib, si-RNAs were used to silence PMBS8 expression in six breast cancer cell lines with 
varying i-proteasome expression. We predicated that this would have lethal consequences 
where cell lines were addicted to i-proteasome. This was indeed observed (Figure 5D), with si-
RNA knockdown (>80% knockdown achieved in all cell lines) of PSMB8 resulting in induction of 
45%, 48% and 39% apoptosis in MDA-MB468, BT-20 and Hs578T respectively. In contrast, 
ZR751 and MCF7 did not show any significant increase in cell death. The MDA-MB-231 cell line 
was an exception as although expressing high levels of PSMB8 and being sensitive to 







Figure 5. A. The bortezomib sensitivity of breast cancer cells lines is highly correlated with 
expression of i-proteasome. Bortezomib sensitivity from Table S6 expressed as log base 10, 
expression of i-proteasome as PSMB8 expression from RNAseq (Klijn et al., 2015). Cancer 
subtype as in (Neve et al., 2006). Bortezomib LD50s determined from dose response graphs 
presented in Supplementary Figure S4 . B. Native in-gel proteasome assay of bortezomib 
treated breast cancer cell lines. MDA-MB-468 and MCF7 were untreated or treated with 
0.037µM bortezomib for 2h. Whole cell lysates without detergents together with ATP were 
electrophoresed on 3.5% acrylamide gels. UV image following incubation with the fluorogenic 
peptide Suc-LLVY-AMC, a chymotrypsin-like specific substrate. C. Incucyte images 
demonstrating effect of 0.037µM bortezomib on MDA-MB-468 and MCF-7 cells after 48h. D 
and E. RNAi silencing of PSMB8 for 56h causes apoptosis in basal-like and HER2+but not luminal 
cell lines. PSMB5 silencing has no apoptotic effect on either MDA-MB-468 or MCF-7 cells under 
the same conditions. F. Pre-treatment with IFN-γ treatment (100U/ml) for 24h does not 
significantly affect sensitivity to bortezomib. 
 
As the sensitivity of breast cancer cells to both bortezomib treatment and RNA interference was 
related to the levels of the i-proteasome, we next investigated whether treatment with IFN-γ 
can alter the sensitivity of cell lines to bortezomib. While treatment with 100 U/ml IFN-γ 
increased PSMB8 levels by 3-fold and 100-fold respectively in MDA-MB-468 and MCF7 
(Supplementary Figure 8), sensitivity to bortezomib was not significantly altered (Figure 5F). 




Unfolded protein response in basal-like breast cancers that have i-
proteasome addiction 
 
We propose addiction of breast cancers to high levels of the i-proteasome with suppression of 
proteasome activity triggering ER stress and the unfolded response pathway (UPR). Three 
signalling pathways responsible for mediating the UPR have been described (Miao Wang & 
Randal J. Kaufman, 2014) ). These can be assessed by increased expression of ATF4 while 
activation of the PERK and IRE1 branches culminate in a spliced form of the X-box transcription 
factor, XBP1s. XBP1s is a key downstream transcription factor that activates the expression of a 
wide variety of genes required for protein folding and secretion, as well as clearance of 
misfolded proteins from ER. To test the effect of proteasome dysfunction on UPR activation, 
two basal-like and two luminal cell lines were treated with the bortezomib. Bortezomib 
treatment significantly increased the ATF4 levels by 4-fold and 2-fold in MDA-MB-468 and 
Hs578T cell lines while in luminal cells, ATF4 increase was only observed for MCF7 cells (Figure 
6A).  
 
We also tested whether treatment of MDA-MB-468 cells with bortezomib increased the XBP1s 
in a time dependent manner. This was indeed observed, with in addition, concomitant with up-
regulation of pro-apoptotic genes FOXO3, NOXA, BIM, CASP3 and CASP7. We also observed a 
significant decrease in NFKB and BCL2 mRNA levels. This is consistent with previous studies in 
multiple myeloma that show bortezomib has pleotropic anti-cancer effects and causes 




Figure 6.Unfolded protein response pathway in breast cancer cells. A. Cells were treated with 
35nM bortezomib or vehicle control for 4h and total mRNA was extracted. ATF4 transcirpt 
levels were calculated via qRT-PCR. B. MDA-MB-468 cells were treated with 35nM bortezomib 
and the mRNA expression levels for the FOXO3, NOXA, BIM, CASP3, CASP7, BCL2 and NFκB 






The proteasome has been successfully targeted for the treatment of multiple myeloma,with 
clinical responses to proteasome inhibitors have been correlated with increased proteasome 
activity (Kuhn & Orlowski, 2012; Niewerth et al., 2013). Therefore, in an attempt to address 
whether proteasome inhibition can be a viable treatment for breast cancer, we analysed mRNA 
expression data from the TCGA breast cancer cohort. Unexpected was the observed variation in 
i-proteasome expression, with particularly high levels in a proportion of basal-like and 
HER2+breast cancers. Based on our finding that the bortezomib LD50 of breast cancer cell lines 
closely parallels the levels of i-proteasome, we propose that high levels of the i-proteasome are 
required for a critical function in these breast cancers. It has been previously proposed from 
siRNA lethality screens of breast epithelial cell lines that basal-like breast cancer cells have a 
proteasome addiction (Petrocca et al., 2013), although this was not specifically attributed to the 
i-proteasome. We propose that the basis for the i-proteasome addiction is its role in the 
maintenance of protein homoeostasis (Seifert et al., 2010) rather than its specific role in 
production of class I antigens. 
 
Our data are consistent with addiction specifically restricted to expression of the i-proteasome. 
Specific RNA interference of the i-proteasome subunit PSMB8 causes rapid cell death in basal-
like and HER2+ but not in luminal cancer cells, whereas under the same conditions, silencing of 
the PSMB5 subunit of the c-proteasome does not have any cytotoxic effects. Since the half-life 
of the c-proteasome is >120h (Heink, Ludwig, Kloetzel, & Krüger, 2005), it is possible that 
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prolonged silencing of PSMB5 is required to induce cell death. However, although blanket 
inhibition of total proteasome activity by the same concentration of bortezomib is observed by 
native in-gel activity assays (Figure 5B) in both a basal-like and luminal cell line, there is no 
effect on the viability of the luminal cell line. In addition, treatment with 100u/ml IFN-γ does 
not increase the cytotoxic sensitivity of breast cancer cell lines to bortezomib despite increasing 
total i-proteasome levels. The latter observation provides a distinction between the intrinsically 
up-regulated i-proteasome levels that are observed in basal-like and HER2+cells that are critical 
for survival and the up-regulation by extrinsic means, for example IFN- γ treatment, that has 
little or no effect on this addiction.  
 
This has notable implications for therapeutic intervention, as tumours possessing high levels of 
i-proteasome are predicted to be responsive to clinically available proteasome inhibitors. We 
observed substantial heterogeneity in mRNA and protein expression of i-proteasome subunits 
among breast cancer subtypes, with basal-like and HER2+cancers having higher levels of i-
proteasome expression than luminal cancers. Up-regulation of i-proteasome activity in these 
cancers is likely to be dependent on an interplay between their genetic instability, metabolic 
demands and requirement for degradative capacity of oxidised and unfolded proteins. As both 
basal-like and HER2+ breast cancers are generally associated with high rates of cancer cell 
proliferation and genomic instability (Shaver et al., 2016), this is likely to drive high levels of 
oxidised and misfolded proteins. To accommodate this, there is an increase in their degradative 
capacity by up-regulating the i-proteasome. The i-proteasome is labile and also has the capacity 
to degrade proteins without the requirement for ATP. This is consistent with the observation 
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that while the c-proteasome levels remain constant in most cancers, i-proteasome levels are 
highly heterogeneous. If i-proteasome function is inhibited in such cancers, for example with 
bortezomib treatment, the endoplasmic reticulum stress and the UPR response will be 
triggered. We show that bortezomib treatment of a basal breast cancer cell line activates 
multiple branches of the IRE-1-XBP1 axis and consequently leads to cell death consistent with 
the up-regulation of NOXA, FOXO, BIM and down-regulation of NFκB. These results are 
consistent with studies in multiple myeloma where treatment with bortezomib initiates the 
UPR stress pathways (Dong et al., 2009; Obeng et al., 2006). 
 
An immune response gene expression module has been shown to identify a good prognosis 
subtype in estrogen receptor negative breast cancer (Teschendorff, Miremadi, Pinder, Ellis, & 
Caldas, 2007). In this context, recognition of tumour-associated antigens by TILs is a significant 
contributor to the detection and ultimate destruction of tumour cells (del Campo, Carretero, 
Aptsiauri, & Garrido, 2012). In our analysis, i-proteasome subunit PSMB8 was significantly 
correlated with good outcome in basal-like and HER2+ cases but not in luminal A and luminal B 
patients. It is expected that the up-regulated i-proteasomes in the presence of intact HLA 
expression and IFN-γ signaling pathways contribute to a more efficient and robust immune 
signal that is recognised by circulating TILs. However, it is unlikely to be the whole story as only 
a very small fraction of all antigens, even in the context of small cell lung cancer with extremely 
high mutation rates, are able to evoke a T cell response (Tripathi et al., 2016). A possible 
explanation is that the immunogenicity of a tumour is determined by both the uniqueness and 
adequate levels of that antigen. Genome sequencing studies show that most tumours have 
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point mutations in protein coding sequences, however only a small proportion will ellicit an 
innate immune response via HLA mediated display of the i-proteasome degraded peptides. 
Although the mutation rates in basal-like cancers are not high, they are associated with high 
levels of genomic instability, which would be predicted to generate high levels of novel 
proteins. Recent developments in the analysis of RNAseq data have identified high rates of 
hybrid and novel transcripts in basal breast cancer (Shaver et al., 2016) and it would be 
predicted that these are potentially immunogenic. This may provide the basis for the improved 
prognosis of basal breast cancers expressing high levels of the i-proteasome. 
 
In conclusion, we propose that to alleviate the UPR driven consequences of high mutational 
load and metabolic demands, cancers preferentially up-regulate i-proteasome activity. By 
appropriate screening with i-proteasome as a marker, cancers can be identified with i-
proteasome addiction which can then be therapeutically exploited by treatment with 
proteasome inhibitors. In such cancers, there is a secondary, unintentional consequence of i-
proteasome up-regulation. Due to its optimal peptide cleave specificity and enhanced 
degradative capacity, this up-regulated activity of the i-proteasome leads to an increased and 
diverse peptide pool and capacity to display antigenic peptide-MHCI repertoires on the surface 
of the cancer cells. This results in more efficient detection of cancer cells by the circulating TILs. 
Such incoming TILs release cytokines such as IFN-γ which has two  effects in the in tumour 
microenvironment, upregulation of the i-proteasome-MHC axis and release of cytokines to 
further reinforce TIL recruitment. This positive feedback loop increases the efficiency of host 
anti-cancer surveillance which translates into an improved patient prognosis.  
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Materials and Methods 
 
In silico analysis 
Breast cancer RNA sequencing data was accessed from cBioPortal (Cerami et al., 2012; Gao et 
al., 2013). The mRNA expression (RNA Seq V2 RSEM) was from TCGA as cited in Ciriello et al 
(Ciriello et al., 2015). Intrinsic breast cancer subgroups categorised as basal-like, luminal A, 
luminal B and HER2+ were used. Gene expression data in cell lines were from the cancer cell line 
Encyclopaedia (Barretina et al., 2012) accessed via cBioPortal. Kaplan Meier analyses used the 
online Kaplan-Meier Plotter (Szasz et al., 2016).  
 
Cell lines 
All human breast carcinoma cancer cell lines were purchased from the American Type Culture 
Collection (ATCC, Manassas, VA, USA). MDA-MB-468, MDA-MB-231, BT-20 and Hs578T were 
cultured in DMEM. SKBR3 and BT-474 were cultured in RPMI. BT483 was cultured in RPMI with 
20% FBS, 0.01mg/ml Insulin (Sigma-Aldrich, MO, USA). T47D was cultured in RPMI, 1mM 
sodium pyruvate (GIBCO, Grand Island, NY) and 0.01mg/ml insulin. ZR751 were cultured in 
RPMI and 1mM sodium pyruvate. MCF7 was cultured in RPMI with 0.01mg/ml insulin. MCF10A 
was cultured in DMEM/F12: (1:1) (Invitrogen) with 5% horse serum (Invitrogen), 10 μg/ml 
insulin, 20 ng/ml human epidermal growth factor (Sigma-Aldrich, MO, USA), 100 ng/ml cholera 
toxin, and 500 ng/ml hydrocortisone (Sigma-Aldrich, MO, USA). All cell lines were 
supplemented with 10% (v/v) fetal bovine serum (FBS, Sigma-Aldrich, MO,USA) unless stated 
otherwise, as well as 1% (vol/vol) penicillin (100 U/mL), streptomycin (100 U/mL), and 1% 
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(vol/vol) L-glutamine (PSG, all from GIBCO-BRL, Grand Island, NY). Cells were regularly screened 
for Mycoplasma (Lonza, Basel, Switzerland). 
 
Western blot 
Cells were trypsinised, centrifuged at 300g for 5min and washed twice with PBS. Cell were lysed 
using cell culture lysis buffer (100 mmol/L HEPES, pH 7.5, 2 mmol/L EDTA, 100 mmol/L NaF, 500 
mmol/L sodium choloride, 50 μg/mL trypsin inhibitor) (Promega) containing cOmplete Mini 
Protease Inhibitor (Roche). The supernatant was collected and protein concentration was 
determined using the BCA protein assay (ThermoFisher Scientific,MA,USA). Whole protein 
lysates (5–20 μg) were resolved using SDS PAGE electrophoresis, and probed overnight at 4 °C 
with the following primary antibodies: PSMB5 (Cell signalling, 1:1000), PSMB6 (Cell Signalling, 
1:1000), PSMB7 (Cell Signalling, 1:1000), PSMB8 (Cell Signalling, 1:1000), β-tubulin (Sigma-
Aldrich, 1:200). Chemiluminescent detection of protein was done using appropriate secondary 
antibodies conjugated with horseradish peroxidase (Amersham) and the enhanced 
chemiluminescence kit according to the manufacturer's instructions (Amersham). 
 
Native in gel activity assay 
Total chymotrypsin-like activity of the proteasome was measured in freshly prepared cell 
lysates as described previously, with some minor modifications to the protocol. In brief, a total 
of 5 × 106 cells were washed 3 times with ice-cold PBS and spun down by centrifugation (5 
minutes, 250g, 4°C). Cell pellets were then resuspended in an ATP-containing lysis buffer (10 
mM Tris-HCl buffer (pH 7.8) containing 5 mM ATP, and 5 mM MgCl2) and kept on ice for 10 
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minutes. For complete lysis, cells were sonicated (MSE sonicator, amplitude 15, for 10 seconds 
at 4°C) followed by centrifugation (5 minutes, 16 000g, 4°C) to remove cell debris. Forty 
microlitres of whole cell lysate from each of the cell lines were run on a 3.5% non-denaturing 
polyacrylamide gel (BIO-RAD, CA, USA) in 10mM Tris-HCl buffer supplemented with 0.5mM ATP 
(Sigma-Aldrich, MO, USA), 5mM MgCl2, 10% (v/v) glycerol, 0.5 mM DTT). The gel was run at 35 
V for 30 min in a 4°C cold cabinet, thereafter the voltage was increased to 75 V for four hours. 
Peptidolytic activity of proteasomes was detected after incubating the gels in a Suc-LLVY-MCA 
substrate dissolved in 50 mM Tris pH 8.0, 5 mM MgCl2, 1 mM DTT, 2 mM ATP, and 0.02% SDS 
for 10 min at 37°C. Proteasome bands were identified by the release of highly fluorescent, free 




Determination of LD50  
Cells were seeded in 96-well microtiter plates at a density of 2×104 cells/well with varying 
concentrations of bortezomib. Cells were harvested 48 hours post- treatment, centrifuged at 
1,300 × g, washed in phosphate buffered saline (PBS) and stained with 7-amino-actinomycin-D 
solution (2 μg/mL) (7AAD, Invitrogen) for 10 minutes at room temperature. Viable cells were 
determined with the use of a FACS Calibur flow cytometer (Becton Dickinson Immunocytometry 
Systems), and analyzed with the use of FLOWJO (Tree Star Inc.) and GraphPad Prism (GraphPad 
Software Inc. version 6).  
 
RNA interference (RNAi) 
For RNA inhibition studies, approximately 3 × 105 cells/well were seeded in six-well plates. Cells 
were transfected with 50 nM of the following siRNAs (GenePharma): PSMB8 -
CCACUCACAGAGACAGCUAUU; IRF1- GAAAGUUGGCCUUCCACGUCU; PSMB5-
AAGCUCAUAGAUUCGACAUUG; non-coding RNA- UUCUCCGAACGUGUCACGUTT using 
Lipofectamine RNAiMAX reagent (Invitrogen) following the manufacturer’s instructions. Cells 
were harvested 72 hours post-transfection for further experiments. The RNA interference 
efficiency for interference of PSMB8 was determined using qPCR. 
 
Real-time Cell attachment 
Cells were seeded in 24 well plates (50,000 cells/wells in triplicate) with cell attachment 
monitored qualitatively over a 24h period using IncuCyte live-cell imaging system (Essen 




Total RNA was extracted from cultured cells using RNeasy mini kit (Qiagen). One microgram of 
total RNA was reverse transcribed using MMLV reverse transcriptase (Life Technologies). qPCR 
was performed using SYBR Green mastermix and run on a CFX96 Bio-Rad real time PCR 
machine. Primer sequences are presented in Table 1. Experiments were repeated three times. 
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Supplementary Table 1. Expression of proteasome subunits across different breast cancer 
subtypes. 
Expression expressed as RSEM derived from RNAseq data (Ciriello et al., 2015); SEM: Standard 
error of mean. 
 
Supplementary Table 2. Correlations between expressions of c- and i-proteasome subunits in 
breast cancer subtypes. 
Correlation coefficients statistically significant (p < 0.01 with Bonferroni correction) unless 
indicated. ns-not significant.  
 
 c-proteasome i-proteasome 















670 2865 2631 1754 2584 2875 
 
 
2716 2324 1142 1133 
 SEM 28 87 101 70 128 163 182 154 106 82 
HER2 Mean 801 3298 2937 1609 2740 4148 3304 2121 791 1090 
 SEM 65 116 174 90 191 403 331 256 100 142 
LumA Mean 555 2522 2061 1433 1972 3960 2306 1536 463 780 
 SEM 13 39 52 37 41 103 87 69 29 39 
LumB Mean 666 2984 2610 1511 2273 4551 3033 1795 680 759 























0.46 0.29 ns 0.30 ns 0.91 0.77 0.79 
 
0.01 ns 
HER2 0.63 0.50 0.54 0.95 0.48 0.50 0.17 ns 
Lum A 0.42 0.56 0.48 0.86 0.82 0.79 0.27 
Lum B 0.45 0.37 0.35 0.84 0.67 0.54 0.29 ns 
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Supplementary Table 3. Basal-like and luminal A breast cancer cases with expression of >2500 
RSEM PSMB8.  
 











ACSL5 0.36 1048.03 0.13 640.32 
 
APOL1 0.35 3407.02 0.43 2843.47 
 
APOL2 0.60 1394.49 0.42 1418.60 
 
APOL3 0.53 1529.15 0.44 1248.63 
 
B2M 0.24 86320.13 0.60 73047.57 
 
BTN3A2 0.38 2386.53 0.53 1996.33 
 
C1QA 0.28 4719.39 0.56 2381.88 
 
C1S 0.57 18930.23 -0.16 8117.87 
 
CCL5 0.30 3366.94 0.56 1416.05 
 
CD2 0.37 897.83 0.45 571.72 
 
CD74 0.59 86455.96 0.52 68460.55 
 
CIITA 0.38 967.43 0.35 433.81 
 
CORO1A 0.47 2140.68 0.60 1815.36 
 
CXCL9 0.22 8159.66 0.28 3565.02 
 
FCER1G 0.27 1191.62 0.16 606.02 
 
FERMT3 0.39 856.66 0.54 603.90 
 
FMNL1 0.37 1047.33 0.37 778.95 
 
GBP1 0.36 7916.98 0.22 1749.36 
 
GBP2 0.21 4394.59 0.13 2488.62 
 
GBP4 0.21 4211.08 0.35 1653.19 
 
GBP5 0.23 3474.53 0.29 599.90 
 
HCLS1 0.29 1550.66 0.37 1078.15 
 
HLA-A 0.55 47843.13 0.77 39174.51 
 
HLA-B 0.51 72681.09 0.84 69223.83 
 
HLA-C 0.37 40223.73 0.78 42023.00 
 
HLA-DMA 0.58 2980.80 0.35 2087.84 
 
HLA-DMB 0.38 2207.65 0.27 1481.64 
 
HLA-DPA1 0.40 12075.63 0.31 9016.45 
 
HLA-DPB1 0.57 7200.12 0.54 5498.39 
 
HLA-DQA1 0.42 6231.44 0.34 3076.99 
 
HLA-DQB1 0.45 5280.92 0.59 3694.48 
 
HLA-DRA 0.46 35077.89 0.39 21567.79 
 
HLA-DRB1 0.53 11666.09 0.69 8506.56 
 




HLA-E 0.49 14271.52 0.70 11422.87 
 
HLA-F 0.75 5238.08 0.74 2846.93 
 
HLA-H 0.59 4631.20 0.69 3696.58 
 
IFI35 0.46 969.00 0.28 1675.83 
 
IL2RB 0.29 986.55 0.40 640.19 
 
IL2RG 0.39 1904.72 0.54 952.76 
 
IRF1 0.56 3231.79 0.54 1974.15 
 
ITGB2 0.25 3734.61 0.35 2204.41 
 
LAP3 0.30 4887.38 0.37 3320.59 
 
LGALS9 0.48 2716.08 0.51 2032.64 
 
MVP 0.52 3162.78 0.04 5446.77 
 
NFKB2 0.38 2008.49 0.41 1251.15 
 
NLRC5 0.28 2020.48 0.28 1012.90 
 
PML 0.04 3206.75 0.31 1961.82 
 
PSMB8 1.00 4030.34 1.00 3602.91 
 
PSME1 0.34 4298.28 0.52 5915.11 
 
PSME2 0.40 4266.86 0.46 4002.40 
 
PTPN6 0.49 1541.36 0.48 1337.84 
 
RAC2 0.34 1541.22 0.61 1245.61 
 
RARRES3 0.34 2125.79 0.41 6345.87 
 
SPI1 0.32 844.55 0.52 547.76 
 
TAP1 0.57 12942.36 0.84 5870.72 
 
TAP2 0.57 5474.91 0.74 2245.24 
 
TAPBP 0.61 11090.77 0.81 8159.85 
 
TCIRG1 0.50 1592.64 0.43 1324.59 
 
TNFRSF14 0.45 1052.90 0.50 1111.30 
 
TNFRSF1B 0.46 1626.59 0.40 1003.91 
 
TYMP 0.46 4108.39 0.55 2683.15 
 
TYROBP 0.29 1442.54 0.54 1026.17 
 
UBA7 0.52 1045.64 0.18 1312.04 
 
UBD 0.40 9537.38 0.51 2368.57 
 
UBE2L6 0.36 4611.63 0.52 4036.45 
 
WARS 0.29 12689.24 0.62 3206.70 
 
Note: Number cases basal-like with expression of PSMB8>2500 is 42. R values >0.483 have 
P<0.05 with Bonferroni correction for multiple testing. Number of cases luminal A with 
expression of PSMB8>2500 is 23. R values>0.647 have P<0.05 with Bonferroni correction for 




Supplementary Table 4. Comparison of MHC expression between breast cancer tissues and 





MHC class I 
 





























0.8 8.5 13.3 9.1 0.6 2.8 1.7 1.1 1.1 7.0 
Correlation 
with PSMB8  






0.2 2.1 1.8 2.3 0.07 0.03 
0.00
7 
0.01 0.03 0.1 
Correlation 
with PSMB8  




 *Expession given as relative to expression of PSMB5 since breast cancer data calculated as 
RSEM and cell line as RPKM (Reads Per Kilobase of transcript per Million mapped reads). Breast 
cancer RNA seq expression from cell 2015 TCGA, breast cell line expression from Klijn et al. 
 
Supplementary Table 5. Summary of the effect of PSMB5 and PSMB8 expression on the survival 
































1764 491 low 8e-09 1205  ns 
Luminal 
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1002 388 low 0.0015 418  ns 
HER2+ 
 
208 24  ns 142  ns 
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Supplementary Table 6. Relative expression of PSMB8 in breast cancer cell lines and cytotoxic 







(µM) ± S.D 
message (PSMB8) 
    




0.020 (0.04) 12.66 
MDA-MB-468 Basal 0.032 (0.018) 12.19 
MDA-MB-231 Basal 0.037 (0.02) 12.09 
BT-20 Basal 0.039 (0.01) 13.18 
BT483 Luminal 0.228 (0.27) 11.27 
T47-D Luminal 0.5 (0.14) 10.57 
ZR75-1 Luminal 0.8 (0.45) 10.71 
MCF7 Luminal 1.0 (0.72) 9.35 





Supplementary Figure 1. Site of expression of the genes highly correlated (>0.5) with PSMB8 
expression divided into high and low expressing groupsaccording to whether the expression of the 
candidate genes was greater or smaller than 5000 RSEM..
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Supplementary Figure 2. Relative survival of sub-types of breast cancer classified by expression 
of c-proteasome gene PSMB5. Plots generated by Kaplan-Meier plotter (Gyorffy et al., 2010) 
using “Jetset” best probe set and auto-selection of best cut-off for classifying high and low 











Supplementary Figure 3. Relative expression of i-proteasome in breast cancer subgroups. 
The relative i-proteasome (PSMB8) expression is presented in groupings from <50% to greater 
than 200% relative to the c-proteasome (PSMB5) expression. Presented is the percentage cases 
in each of the four intrinsic breast cancer subgroups. 
 
Supplementary Figure 4. Expression of C1S in breast cancer cell lines.  
Expression levels of C1S from Affymetrix expression arrays (Barretina et al., 2012). Black bars 
are basal type cell lines, blue bars luminal type cell lines (Neve et al., 2006). 
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Supplementary Figure 5. Representative LD50graphs. 
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Supplementary Figure 6. Basal-like breast cancer cell lines have higher i-proteasome subunits 













Supplementary Figure 7. Bortezomib induces growth arrest in MCF7. A. Breast cancer cell line 
MCF7 was grown in absence (blue line) or presence of 35nM bortezomib (black line). 
Proliferation was inhibited and cell death occurred after 4 days of culture. B. Proliferation 







Supplementary Figure 8. Treatment with IFN-ɣ induces i-proteasome expression. Cell were 
treated with 100U/ml IFN-ɣ for 24h. RT-qPCR analysis was done on mRNA expression of the 
PSMB8 subunit of the i-proteasome. In MDA-MB-468 cells, PSMB8 expression was induced over 
3-fold compared to untreated cells. In MCF-7 cells, IFN- ɣ treatment caused over 100-fold 
induction in the PSMB8 levels. These induced mRNA levels were comparative to that observed 
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The 26S proteasome has emerged over the past decade as an attractive therapeutic target in 
the treatment of many cancers, in particular hematological malignancies. Here, we report new 
peptidomimetic boronates that demonstrate superior in vivo activity and less toxicity compared 
to benchmark proteasome inhibitors Bortezomib and Carfilzomib. 
 
This research has been published in ACS Med. Chem. Lett. (Dec, 2016) and this chapter is the 
published version of the manuscript.  
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Proteasome is a large proteinase complex that degrades proteins via its three catalytic 
activities. Among these activities, the ‘chymotrypsin-like’ activity has emerged as the focus of 
drug discovery in cancer therapy. Here, we report new peptidomimetic boronates that are 
highly specific for the chymotrypsin-like catalytic activity of the proteasome. These new specific 
proteasome inhibitors demonstrated high in vitro potency and selective cytotoxicity for cancer 
cells, with therapeutic windows superior to those observed for the benchmark proteasome 
inhibitors, bortezomib and carfilzomib. Treatment with the new inhibitors induced 
accumulation of high molecular weight polyubiqutinated proteins in the cancer cell lines, 
indicative of inhibition of 26S proteasome and subsequent cancer cell death due to unfolded 
































Inhibition of the 26S proteasome is a recognised therapy for the treatment of certain 
haematological cancers, with bortezomib and carfilzomib (Figure 1) being FDA approved for the 
treatment of multiple myeloma. Several other proteasome inhibitors are currently in clinical 
trials.1 These proteasome inhibitors share some common structural features, with a linear 
peptide backbone and a C-terminal electrophile that forms a covalent bond with N-terminal 
threonine of β1, β2, or β5 catalytic subunits of the 26S proteasome. Bortezomib is a dipeptide 
boronic acid that reversibly inhibits chymotrypsin-like (CT-L) activity of the 26S proteasome by 
preferentially binding to the active site of the β5 subunit.2 However, at higher doses it also 
inhibits the caspase-like (C-L) and trypsin-like (T-L) activities associated with the β1 and β2 
subunits respectively. Studies have shown that bortezomib has broad off-target inhibitory 
effect on other proteases, which are likely to contribute to its multiple clinical side effects.3 In 
comparison, the C-terminal epoxyketone of carfilzomib is highly selective for β5 and β5i 
subunits with minimal cross reactivity to other proteases, allowing more sustained and specific 
inhibition of the 20S proteasome.4 While carfilzomib has reduced side effects compared to 
bortezomib, its C-terminal epoxyketone is highly unstable in vivo, resulting in a short plasma 
half-life (5-20 minutes) and, therefore, low tissue distribution.5 These shortcomings restrict the 
use of bortezomib and carfilzomib in treating multiple myeloma and mantle cell lymphoma. 
Despite excellent in vitro efficacy in preclinical models, these inhibitors have so far failed to 
show a similar clinical benefit in patients with solid tumours.6 This is likely associated with the 
low bio-stability and selectivity of carfilzomib and bortezomib.7,8 Thus, new proteasome 
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inhibitors are required with improved overall anti-cancer efficacy, especially for the treatment 
of solid cancers.  
Results and Discussion 
 
Here we report new peptidomimetic boronate-based 26S proteasome inhibitors (see 1a,b and 
2a,b in Figure 1) that have high specificity for β5 catalytic subunit and low toxicity to non-
malignant cells. Compounds 1a and 2a induced robust accumulation of high molecular weight 
proteins by inhibiting the 26S proteasome. Compared to bortezomib and carfilzomib, 
compound 1a was significantly more toxic towards many cancer cell lines tested. Importantly, 
both compounds displayed less toxicity towards non-malignant cell lines. The combination of 
high cancer cell cytotoxicity and low non-malignant cytotoxicity endows compounds 1a and 2a 
with excellent therapeutic potential.  
 
Figure 1. Structures of FDA-approved proteasome inhibitors bortezomib and carfilzomib and 




Previous reports9,10 have shown that the incorporation of a hydrophobic substituent, such as 
isoleucine, at P2 of peptidic aldehydes enhances selectivity for the CT-L activity over the T-L and 
C-L activities of the 20S proteasome. One such example (compound 3, Figure 2) shows an 
excellent in vitro activity of 21 nM for CT-L. This peptidic aldehyde also bears a unique aliphatic 
azide at P3 to provide additional opportunities for hydrogen bonding interactions with the 
active site. Compound 4, (Figure 2), with an O-allylated tyrosine at P2 and a pyrrole replacing 
the P3 residue and an associated peptide bond, also shows selectivity for the CT-L activity. The 
backbone pyrrole moiety reduces the peptide-like character of the inhibitor and defines the 
backbone into an extended conformation. However, C-terminal aldehyde-based 
peptidomimetics of type 3 and 4 are known to react with a variety of other proteases, e.g. 
chymotrypsin11,12, calpains13,14 and cathepsins.15,16 Here we replace the aldehyde with a 
boronic pinanediol ester (highlighted in pink, Figure 1), a group reported to provide similar 
activity toward CT-L of the 26S proteasome compared to the corresponding boronic acid,17 
while being easier to prepare and purify. The chiral ester also defines the absolute 
configuration of the P1 group introduced during synthesis and negates the need for a final and 
somewhat problematic deprotection to produce boronic acid. Target compounds 1a and 2a 
have a leucine at P1 as found in known proteasome inhibitors such as bortezomib and 
carfilzomib.18-20 In comparison, compounds 1b and 2b have a phenylalanine at this position 
since the S1 binding pocket of the CT-L activity is known to favour the binding of a large 




Figure 2. Structures of proteasome inhibitors reported by Abell et al. The amino acid residues 
of the inhibitors are defined according to nomenclature developed by Schechter and 
Berger.22 
The key azide 6 was prepared by reacting Cbz-Lys-OH (5) with triflic anhydride and sodium azide 
under basic conditions. Subsequent EDCI-mediated coupling of azide 6 to Ile-OMe gave the 
dipeptide 7. Hydrolysis of the methyl ester of 7 in the presence of LiOH gave the free acid 8 in 
an excellent yield of 93%. This free acid was then coupled with amino boronate 9a,b17 in the 
presence of HATU, HOBt and DIPEA to give the target inhibitors 1a,b. 
 
Scheme 1. Synthesis of compounds 1a,b. 
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The key acid chloride 12 was prepared from commercially available methyl 3-(4-hydroxyphenyl) 
propionate (10) in three steps in an overall yield of 86%. Specifically, reaction of 10 with allyl 
bromide gave 11, the ester of which was hydrolysed with LiOH to give carboxylic acid 12. 
Reaction with SOCl2 gave the acid chloride 13, which was used in a Friedel-Crafts acylation of 
pyrrole 14,15 using Yb(OTf)3, to give the key dipeptide-mimic 15. Subsequent hydrolysis of the 
ester of 15 with KOH gave carboxylic acid 16, which was subsequently coupled with Tyr(All)-
OMe in the presence of HATU, HOBt and DIPEA to give diene 17 in 78% yield over two steps. 
The methyl ester of diene 17 was hydrolysed with NaOH to give free acid 18 in excellent yield. 
HATU-mediated coupling of 18 with amino boronates 9a,b gave the target inhibitors 2a,b.  
 
The 20S proteasome exhibits T-L, C-L and CT-L protease activities. Of the three activities, the CT-
L activity carries out the bulk of the proteolytic breakdown, and is the most common target of 
pharmacologically designed proteasome inhibitors.23 Therefore, we first evaluated whether 
the compounds 1a,b and 2a,b were potent and selective for the CT-L activity.  
 
As expected, both bortezomib and carfilzomib were highly potent inhibitors of CT-L activity in 
this assay with IC50 values of 34.6 nM and 23.1 nM respectively. Bortezomib also significantly 
inhibited the C-L activity, which is consistent with a previous report.24 The new peptidic 
boronates 1a,b and 2a,b were also highly active against the CT-L activity, with derivatives 1a,b 
and 2a proving to be more potent than bortezomib and carfilzomib. The most potent inhibitor 
in this series, 1a, has an IC50 of 14.1 nM against the CT-L activity, which is more than 2-fold 




Scheme 2. Synthesis of compounds 2a,b. 
inhibited the CT-L activity with higher potencies compared to the inhibitors bearing a P1 
phenylalanine (1b, 2b), suggesting that the S1 subsite of β5 subunit favours the binding of 
branched hydrophobic amino acids over planar aromatic residues. Unlike bortezomib, all of the 
compounds were at least 10-fold less active against the C-L activity compared to the CT-L 
activity. Compound 2a was the most selective inhibitor of CT-L over C-L, with a 200-fold 
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difference in activities. Following administration of carfilzomib, patients display less of the 
“typical” toxicities associated with bortezomib, and this has been attributed to its higher 
selectivity for inhibiting CT-L activity over T-L, C-L as well as other serine proteases’ activities. 
Therefore, the combination of excellent potency and high selectivity for the CT-L activity 
observed for the peptidic boronates 1a,b and 2a,b provides an opportunity to reduce side 
effects associated with the low subunit selectivity of bortezomib and limit drug resistance 
caused by the mutation in CT-L activity of the proteasome found in bortezomib-resistant cell 
lines.25 
 
Table 1. Inhibition of purified 20S proteasome from rabbit reticulocytes by compounds 1a,b, 
2a,b, bortezomib and carfilzomib. 
 IC50 
 (CT-L) (nM)a 
IC50 
 (T-L) (nM)a 
IC50 
 (C-L) (nM)a 
1a 14.1 ± 4.2 >25000 1598.0 ± 98.3 
1b 21.0 ± 4.4 >25000 2448.3 ± 73.2 
2a 20.9 ± 7.7 >25000 4179.0 ± 341.4 
2b 104.0 ± 15.9 >25000 3343.3 ± 416.1 
bortezomib 34.6 ± 4.2 >25000 108.4 ± 34.0 
carfilzomib 23.1 ± 4.4 >25000 >25000 




We next investigated whether the high potency and selectivity of 1a and 2a for CT-L activity 
translated into improved cytotoxic activity against cultured cancer cell lines. The cytotoxic LD50 
 across a panel of sarcoma, ovarian, breast and myeloma cell lines was determined using 7AAD 
assays following a 48 h exposure to titrations (0-5000 nM) of 1a, 2a, bortezomib and 
carfilzomib. Viability studies were also performed with a non-malignant breast epithelial cell 
line MCF-10A, a primary human lung fibroblasts cell line IMR-90, a primary human skin 
fibroblast line NDF and a normal human immortalised lymphoblastoid cell line LCL, thus 
allowing us to determine if the cytotoxicity of these compounds was cancer cell-specific. 
 
Compounds 1a and 2a were both potent cytotoxic agents and dose-dependently decreased cell 
viability. Of the two inhibitors, in both solid and liquid cancer cell lines, compound 1a 
consistently resulted in equal or greater cytotoxicity compared to bortezomib and carfilzomib. 
Myeloma cell lines are known to be highly sensitive to proteasome inhibitors. Consistent with 
this, the myeloma cell lines NCI-H929 and U266 showed the highest levels of sensitivity, with 
LD50 values of 6.4 nM and 15 nM, respectively. Sensitivity to compound 1a varied considerably 
between solid cancer cell lines, with LD50 values ranging from 35 nM in the RD-ES sarcoma cell 
line to 1500 nM in the MCF-7 breast carcinoma cell line. In particular, compound 1a induced 
cell death in the Ewing sarcoma cell line WE-68 (LD50 35 nM) and ovarian cancer cell line SK-OV-
3 (LD50 370 nM) at significantly lower doses compared to bortezomib (100 nM; 1600 nM 
respectively, p<0.01; n=3). Importantly, the cytotoxicity of compounds 1a and 2a was more 
specific to cancer cells, compared to bortezomib and carfilzomib. Compound 1a was 
approximately 3-fold, and compound 2a 6-fold less toxic to non-malignant cells compared to 
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bortezomib. The relative sensitivity of the cell lines to each inhibitor was essentially identical, 
suggesting a common mechanism of cytotoxic action of each inhibitor in a particular cell line. 
 
Table 2. Cytotoxicity of proteasome inhibitors against a panel of solid cancer cell lines or non-
malignant cell lines. 






























































































































aDose-response curves are provided in Supporting Information. *indicates statistical 
significance (<0.05) compared to bortezomib. ND-not determined. 
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Previous studies report that inhibition of the proteasome causes stabilisation of the tumour 
suppressor p53, leading to activation of downstream pathways and as a consequence cancer 
cell cycle arrest or cell death.26,27 Therefore, to determine if the cell death observed upon 
treatment with 1a and 2a was influenced by p53 signalling, a pair of p53 wild-type and p53 
mutant/null cell lines were used for each cancer type. There was no significant difference 
between the average LD50 values of the p53 wild-type and p53 mutant/null cell lines (Figure S2, 
supporting information), albeit there was considerable variation within each cancer type. In 
multiple myeloma and ovarian cancer, p53-proficient cell lines NCI-H929 and KGN were 
approximately 2-fold and 5-fold more sensitive than U266 and SKOV-3 cell lines in which p53 
was mutated or null. However, in breast cancer cell lines the trend was reversed, with p53 
mutated cell line MDAMB-468 being markedly more sensitive than MCF7 with wild-type p53. As 
the overall pattern of sensitivity of the cell lines was individually consistent across a small 
library of proteasome inhibitors (bortezomib, carfilzomib, 1a and 2a), it is possible that 
stabilization of p53 may mediate cytotoxic effects in a cancer or tissue dependent manner. 
 
Next, the accumulation of polyubiquitinated proteins in intact cells was analysed to verify that 
the observed cell death was a result of proteasome inhibition by compounds 1a/2a. Cellular 
proteins destined for degradation are first “tagged” with multiple ubiquitin molecules to be 
recognised by the 26S proteasome. Therefore, inhibition of the proteasome results in rapid 
accumulation of high molecular weight polyubiquitin-conjugated proteins, which can be 
detected with an anti-ubiquitin antibody. Western blot analyses revealed that treatment with 
35 nM of compounds 1a and 2a for 4 h substantially increased high molecular weight 
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polyubiquitinated proteins in both MDA-MB-468 and MCF7 cell lines (Figure 3). This 
observation excludes the possibility that reduced uptake of proteasome inhibitors by MCF7 is 
responsible for the cytotoxic insensitivity of this cell line. For both 1a and 2a, the extent of 
polyubiquitin accumulation was quantitatively similar to that observed using bortezomib. This is 
largely consistent with cytotoxic efficacies observed for these compounds. Defects or mutations 
in downstream signalling pathways that drive proteasome inhibitor mediated cell death are 
likely responsible for the variation in sensitivity seen across cell lines. However, the mechanism 
that drives cell death requires further assessment and falls outside the scope of this study. 
 
Figure 3. Compounds 1a and 2a induce accumulation of high molecular weight ubiquitin 
conjugates. MDAMB468 and MCF7 were treated with 35 nM of compounds 1a, 2a, bortezomib 
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or carfilzomib for 4 h, and Western blots of cell homogenates hybridised to an anti-ubiquitin 
antibody. β-tubulin was used as a loading control. 
 
In summary, we report examples of a new class of proteasome inhibitor 1a,b and 2a,b with 
improved in vitro activity against the purified enzyme and higher specificity for the CT-L activity 
compared to bortezomib. Inhibitor 1a was shown to be significantly more cytotoxic against 
solid tumour cells compared to both bortezomib and carfilzomib. More importantly, 1a 
provides a larger therapeutic window than the benchmarks for all tested tumour types 
including myeloma. We also demonstrate that the observed cytotoxicity of compounds 1a and 
2a was due to inhibition of the 26S as Western blot analysis of the cell lines treated with these 
compounds showed a significant accumulation of polyubiquitinated proteins as a result of 
decreased proteasome function. Thus compound 1a is an attractive drug candidate that offers 
potential benefits as it is predicted to possess reduced clinical side effects compared to the 
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Methods and Materials 
 
General Information 
Bortezomib (Selleckchem, Houston, TX, USA), Carfilzomib (Selleckchem, Houston, TX, USA), or 
in-house generated derivatives were dissolved in 10 mM DMSO and stored at −20 °C. 
Antibodies used for western blot analysis included a mouse anti-tubulin (Sigma), anti-ubiquitin 
(Cell Signalling), sheep anti-mouse IgG-HRP (GE, USA), or donkey anti-rabbit IgG-HRP (GE, USA). 
All human cell lines (WE-68, RD-ES, SKOV3, KGN, MCF7, MDA-MB-468, NCI-H929, U266, MCF-
10A, and IMR-90) were purchased from American Type Tissue Culture. WE-68, NCI-H929, U266, 
MCF7 and LCL cell lines (established from a normal individual) were grown in RPMI-1640 media. 
RD-ES, MDA-MB-468, SKOV-3, KGN and a primary human embryonic fibroblast cell line were 
grown in Dulbecco’s Modified Eagle’s Medium (DMEM). The medium was supplemented with 
10% FCS, 1% PSG and 10 mM HEPES. MCF-7 cells were supplemented with 1% insulin. All cells 
were maintained at 37 °C in a humidified atmosphere of 5% CO2. 
 
 In Vitro Proteasome Activity Assay  
 
Proteasome CT-L, C-L and T-L activities were determined using hydrolysis of specific short 
peptide substrates conjugated to the fluorescent tag 7-amido-4-methylcoumarin (AMC). 
Purified rabbit 20S proteasome and fluorogenic CT-L substrate (Suc-Leu-Leu-Val-Tyr-AMC) were 
purchased from Boston Biochem (Cambridge, MA, USA). The T-L and C-L fluorogenic substrates 
(Bz-Val-Gly-Arg-AMC and Ac-nLPnLD-AMC) were purchased from Enzo Life Sciences 
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(Farmingdale, NY, USA). Purified 20S proteasome (Enzo Life Sciences, Farmingdale, NY, USA) (0-
2 µg) was pre-incubated with the indicated concentrations of inhibitors at 37 °C for 15 minutes 
and subsequently added to the AMC-labelled substrate peptide (50 μM) in assay buffer (20 mM 
Tris-HCl, pH 7.5, 0.5 mM EDTA, and 0.001% SDS (w/v)) for a further 2 hours. Fluorescent 
substrate cleavage by the 20S proteasome was linear during this incubation period. Hydrolysed 
AMC was subsequently detected with the Synergy™ H4 Hybrid Multi-Mode Microplate Reader 
(BioTek, USA) at excitation/emission wavelengths of 390/460 nm. Hydrolysis activity was 
measured as relative fluorescence units allowing IC50  values to be calculated that represented 
half of the maximal inhibitory activity of the proteasome. A minimum of three biological 
replicates was performed for each data point. 
 
In Vitro α-chymotrypsin Activity Assay 
 
The activity of α-chymotrypsin was assayed spectrophotometrically at 25 ºC using Synergy H4 
Hybrid Multi-Mode Microplate Reader (Bio-Tek Instruments, Inc.). A solution of α-chymotrypsin 
(21.9 µg/mL) in 1 mM aqueous HCl was prepared fresh by a 1:40 dilution of a stock solution 
(874 µg/mL) in 1 mM aqueous HCl and kept on ice. A 1:100 dilution of the 21.9 µg/mL solution 
in ice-cold 1 mM aqueous HCl was prepared immediately before the start of each 
measurement. The assay was conducted in black 96-well plates as below: To each well were 
added Ala-Ala-Phe-7-AMC (Sigma Aldrich, Castle Hill, NSW) substrate in DMSO (5 µL, final 
concentrations = 0.25, 0.5 mM), α-chymotrypsin in 1 mM aqueous HCl (10 µL, final 
concentration = 4 nM), an inhibitor (0.25 nM-25 nM) in DMSO (10 µL) and N-
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[Tris(hydroxymethyl)methyl]-2-aminoethanesulfonic acid (TES) buffer (50 mM, pH 8.0, adjusted 
with NaOH) (175 µL). The excitation and emission wavelengths of the substrate were 380 nm 
and 460 nm respectively. Progress curves were monitored over 10 min for each concentration 
of every inhibitor. The Ki values of inhibitors were determined graphically according to Dixon 1 
using mean values of relative rates obtained from triplicate measurements at two different 
concentrations. 
 
Cell Viability Assays  
 
Cell viability assays were performed as previously described 2. Briefly, cells were seeded in 96-
well microtiter plates at a density of 3 × 104 cells per well in the presence of the indicated 
proteasome inhibitor. Cells were harvested 48 hours post-treatment, centrifuged at 1,300 × g, 
washed in phosphate-buffered saline (PBS), and stained with 7AAD solution (2 μg/mL) (7-
amino-actinomycin-D, Invitrogen, Carlsbad, CA) for 10 minutes at RT. Viable cells were 
determined using a FACS Calibur flow cytometer (Becton Dickinson Immunocytometry Systems) 
and analyzed with FLOWJO (Tree Star, Inc.) and GraphPad Prism (GraphPad Software Inc.). For 








 Western blot analysis 
 
Western blot analysis was performed as previously described 3. Whole protein lysates (5–
20 μg) were resolved using SDS PAGE electrophoresis, and probed overnight at 4 °C with the 
anti-Ubiquitin primary antibody (3933, 1:1000, Cell Signaling Technology). Chemiluminescent 
detection of protein was done using appropriate secondary antibody conjugated with 
horseradish peroxidase (Amersham) and the enhanced chemiluminescence kit according to the 



















Supplementary Figure S1: Dose response curves- Compound 1a 

























































Supplementary Figure S1: Dose response curves- Compound 1b 
























































Supplementary Figure S1: Dose response curves- Compound 2a  


























































Supplementary Figure S1: Dose response curves- Compound 2b 
























































Supplementary Figure S1: Dose response curves- Bortezomib 
























































Supplementary Figure S1: Dose response curves- Carfilzomib 




























Supplementary Figure S1: Dose-response curves for proteasome inhibitors on purified rabbit 
20S proteasome. The purified proteasome was incubated with the indicated concentrations of 
bortezomib, carfilzomib, compounds 1a,b and 2a,b and specific AMC-tagged peptide substrates 
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(Suc-Leu-Leu-Val-Tyr-AMC for CT-L, Bz-Val-Gly-Arg-AMC for T-L and Ac-nLPnLD-AMC for C-L) for 
2 h. Hydrolysed AMC was subsequently detected with the Synergy™ H4 Hybrid Multi-Mode 
Microplate Reader (BioTek, USA) at excitation/emission wavelengths of 390/460 nm. Dose-
response curves and IC50 values (concentration of proteasome inhibitor required to inhibit 50% 
of enzyme activity) were calculated using GraphPad Prism software (GraphPad Software Inc). 
 
Dose-response Curves for Cell Cytotoxicity Experiments 
 
Supplementary Figure S2: Dose response curves- Compound 1a 
RDES










































































































































































































































Supplementary Figure S2: Dose response curves- Compound 2a 
LCL




































































































































































































































Supplementary Figure S2: Dose response curves- Bortezomib 
MDAMB468










































































































































































































































Supplementary Figure S2: Dose response curves- Carfilzomib 
LCL





































































































































































































































Supplementary Figure S2: Dose-response curves for proteasome inhibitors on a panel of normal 
and cancer cell lines. WE-68 and RDES Ewings sarcoma cells, KGN and SKOV3 ovarian cancer 
cells, NCI-H929 and U266 multiple myeloma cells, MDAMB468 and MCF7 breast carcinoma cells 
(cancer cells) or primary lung and skin fibroblasts, immortalized non-malignant MCF10A or 
normal b-lymphoblastoids (normal cells) and were incubated with the indicated concentrations 
of bortezomib, carfilzomib, compounds 1a and 2a for 48 hours. The viability of the cell cultures 
was subsequently assessed following the protocol outlined in the Materials and Methods. Dose-
response curves and IC50 values (concentration of proteasome inhibitor required to kill 50% of 
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Although the FDA has approved the use of proteasome inhibitors for the treatment of multiple 
myeloma and refractory mantle cell lymphoma, their administration results in severe toxicities 
due to their non-specific damage to healthy tissue. Here, we have assessed whether a 
photopharmacological approach, using switchable moieties incorporated into the molecular 
structure of proteasome inhibitors can potentially be used to activate drugs specifically in 
cancerous tissue.  
 
This chapter is presented as a manuscript in preparation for submission to a journal for 
publication.  
 
Contribution by the candidate: All biological/cell line experimental work and manuscript writing 













A series of azobenzene-containing peptidic boronate esters was prepared and the activity of 
the thermally adapted states (TAS), enriched in trans isomer, and the photostationary states 
(PSS), enriched in cis isomer, for each compound were evaluated against β5 and β1 proteasome 
subunits. Compounds with a sterically demanding phenyl-substituted azobenzene at P2 (4c), 
and a less sterically demanding unsubstituted azobenzene at the N-terminus (5a), showed the 
greatest difference in activity between the two states. In both cases, the more active trans-
enriched TAS had activity comparable to bortezomib and delanzomib. Furthermore, cis-
enriched 4c inhibited tumor growth in both breast and colorectal carcinoma cell lines. 

















The 26S proteasome is a supramolecular protein assembly that plays a pivotal role in the 
degradation of proteins that regulate the cell cycle.1 Its over activity is associated with the 
development and progression of some cancers and as such it has recently been identified as an 
attractive target for anticancer drugs, particularly for the treatment of multiple myeloma 
(MM).2 Its substrates are degraded at three sites located within the inner cavity of the 
component 20S proteasome, i.e., chymotrypsin-like (β5), trypsin-like (β2), and caspase-like (β1) 
subunits. 3; 4; 5 ;  6 The clear link between the proteasome and the development of a number of 
human diseases has encouraged the development of a range of inhibitors and an evaluation of 
their therapeutic potential. 7; 8; 9; 10; 11; 12; 13; 14 ;15. In fact, the FDA has now approved three 
such inhibitors (bortezomib (1), carfilzomib and ixazomib) for the treatment of multiple 
myeloma and refractory mantle cell lymphoma, with others in development. 16; 17 ; 18 Several 
other proteasome inhibitors have entered clinical trials, including delanzomib (2) and 
oprozomib.19 While delanzomib20 is reported to overcome resistance reported for 
bortezomib in vitro, 21 it shows limited efficacy in the treatment of other types of cancer. It also 
displays severe side effects due to non-specific cytotoxicity towards healthy tissue 
(Fig. 1). 22 ;  23 
 
 






There is a clear need to develop new proteasome inhibitors with improved safety and efficacy 
profiles. One approach described herein is to develop inhibitors that undergo specific activation 
at the site of action, e.g., through the action of light.24 Light is ideally suited to control the 
activity of a pharmacophore as it can be delivered with very high spatiotemporal 
precision.25 With this in mind, Feringa et al.26 recently reported an analogue of bortezomib 
containing an N-terminal azobenzene, see structure 3 in Fig. 2. A photostationary state (PSS) 
of 3 enriched in the cis isomer proved to be moderately (two- to three-fold) more active than a 
thermally adapted state (TAS) enriched in the transisomer, with the magnitude of difference 
showing some dependence on the nature of the component azobenzene. Related studies have 
been carried out on other proteases. 27;28 ;  29 We now report studies on an extended series of 
photoswitchable proteasome inhibitors with a number of different azobenzenes at the N-
terminus (see 5) and at P2 (see 4), to further investigate the effect of azobenzene substitution 
on activity and also to explore the S2 binding site 30 ;  31 as an alternative site for modification. 
All compounds contain a boronate ester, rather than the boronic acid of bortezomib and 
delanzomib, with this prodrug presenting similar potency while being easier to 
prepare. 32 ;  33 The P2 positioned azobenzene of 4 replaces the phenylalanine of bortezomib, 
where this site is known to accommodate larger groups.5 The N-terminal azobenzene-based 
peptide boronates 5 provide an opportunity to investigate the influence of an alternative 
backbone sequence with a threonine at P2 as found in delanzomib. Azobenzene substituents 
were chosen to investigate potential steric effects and to expand on earlier studies. 
Synthetic trans-enriched azobenzenes 4 and 5 were photochemically isomerized to give an 
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alternative PSS enriched in the cis isomer. All states were assayed against 






Figure 2. Photoswitchable proteasome inhibitors 3. Residues are designated P1, P2 etc from 
the boronic acid, where these groups interact with corresponding proteasomal specificity 
pockets according to the nomenclature of Schechter and Berger. 34. 
 
Figure 3. Photoswitchable target compounds 4 and 5. 
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The bortezomib analogues 4a–c were prepared as shown in Scheme 1. The key 
intermediates 8b and 8c were prepared by oxidation of the aniline 6 to the nitroso 
derivative 7 using Oxone® followed by condensation with the appropriate aniline. The other key 
intermediate 8a was synthesized by condensation of 6 directly with commercially available 
nitrosobenzene. The proposed inhibitors 4a–c were then prepared by coupling of 8a–
c with 935 ;  36 using N,N,N′,N′-tetramethyl-O-(benzotriazol-1-yl)uronium tetrafluoroborate 
(TBTU) as the coupling agent. The alternative delanzomib derivatives 5a–c, containing an N-
terminal azobenzene, were synthesized as outlined in Scheme 2. The key 
azobenzenes 12b and 12c were prepared by oxidation of the aniline 10 to the nitroso 1137 using 
Oxone® followed by condensation with the corresponding aniline. The remaining key 
azobenzene 12a was prepared by condensation of 10 directly with commercially available 
nitrosobenzene. TBTU mediated coupling of 12a–c with 1338then gave the desired boronate 






Proteasome inhibitory activities 
 
1H NMR analysis of compounds 4–5 in DMSO-d6 revealed an initial TAS strongly 
enriched in the trans isomer, with the results shown in Table 1a. A solution of each 
compound in DMSO-d6 (∼1 mg/mL) was then irradiated with UV light using a UVP 
BL6SV lamp (λ = 365 nm) for 1 h to give the corresponding cis-enriched PSS of 4–5. 1H 
NMR again defined the trans/cis compositions, with the results also shown in Table 1a. 
All compounds analysed after irradiation gave a PSS strongly enriched in the cis isomer 
(>76%), with the exception of 5a with its relatively small N- terminal azobenzene 
(46% cis). Compound 5c, with its sterically large N-terminal  azobenzene, gave the 
highest enrichment of cis isomer (92%). In comparison, compounds with a less 
sterically demanding azobenzene substituent (as in 4a and 5a) give the highest isomer 
differential prior to UV irradiation, with the trans isomer being the major in this case. 
 
Scheme 1. Synthesis of photoswitchable inhibitors 4. Reagents and conditions: i) Oxone®, 
DCM:water, RT, 3 h; ii) ArNH2, DMSO, HOAc, 60 °C, O/N; iii) Nitrosobenzene, HOAc, RT, 







Scheme 2. Synthesis of photoswitchable inhibitors 5. Reagents and conditions: i) 
Oxone®, DCM:water, RT, 4 h, (71 %); ii) ArNH2, DMSO, HOAc, 60 °C, O/N; iii) 








Table 1. a) trans/cis ratios of compounds 4–5 before and after irradiation ( = 365 nm, in DMSO-d6). b) IC50 
 (nM) values for compounds 4–5, bortezomib and delanzomib at 5 and 1 active sites before and after irradiation (365 nm 
light). 
 
Active site Compound 4a  4b  4c  Bort. 5a  5b  5c  Delanz. 
a)  non-irradiated (trans/cis) 99:1 91:9 95:5 - 97:3 78:22 77:23 - 
  irradiated (trans/cis) 17:83 11:89 16:84 - 54:46 24:76 8:92 - 
b) 5 trans 10 53 11 5.4 17 55 22 10 
  cis 12 41 54 7.9 84 249 29 12 
  fold 1.2 1.3 5 1.5 5 4.5 1.3 1.2 
           
 1 trans 107 211 460 76 868 1624 498 59 
  cis 110 214 303 70 759 1633 1088 55 
  fold 1.1 1 1.5 1 1.1 1 2 1.1 






Both states of 4 and 5 were then evaluated for inhibitory activity 
against β5 and β1proteasome subunits and the results are shown in Table 1b. 
IC50 values were determined graphically according to Dixon methodology and as 
detailed in Supplementary data.39Potency data is also included in Table 1b for 
bortezomib and delanzomib for comparison. All azobenzene derivatives inhibited 
the β5 and β1 active sites, with IC50 values ranging from low nanomolar to micromolar. 
Compounds were generally more potent against β5than β1, with 
critical β5 potency 5 being similar to that of bortezomib and delanzomib. The non-
irradiated (trans-enriched) TASs of 4a, 4c and 5a were the most potent, with IC50values 
of 10, 11 and 17 nM, respectively. It is interesting to note that a large azobenzene is 
generally well tolerated in both series, with both 4c and 5c showing good β5 potency. 
The incorporation of an azobenzene into the structures does somewhat compromise 
activity against β1, especially for those derivatives containing an N-terminal 
azobenzene (5). The best photoswitching of activity was obtained with 
compounds 4c, 5a and 5b, with an approximate 5-fold decrease in β5 activity observed 
on irradiation in each case. The result for 5a is particularly significant given that 
irradiation only gave modest isomerism to the cis isomer, see Table 1a. A more 
hindered azobenzene at P2 (4c) but less hindered N-terminal azobenzene (5a and 5b) 
gave the best photoswitching of activity. The effect on β1 activity is both less 










Effect of compounds on cells 
 
The bortezomib analogue 4c, with a combination of the most potent β5 activity, good 
conversion to the cis isomer (84% cis) and the best differential in activity between the 
two states (5-fold), was investigated further to define global cytotoxicity against 
different cell lines. Colon colorectal (HCT-116) and breast carcinoma (MDA-MB-468) 
cancer cell lines were chosen for these studies as they are known to be sensitive to 
proteasome inhibitors. 40 ;  41 Cytotoxic LD50 values were determined using 7AAD 
assays following a 48 h exposure to titrations (0–5000 nM) with the results shown 
in Fig. 3. 
Interestingly, the cis-enriched PSS of 4c proved to be more active against both cell 
lines, despite it being less active than the corresponding trans-TAS against the 
proteasome β5subunit (see Table 1). This is an important finding for potential 
photopharmacological applications that necessarily require photoactivation at the site 
of action. In particular, cis-enriched 4c induced cell death in the colon colorectal cancer 
cell line HCT-116 with a LD50 of 212 nM compared to 1.03 µM for trans-enriched 4c. 
Nearly full selectivity was observed at 310 nM, with cis-enriched 4c killing almost all 
cells (cell viability = 27%), and trans-enriched 4c having limited cytotoxicity (cell 
viability = 91%), see Fig. 4a. While the cis-enriched PSS of 4c is stable for >48 h in 
DMSO, it does undergo slow isomerism to the trans isomer in buffer without evidence 
of decomposition. The cytotoxicity of cis-enriched 4c is thus likely evident well before 
the 48 h time-course of the assay, where the trans-enriched state of 4c displays limited 
cytotoxicity. A diminished differential was observed between the two isomeric states 
against the MDA-MB-468 breast cancer cell line, with an LD50 of 144 nM and 246 nM 





Fig. 4. 4c-(trans)-TAS (blue) and 4c-(cis)-PSS (pink) apoptotic dose response curves 
against (a) colon colorectal HCT-116 and (b) breast carcinoma MB-468 cancer cell lines 






Fig. 5. 4c-(trans)-TAS (blue) and 4c-(cis)-PSS (pink) apoptotic dose response curves 
against normal cell line MDF-10A following 48 h of treatment. 
 
Interestingly, the cis-enriched PSS of 4c showed moderate cytoxicity against the non-
malignant MCF-10A cell line with an LD50 of 683 nM. In comparison, the trans-enriched 
state of 4c was inactive at the highest concentration tested (5000 nM) (Fig. 5). This 
suggests that the biological activity of the trans-TAS would be low in healthy tissue, to 






















In summary, a series of photoswitchable proteasome inhibitors was designed, 
synthesized and evaluated for activity against β5 and β1 proteasome subunits. The 
most active inhibitors displayed activity comparable to bortezomib and delanzomib. 
Derivatives 4c, 5a and 5b gave the best photoswitching differential in activity against 
the β5 subunit, with an approximate 5-fold lower activity observed for cis-enriched 
PSSs. This compares to a somewhat more modest two- to three- fold increase in 
activity observed for a cis-enriched PSS of bortezomib analogues 3.26 The sterically less 
demanding N-terminal azobenzene of 5a appears to particularly favor photoswitching 
of activity, given that irradiation in this case only gave modest isomerism to the less 
active cis isomer. The cis-enriched PSS of bortezomib derivative 4c displayed good 
cytotoxicity to proteasome inhibitor-sensitive cancer cell lines, with LD50 values of 212 
and 144 nM against the colon colorectal cancer HCT-116 and the breast carcinoma 
MB-468 cell lines, respectively. The corresponding trans-TAS displayed significantly 
lower cytoxicity, particularly against the colon colorectal cancer cell line. Importantly, 
the trans-enriched TAS of 4c was devoid of cytotoxicity against a non-malignant breast 
epithelial cell line MCF-10A. This suggests that the more stable trans isomer should 
have reduced side effects to facilitate and reinforce any potential therapeutic effect of 
the cis isomer. Further studies to investigate any off-target effects of the compounds 
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a. Chemical Synthesis 
General Information. Unless otherwise indicated, all starting materials and reagents 
were purchased from AK Scientific or Sigma-Aldrich and used without further 
purification. The boronic ester 13 was prepared following literature procedures.1 TLC 
analysis was performed on 60 F254 Silica gel TLC plates, and spots were visualised under 
UV light (254 nm) and using either CAM or KMnO4 stains. LC60A 40-63 micron silica 
was used for flash chromatography purifications. 1H and 13C NMR spectra were 
obtained using either an Agilent DD2 console 500 MHz or a Varian Inova 600 MHz 
spectrometer, at the indicated frequencies, using either CDCl3, CD3OD or DMSO-d6. 1H 
chemical shifts are reported in ppm (δ) to 2 decimal places and 13C chemical shifts are 
reported in ppm to 1 decimal place. 1H coupling constants are reported to 1 decimal 
place. Infra-red spectra were obtained using a PerkinElmer FTIR 100 spectrometer 
(ATR), and all peaks are reported to 1 decimal place. HRMS (ESI) spectra were recorded 
using an Agilent QTOF HRMS and m/z masses are reported to 4 decimal places. 
Chemical structures and their systematic names were generated using ChemDraw 
Ultra 12.0. A UVP BL6SV lamp (358 nm) was used as the UV light source in 
photoswitching experiments. 
Abbreviations used: NMM: N-methylmorpholine; TBTU: N,N,N',N'-tetramethyl-O- 
(benzotriazol-1-yl)uronium tetrafluoroborate; DCM: dichloromethane; MgSO4: 
magnesium sulfate; DMSO: dimethyl sulfoxide; DIPEA: N,N-Diisopropylethylamine; 
EtOAc: ethyl acetate;  








(phenyldiazenyl)phenyl)propanoic acid (8a) 
Nitrosobenzene (346 mg, 3.23 mmol, 1 eq) and and 4-aminophenylalanine (500 mg, 
1.78 mmol, 1.1 eq) were added to acetic acid (15 mL) and the mixture was stirred at 
room temperature for 12 h. The solution was diluted with water, extracted with DCM, 
dried over MgSO4 and the solvent evaporated under reduced pressure. Purification by 
flash chromatography (20% EtOAc:Hexane) gave 8a (537 mg, 82%) as an orange foam. 
1H NMR (500 MHz, CDCl3) δ 7.90 (d, J = 7.3 Hz, 2H, 2xArH), 7.87 (d, J = 8.3 Hz, 2H, 
2xArH), 7.537.44 (m, 3H, 3xArH), 7.34 (d, J = 8.2 Hz, 2H, 2xArH), 4.98 (d, J = 7.1 Hz, 1H, 
NH), 4.66 (dd, J = 12.8, 6.8 Hz, 1H, TyrH), 3.30 (dd, J = 13.7, 5.1 Hz, 1H, 
TyrCHH), 3.17 (dd, J = 13.7, 6.0 Hz, 1H, TyrCHH) and 1.43 (s, 9H, C(CH3)3) ppm. 
13C NMR (126 MHz, CDCl3) δ 176.1, 155.5, 152.8, 151.9, 139.4, 131.1, 130.3, 129.2, 
123.1, 123.0, 80.6, 54.4, 38.0 and 28.4 ppm. 
HRMS (ESI) calcd for C20H23NaN3O4 (M+Na)+ 392.1586, found 392.1584. 





Synthesis of (S,E)-2-((tert-butoxycarbonyl)amino)-3-(4-((3,5-dimethylphenyl)diazenyl) 
phenyl)propanoic acid (8b) 
A biphasic mixture of 4-aminophenylalanine 6 (500 mg, 1.8 mmol, 1 eq) and Oxone® 
(1.6 g, 5.34 mmol, 3 eq) in DCM (25 mL) and water (13 mL) was stirred vigorously at 
room temperature for 3 h. The organic layer was separated and the aqueous layer was 
extracted with DCM (x2). The combined organic layers were washed with brine, dried 
over MgSO4, filtered and evaporated under reduced pressure. Crude 7 was used 
immediately in the next step and without further purification. 
To a solution of 7 (524 mg, 1.8 mmol, 1 eq) and 3,5-dimethylaniline (0.17 mL, 1.42 
mmol, 0.8 eq) in DMSO (4.5 mL) was added acetic acid (0.4 mL) and the mixture was 
stirred at room temperature for 18 h. The crude product was partitioned between 
water and EtOAc and the organic phase was washed with water (x2). The organic 
phase was dried over MgSO4, filtered and evaporated under reduced pressure. 
Purification by flash chromatography (30-50% EtOAc:hexane) gave 8b (103 mg, 15%) as 
an orange solid. 
1H NMR (500 MHz, CD3OD): δ 7.80 (d, J = 8.1 Hz, 2H), 7.48 (s, 2H), 7.39 (d, J = 8.1 Hz, 
2H), 7.12 (s, 1H), 4.42 (dd, J = 8.7, 5.0 Hz, 1H), 3.25 (dd, J = 13.8, 4.9 Hz, 1H), 3.00 (dd, J 




13C NMR (125 MHz, CD3OD): δ 175.4, 157.7, 154.1, 152.8, 142.3, 140.0, 133.6, 131.2, 
123.7, 121.5, 80.5, 56.2, 38.6, 28.7 and 21.3 ppm. 
HRMS (ESI) calculated for C22H28N3O4+ (M+H)+ 398.2074, found 398.2045. 
IR (ATR): νmax = 2922.1 and 2853.1 (NH and OH) and 1704.3 (CO)cm-1. 
 
Synthesis of (S,E)-3-(4-([1,1'-biphenyl]-4-yldiazenyl)phenyl)-2-((tert-butoxycarbonyl) 
amino)propanoic acid (8c) 
To a solution of 7 (524 mg, 1.8 mmol, 1 eq) and [1,1'-biphenyl]-4-amine (244 mg, 1.44 
mmol, 0.8 eq) in DMSO (4.5 mL) was added acetic acid (0.4 mL) and the solution stirred 
at room temperature for 18 h. The crude product was partitioned between water and 
EtOAc and the organic phase was washed with water (x2). The organic phase was dried 
over MgSO4, filtered and evaporated under reduced pressure. Purification by flash 
chromatography (30-50% EtOAc:hexane) gave 8c (138 mg, 17%) as an orange solid. 
1H NMR (500 MHz, CD3OD): δ 7.97 (d, J = 7.9 Hz, 2H), 7.85 (d, J = 7.7 Hz, 2H), 7.78 (d, J 
= 7.8 Hz, 2H), 7.69 (d, J = 7.8 Hz, 2H), 7.497.41 (m, 4H), 7.38 (t, J = 7.3 Hz, 1H), 4.44 
(dd, J = 8.3, 4.9 Hz, 1H), 3.27 (dd, J = 13.8, 4.5 Hz, 1H), 3.01 (dd, J = 13.4, 9.6 Hz, 1H) 




13C NMR (125 MHz, CD3OD): δ 175.1, 157.8, 153.1, 152.9, 145.1, 142.5, 141.3, 131.3, 
130.0, 129.0, 128.7, 128.1, 124.4, 123.8, 80.6, 56.1, 38.6 and 28.7 ppm. 
HRMS (ESI) calculated for C26H28N3O4+ (M+H) + 446.2074, found 446.2054. 
IR (ATR): νmax 3261.4 and 2923.1 (NH and OH) and 1719.8 and 1651.7 (CO) cm-1. 
 
Synthesis of tert-butyl ((2S)-1-(((1R)-3-methyl-1-((3aS,4S,6S)-3a,5,5-
trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)amino)-1-oxo-
3-(4-((E)-phenyldiazenyl)phenyl)propan-2-yl)carbamate (4a)  
A solution of 8a (117 mg, 0.31 mmol, 1 eq) and 9 (100 mg, 0.33 mmol, 1.05 eq) in DCM 
(3 mL) was cooled in ice. TBTU (99 mg, 0.31 mmol ,1 eq) and DIPEA (0.21 mL, 1.24 
mmol, 4 eq) were added, and the mixture was warmed to room temperature over 18 
h. The mixture was diluted EtOAc, washed with saturated ammonium chloride solution 
(x3), dried over MgSO4, filtered and evaporated under reduced pressure. Purification 
by flash chromatography (40% diethyl ether:hexane) gave 4a (76 mg, 95%) as an 
orange solid. 
1H NMR (500 MHz, CD3OD) δ 7.87 (m, 4H, 2xArH), 7.51 (m, 3H, 3xArH), 7.44 (d, J = 8.1 
Hz, 2H, ArH), 4.55 (t, J = 7.3 Hz, 1H, Tyr--H), 4.20 (d, J = 7.3 Hz, 1H, CH), 3.14 (dd, J = 
13.5, 7.3 Hz, 1H, Tyr--CHH), 3.05 (d, J = 8.0 Hz, 1H, Tyr--CHH), 2.70 (t, J = 7.7 Hz, CH), 




1H, CH), 1.80 (d, J = 14.1 Hz, 1H, CH), 1.531.44 (m, 1H, CH), 1.41 (d, J = 10.6 Hz, 1H, 
CH), 1.39 (s, 3H, CH3), 1.38 (s, 9H, 3xCH3), 1.27 (s, 3H, CH3), 1.24 (m, 2H, CH2), 0.86 (s, 
3H, CH3), 0.85 (d, J = 6.7 Hz, 3H, CH3) and 0.82 (d, J = 6.5 Hz, 3H, CH3) ppm. 
13C NMR (125 MHz, CD3OD) δ 177.3, 157.2, 154.0, 152.9, 141.2, 132.2, 131.4, 130.2, 
124.0, 123.7, 84.3, 80.8, 77.4, 54.2, 53.5, 41.6, 41.3, 39.1, 38.9, 37.6, 29.7, 28.6, 27.8, 
27.4, 26.5, 24.6, 23.6 and 22.2 ppm. 
IR (ATR) ʋ: 2931 (NH), 2346 (NN) and 1684 (C=O) cm-1. 
HRMS (ESI) calcd for C35H49BN4NaO5 (M+Na) + 639.3688, found 639.3699. 
 




Compound 4b was obtained as an orange solid (38 mg, 50%) using the above 
procedure. 
1H NMR (500 MHz, CD3OD): δ 7.84 (m, J = 8.2 Hz, 2H), 7.50 (s, 2H), 7.44 (d, J = 8.2 Hz, 
2H), 7.17 (s, 1H), 4.574.51 (m, 1H), 4.21 (dd, J = 8.4, 1.9 Hz, 1H), 3.13 (dd, J = 13.7, 7.3 
Hz, 1H), 3.04 (dd, J = 13.5, 8.1 Hz, 1H), 2.69 (t, J = 7.7 Hz, 1H), 2.40 (s, 6H, 2xCH3), 




1.821.77 (m, 1H), 1.49 (dd, J = 13.3, 6.3 Hz, 1H), 1.441.36 (m, 9H, CH3 + (C(CH3)3), 
1.29 (s, 4H), 0.88 (s, 3H, CH3), 0.86 (d, J = 6.3 Hz, 3H, CH3) and 0.83 (d, J = 6.5 Hz, 3H, 
CH3) ppm. 
13C NMR (150 MHz, CD3OD): δ 177.4, 157.7, 154.6, 153.4, 141.8, 140.5, 134.0, 131.7, 
124.2, 121.9, 85.2, 81.2, 78.0, 53.9, 41.7, 39.7, 37.7, 31.3, 30.0, 29.0, 28.1, 27.6, 27.1, 
24.9, 24.0, 22.7 and 21.6 ppm. 
HRMS (ESI) calculated for C37H54BN4O5+ (M+H)+ 645.4182, found 645.4141. 
IR (ATR): νmax = 2961.8 and 2923.6 (NH), 1695.4 and 1646.5 (CO) cm-1. 
 




Compound 4c was obtained as an orange solid (46 mg, 60%) using the above 
procedure. 
1H NMR (500 MHz, CDCl3) δ 7.98 (d, J = 8.1 Hz, 2H, 2xArH), 7.87 (d, J = 7.8 Hz, 2H, 
2xArH), 7.74 (d, J = 8.0 Hz, 2H, 2xArH), 7.66 (d, J = 7.9 Hz, 2H, 2xArH), 7.47 (s, 3H, 




CH), 4.25 (d, J = 8.4 Hz, 1H, CH), 3.233.07 (m, 3H, 3xCH), 2.29 (s, 1H, CH), 2.212.12 
(m, 1H, CH), 2.01 (t, J = 5.2 Hz, 1H, CH), 1.87 (s, 1H, CH), 1.80 (d, J = 14.4 Hz, 1H, CH), 
1.50 (dd, J = 13.1, 6.6 Hz, 2H, 2xCH), 1.42 (s, 9H, C(CH3)3), 1.38 (s, 3H, CH3), 1.281.22 
(m, 3H, CH3), 0.86 (d, J = 6.4 Hz, 6H, 2xCH3) and 0.80 (s, 3H, CH3) ppm. 
13C NMR (126 MHz, CDCl3) δ 173.9, 154.4, 146.3, 142.8, 132.9, 131.6, 130.6, 130.4, 
129.8, 126.0, 125.8, 88.5, 80.4, 79.9, 54.0, 42.8, 42.2, 41.0, 40.8, 38.2, 31.2, 30.9, 29.8, 
29.0, 28.0, 26.7, 25.7 and 24.6 ppm. 
HRMS (ESI) calcd for calculated for C27H29N3O4Na+ (M+Na) + 482.2050, found 482.2020. 
IR (ATR) ʋ: 3377.8 and 2982.8 (NH), 1694.6 and 1515.8 (C=O) cm-1. 
 
Synthesis of 3-nitrosobenzoic acid (11)2 
3-Aminobenzoic acid 10 (1 g, 7.2 mmol, 1 eq) was dissolved in DCM (18 mL). A solution 
of Oxone® (4.4 g, 14.4 mmol, 2 eq) in water (80 mL) was added and the solution stirred 
under nitrogen for 3 h. The precipitate was filtered and washed with water, to give 11 
as a beige solid (1 g, 91%). 
 
Synthesis of (E)-3-(phenyldiazenyl)benzoic acid (12a)3 
                                                        




A solution of nitrosobenzene (171 mg, 1.6 mmol, 1 eq) in glacial acetic acid (13 mL) 
was added to a suspension of p-aminobenzoic acid (263 mg, 2.24 mmol, 1.4 eq) in 
glacial acetic acid (13 mL) and the mixture was stirred at room temperature for 18 h. 
Excess water was added and the precipitate was filtered and washed with water, to 
give 12a (341 mg, 94%) as an orange solid.  
 
Synthesis of (E)-3-((3,5-dimethylphenyl)diazenyl)benzoic acid (12b) 
A solution of 11 (150 mg, 1 mmol, 2.5 eq) in DMSO (2.5 mL) and 3,5-dimethylaniline 
(0.1 mL, 0.8 mmol, 1 eq) in acetic acid (0.23 mL) was stirred at room temperature for 
18 h. Excess water was added and the precipitate was filtered and washed with water, 
to give 12b (340 mg, 57%) as a brown solid. 
1H NMR (500 MHz, DMSO-d6) δ 13.25 (s, 1H, OH), 8.36 (s, 1H, ArH), 8.12 (t, J = 8.4 Hz, 
2H, 2xArH), 7.74 (t, J = 7.8 Hz, 1H, ArH), 7.56 (s, 2H, 2xArH), 7.25 (s, 1H, ArH) and 2.39 
(s, 6H, 2xCH3) ppm. 
13C NMR (125 MHz, DMSO-d6) δ 166.7 (C), 152.0 (C), 151.9 (C), 138.8 (2xC), 133.3 (CH), 
132.2 (C), 131.7 (CH), 129.9 (CH), 127.4 (CH), 122.0 (CH), 120.5 (2xCH) and 20.8 (2xCH3) 
ppm. 
HRMS (ESI) calcd for C15H15N2O2 (M+H) + 255.1128, found 255.1135. 
IR (ATR) ʋ: 3224 (OH), 2345 (NN) and 1683 (C=O) cm-1. 
                                                                                                                                                                  
3 Fatás, P., Longo, E., Rastrelli, F., Crisma, M., Toniolo, C., Jiménez, A. I., Cativiela, C. and Moretto, A. 





Synthesis of (E)-3-([1,1'-biphenyl]-4-yldiazenyl)benzoic acid (12c) 
To a solution of 11 (300 mg, 2 mmol, 2.5 eq) in DMSO (5 mL) was added [1,1'-
biphenyl]-4-amine (268 mg, 1.58 mmol, 1 eq) in acetic acid (0.5 mL) and the solution 
was stirred at room temperature for 18 h. Excess water was added and the precipitate 
was filtered and washed with water, to give 12c (340 mg, 57%) as a brown solid. 
1H NMR (500 MHz, CDCl3) δ 8.68 (s, 1H, ArH), 8.24 (d, J = 7.6 Hz, 1H, ArH), 8.20 (d, J = 
7.8 Hz, 1H, ArH), 8.06 (d, J = 8.3 Hz, 2H, 2xArH), 7.79 (d, J = 8.4 Hz, 2H, 2xArH), 7.68 (dd, 
J = 17.5, 7.6 Hz, 3H, 3xArH), 7.50 (t, J = 7.6 Hz, 2H, 2xArH) and 7.42 (t, J = 7.3 Hz, 1H, 
ArH) ppm. 
13C NMR (126 MHz, DMSO-d6) δ 166.7 (C), 152.0 (2xC), 138.9 (2xC), 132.2 (C), 130.0 
(2xCH), 129.1 (2xCH), 128.8 (2xCH), 127.8 (CH), 127.5 (2xCH), 126.9 (2xCH), 125.9 (CH) 
and 123.4 (CH) ppm. 
HRMS (ESI) calcd for C19H15N2NaO2 (M+H) + 303.1128, found 303.1151. 








A solution of 12a (35 mg, 0.15 mmol, 1.1 eq) and 13 (56 mg, 0.14 mmol, 1 eq) in N,N-
dimethylformamide (0.2 mL) was cooled in ice and to this was added TBTU (53 mg, 
0.16 mmol, 1.1 eq) and NMM (66 L, 0.6 mmoL, 4 eq). The mixture was warmed to 
room temperature over 18 h. Excess EtOAc was added and the mixture washed with 
saturated ammonium chloride solution (x3), dried over MgSO4, filtered and evaporated 
under reduced pressure. Purification by flash chromatography (30-40% EtOAc:hexane) 
gave 5a (21 mg, 26%) as an orange solid. 
1H NMR (500 MHz, CDCl3) δ 8.33 (s, 1H, ArH), 8.10 (d, J = 7.7 Hz, 1H, ArH), 7.96 (d, J = 
6.9 Hz, 3H, 3xArH), 7.63 (t, J = 7.7 Hz, 1H, ArH), 7.587.51 (m, 3H, 3xArH), 4.59 (s, 1H, 
Thr--H), 4.53 (d, J = 21.7 Hz, 1H), 4.29 (d, J = 8.3 Hz, 1H, Leu--H), 3.34 (m, 2H, Thr--
H + CHH), 2.312.23 (m, 1H), 2.16 (m, 1H), 1.97 (t, J = 5.5 Hz, 1H), 1.85 (m, 1H), 1.77 
(dd, J = 14.5 Hz, 1H), 1.67 (m, 1H), 1.581.50 (m, 1H), 1.47 (m, 1H), 1.35 (s, 3H), 1.29 
(m, 3H, CH3), 1.23 (s, 3H), 1.20 (s, 3H), 0.92 (dd, J = 6.3, 3.2 Hz, 6H) and 0.79 (s, 3H) 
ppm. 
13C NMR (125 MHz, CD3OD) δ 167.8, 152.7, 152.5, 134.8, 131.6, 129.6, 129.6, 129.3, 
126.2, 123.2, 121.6, 86.3, 78.1, 66.8, 56.8, 51.4, 39.8, 39.6, 38.3, 35.6, 28.6, 27.2, 26.4, 
25.7, 24.1, 23.2 and 22.1 ppm.  
IR (ATR) ʋ: 3311 and 2933 (OH and NH) and 1639 (C=O) cm-1. 









Compound 5b was obtained as an orange solid (17 mg, 20%) using the above 
procedure.  
1H NMR (500 MHz, CD3OD) δ 8.41 (s, 1H, ArH), 8.09 (d, J = 7.9 Hz, 1H, ArH), 8.03 (d, J = 
7.7 Hz, 1H, ArH), 7.68 (t, J = 7.8 Hz, 1H, ArH), 7.57 (s, 2H, 2xArH), 7.20 (s, 1H, ArH), 4.82 
(d, J = 3.5 Hz, 1H, Thr--H), 4.34 (s, 1H), 4.20 (d, J = 8.2 Hz, 1H, Leu--H), 2.862.81 (m, 
1H, Thr--H), 2.42 (s, 2H, 2xCH3), 2.372.30 (m, 1H), 2.162.11 (m, 1H), 1.97 (t, J = 5.3 
Hz, 1H), 1.85 (s, 1H), 1.831.72 (m, 2H), 1.53 (d, J = 10.3 Hz, 1H), 1.43 (dd, J = 13.7, 6.5 
Hz, 2H), 1.38 (s, 3H), 1.28 (d, J = 7.0 Hz, 6H), 0.93 (t, J = 6.3 Hz, 6H) and 0.86 (s, 3H) 
ppm. 
13C NMR (125 MHz, CD3OD) δ 177.5, 170.9, 155.3, 155.3, 141.5, 137.5, 135.4, 132.1, 
131.8, 128.4, 123.8, 123.0, 86.0, 78.8, 69.4, 59.4, 54.8, 42.6, 42.3, 40.6, 38.6, 30.9, 
29.0, 28.5, 28.1, 25.8, 24.8, 23.7, 22.5 and 21.5 ppm. 
IR (ATR) ʋ: 3316 and 2933 (OH and NH) and 1651 (C=O) cm-1. 









Compound 5c was obtained as an orange solid (10 mg, 13%) using the above 
procedure. 
1H NMR (500 MHz, CDCl3) δ 8.35 (d, J = 1.7 Hz, 1H), 8.128.09 (m, 1H), 8.04 (d, J = 8.5 
Hz, 2H), 7.96 (d, J = 7.8 Hz, 1H), 7.78 (d, J = 8.5 Hz, 2H), 7.717.67 (m, 2H), 7.64 (d, J = 
7.8 Hz, 1H), 7.50 (t, J = 7.6 Hz, 2H), 7.42 (d, J = 7.4 Hz, 1H), 7.31 (d, J = 8.0 Hz, 1H), 6.91 
(d, J = 5.7 Hz, 1H), 4.62 (dd, J = 7.9, 1.7 Hz, 1H, Thr--H), 4.54 (d, J = 21.1 Hz, 1H), 4.29 
(d, J = 10.8 Hz, 1H, Thr--H), 3.34 (dd, J = 15.4, 6.0 Hz, 1H, Leu--H), 3.04 (s, 1H), 
2.322.27 (m, 1H), 2.24 (d, J = 19.1 Hz, 2H), 2.16 (d, J = 22.4 Hz, 1H), 1.97 (t, J = 5.5 Hz, 
1H), 1.85 (d, J = 16.8 Hz, 1H), 1.78 (d, J = 19.7 Hz, 1H), 1.68 (d, J = 26.6 Hz, 1H), 1.55 (d, 
J = 33.0 Hz, 1H), 1.45 (s, 1H), 1.36 (s, 3H), 1.27 (m, 6H), 1.24 (s, 3H) and 0.92 (dd, J = 
6.5, 3.5 Hz, 6H) ppm. 
13C NMR (125 MHz, CDCl3) δ 171.6, 167.8, 152.8, 151.7 144.4, 140.2, 134.8, 129.6, 
129.6, 129.1, 128.2, 128.0, 127.4, 126.2, 123.7, 121.6, 86.3, 78.1, 66.8, 56.8, 51.4, 39.8, 
39.6, 38.3, 35.6, 29.8, 28.6, 27.2, 26.4, 25.8, 24.1, 23.2, 22.1, 18.4 and 14.3 ppm.  




















































































c. In Vitro Proteasome Activity Assay 
Proteasome inhibition assays were conducted following a modified literature 
procedure.4 In order to ensure that the assay was within the linear range, a standard 
curve was prepared in duplicate using 8 different concentrations (0-250 M). Rabbit 
20S proteasome was used, at a concentration of 12.5 µg/mL in Tris buffer (20 mM Tris-
HCl, pH 7.5, 0.5 mM EDTA, and 0.001% SDS (w/v)). Proteasome CT-L (β5) and C-L (β1) 
activities were determined using hydrolysis of specific short peptide substrates 
conjugated to the fluorescent tag 7-amido-4-methylcoumarin (AMC). Fluorogenic CT-L 
substrate (Suc-Leu-Leu-Val-Tyr-AMC) was purchased from Boston Biochem 
(Cambridge, MA, USA) and C-L fluorogenic substrate (Ac-nLPnLDAMC) was purchased 
from Enzo Life Sciences (Farmingdale, NY, USA). Both substrates were made up to 62.5 
µM in Tris buffer (20 mM Tris-HCl, pH 7.5, 0.5 mM EDTA, and 0.001% SDS (w/v)). 
GraphPad Prism 5.0, GraphPad Software, Inc. GraphPad was used for the 
determination of kinetic values and of the half maximal inhibitory concentration (IC50) 
of each inhibitor. The mean IC50 and standard error were determined by fitting the 
dose-response data to the built-in model- (inhibitor) vs. response- variable 
slope (without log transformation). IC50 with standard error for the key derivative: 4c 
(thermally adapted state) β5- 11 ± 5 nM, β1-460 ± 77 nM; 4c (photostationary state) 
β5-54 ± 10 nM, β1- 303 ± 40 nM 
Assay procedure: 10 mM stock solutions of the test inhibitors in DMSO were diluted to 
500 M in DMSO. 50 L of the 500 μM stock solutions were transferred into a 96 clear 
well round-bottom plate (in duplicate) and each was diluted to 250 μM by adding 50 
                                                        
4 a) K. C. H. Chua, M. Pietsch, X. Zhang, S. Hautmann, H. Y. Chan, J. B. Bruning, M. Gütschow, A. D. Abell, 
Angew. Chem. Int. Ed. 2014, 53, 78287831; b) S. J. Gendler, Z. A. Tökés, Biochimica et Biophysica Acta (BBA) -




μL of DMSO. Serial ten-fold dilutions of the 250 μM inhibitor solutions with DMSO 
were performed within the next 7 wells, giving duplicates of each compound at 8 
different concentrations (0-250 μM). The above dilutions were performed identically 
on another 96 clear well round-bottom plate, however this plate was then irradiated 
with UV light (λ = 365 nm) for 1 h using a UVP BL6SV lamp, and the plate then 
concealed from light using aluminium foil. Compounds on the non-irradiated plate 
were used to test trans-enriched TAS of each inhibitor, while compounds on the 
irradiated plate were used to test cis-enriched PSS of each inhibitor. 10 L of each non-
irradiated compound at the 8 different concentrations was transferred into another 96 
well round-bottom plate (in duplicate), followed by 10 L of 20S proteasome (12.5 
µg/mL in Tris buffer) and the plate was left to incubate for 10 min at rt. 40 L of the 
corresponding fluorogenic substrate (62.5 µM in Tris buffer) was added to each well, 
and the plate left to incubate for 2 h at 37°C. Similarly, 10 L of each irradiated 
compound at the 8 different concentrations was transferred to another 96 well round-
bottom plate (in duplicate), followed by 10 L of 20S proteasome (12.5 µg/mL in Tris 
buffer) and the plate was left to incubate (wrapped in aluminium foil) for 10 min at rt. 
40 L of the corresponding fluorogenic substrate (62.5 µM in Tris buffer) was added to 
each well, and the plate left to incubate for 2 h at 37°C (wrapped in aluminium foil). 
Fluorescence caused by the release of AMC was measured at λem= 445 nm and λex= 390 
nm on a Synergy H4 Hybrid Multi-Mode Microplate Reader, (Bio-Tek Instruments, Inc.). 
Proteasome activity was determined under conditions in which substrate hydrolysis 
increased linearly with time and the change in fluorescence signal was proportional to 





d. Cell Viability Assay 
Cell culture. Derivative 4c was dissolved in DMSO (10 mM) and the solution stored at 
−20°C. Human cell lines (HCT116, MDA-MB-468, and MCF-10A) were purchased from 
American Type Tissue Culture. MDA-MB-468 and HCT116 cells were grown in 
Dulbecco’s Modified Eagle’s Medium (DMEM) and supplemented with 10% FCS, 1% 
PSG and 10 mM HEPES. MCF10A cells were cultured in DMEM/F12: (1:1) (Invitrogen) 
with 5% horse serum (Invitrogen), 10 μg/mL insulin, 20 ng/mL human epidermal 
growth factor (Sigma-Aldrich, MO, USA), 100 ng/mL cholera toxin, and 500 ng/mL 
hydrocortisone (Sigma-Aldrich, MO, USA). All cells were maintained at 37°C in a 
humidified atmosphere of 5% CO2. 
Determination of LD50. Cells were seeded in 96-well microtiter plates at a density of 
2×104 cells/well with varying concentrations of proteasome inhibitors. For 4c-(cis)-
enriched compound, cells were wrapped in aluminum foil and kept in the dark. Cells 
were harvested 48 hours post treatment, centrifuged at 1,300 × g, washed in 
phosphate buffered saline (PBS) and stained with 7-amino-actinomycin-D solution (2 
μg/mL) (7AAD, Invitrogen) for 10 min at room temperature. Viable cells were 
determined with the use of a FACS Calibur flow cytometer (Becton Dickinson 
Immunocytometry Systems), and analyzed with the use of FLOWJO (Tree Star Inc.) and 














Figure S1. Determination of the ratio of trans/cis isomers for each state for each compound 
before and after irradiation (λ= 365 nm, 1 h) in DMSO-d6 (~2 mg/mL), by 1H NMR analysis. The 
figures show spectra of trans-enriched TAS (non-irradiated, blue line) and cis-enriched PSS 





   
   
   
   
Figure S2. UV-Vis spectra of compounds 4-5 (250 M in DMSO). Non-irradiated (trans-enriched 






   
   
   
Figure 3. IC50 curves of 4−5 against β1 proteasome subunit before and after irradiation. The 
trans TAS is indicated in blue and the cis-PSS in pink. 
 
   
   




Figure 4. IC50 curves of 4−5 against β5 proteasome subunit before and after irradiation. The 
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The dipeptide boronic acid bortezomib, is a FDA approved proteasome inhibitor now in use for 
the treatment of multiple myeloma and few other malignancies. The major drawback to 
bortezomib use is its dose-limiting toxicity that arises due to its cross-reactive peptidic 
structure. Here we have explored whether modification at P1 and P2 position of bortezomib 
based derivatives increases affinity, specificity and cytotoxicity.  
 
This chapter is presented as a manuscript in preparation for submission to a journal for 
publication.  
 
Contribution by the candidate: All biological/cell line experimental work and manuscript writing 















The 26S proteasome is a supramolecular protein complex that plays a pivotal role in the 
ubiquitin-dependent protein degradation pathway [1]. The proteins are degraded at three 
active sites located within the inner cavity of the 20S proteasome: chymotrypsin-like (β5), 
trypsin-like (β2), and caspase-like (β1) [2]. The 19S regulatory particle is responsible for 
unfolding protein-substrates and stimulating proteolytic activity In cancer cells, up-regulated 
proteasome activity is essential to the mechanisms underlying tumourigenesis, metastasis, and 
angiogenesis. Indeed, since the approval of Bortezomib (Velcade) for multiple myeloma in 2003 
by the FDA (Figure 1), the proteasome has been validated as an important target for cancer 
therapy [3-5]. 
 
Most proteasome inhibitors, including bortezomib, inhibit proteasome activity by forming an 
antiparallel β-sheet with the substrate-binding channel of the active sites. The boron atom 
covalently interacts with the nucleophilic oxygen lone pair of Thr1O [6]. However, due to cross-
reactivity[7], bortezomib also exhibits permanent abrogation of global protein degradation and 









In this regard, it is imperative to develop proteasome inhibitors with different structural 
characteristics and, to explore new binding sites with the goal of achieving improved 
pharmacokinetic and pharmacodynamic profiles. Recent reports of non-peptidic proteasome 
inhibitors have widened the range of potential scaffolds as a way forward to address 
shortcomings associated with bortezomib non-specificity [8]. Therefore a plausible approach to 
improve proteolytic stability is to modify the chemical structure of the peptide backbone by 
introduction of L-amino acids or alkylated residues on the peptidic scaffold [8, 9]. The analysis 
of the crystal structure of bortezomib in complex with the yeast proteasome revealing an 
antiparallel beta sheet conformation and a spacious S2 pocket, in which the P2 phenylalanine of 
bortezomib lacked interactions with the protein (Figure 2)[6]. This observation presents an 
opportunity to introduce L-amino acids or alkylated residues at P2 without necessarily affecting 
binding properties. Although early structure-activity relationship studies on bortezomib at P2 
indicated that bulky groups decrease potency (ref), recent reports have proven that inhibitors 
bearing sterically demanding moieties at P2 can show highly potent proteasome inhibition. In 
addition, the introduction of such sterically demanding moieties can provide new information 







Figure 2. β5 active site of the yeast proteasome in complex with bortezomib. 
 
 
In this work, we investigate the biological profile of bortezomib-type inhibitors bearing side 
chains of different length, nature and configuration at P2 to obtain useful structural 
information for future design of proteasome inhibitors and with the aim to improve proteolytic 
sensitivity (Figure 3). Firstly, we studied the effect of the non-natural configuration on the 
binding properties at S1 (2a-g) and S2 (3a-g) pockets. Secondly, we explored the variation in the 
electron density of the aromatic system by introducing substituents at the para position of the 
phenyl moiety in P2. Both electron donating (1-3h, 1-3f) and electron withdrawing groups (1-
3b, 1-3c) were analyzed. The influence of the pi interactions was also investigated by 








































Inhibitors 1, 2 and 3 were prepared as depicted in Scheme 1. Commercially available Boc-L-
tyrosine methyl ester (4) was first alkylated in the presence of K2CO3 and the corresponding 
bromide in DMF. Ester hydrolysis of 4 followed by coupling of the resulting acids 5 with (+)-
pinanediol ester of leucineboronic ester 7. in the presence of HATU and DIPEA gave the desired 
dipeptidic boronates 1. During the purification process of boronic esters 1, it was isolated the 
corresponding epimers at P1 (3) as well. This was caused by the partial loss of quiral integrity on 
the leucine alpha proton during the preparation of 7.i To assign the absolute configuration of 
these two sets of boronic esters, one of the inhibitors was crystallized. The X-ray of 1e confirms 
that the major epimer isolated possesses the natural configuration at P2 (Figure 4). Epi-P2 
Boronic esters 2 were synthesized following the same synthetic pathway but starting with Boc-
D-tyrosine methyl ester (8). 






Scheme 1. Synthesis of target compounds 1, 2 and 3. 
 
Reagents and conditions: (i) BrCH2R1, K2CO3, DMF, 60 ºC, 16h; (ii) LiOH, 0 ºC, 2h; (iii) HATU, 






Compounds were tested against chymotrypsin-like (β5), trypsin-like (β2), and caspase-like (β1) 
binding pockets of core particle (Table 1). Like bortezomib, all compounds were most active at 
inhibiting β5 activity, while the inhibitory activity was reduced by approximately 10-fold when 
they were tested against β1, and were depleted of activity on the β2 binding pocket. In line 
with previous reports [10,11] , the corresponding boronic acids of 3 showed similar activity to 
their boronic ester analogues. Stereochemistry at P1 proved to be crucial as compounds with 
the natural configuration (1) were 7 to 30 fold more active than their epimer counterparts (3). 
This indicates that the orientation of the D-alanine is not favorable for the interaction with the 
S1 pocket at the binding site. In contrast, the configuration at P2 has less impact on the IC50  
values. The difference in activity between natural (1) and P2-epi inhibitors (2) only differ by 1 to 




the spacious S2 site. For natural inhibitors 1, the nature of the ring had an effect on the 
inhibition. The S2 binding pocket seems to have a preference for aromatic rings (1a) over 
aliphatic rings (1d). Incorporation of an electro-withdrawing group in the para-position of 
phenyl ring such as in 1c did not markedly change the inhibition, however, the presence of 
fluorine atom at the same position as in 1b led to an increase of potency (36 nM). The presence 
of a free phenol (1h) led to a considerable loss of potency probably due to the lack of hydrogen 
bonding to stabilize it. In contrast, stereoisomers 2 did not show a clear pattern. Remarkably, all 
the activities for the inhibitors where below 250 nM even though they present a D-aminoacid at 
P2.  
 




Compd β5 β1 β2 
1a 0.088 0.43 >125 
1b 0.036 0.28 >125 
1c 0.074 0.26 >125 
1d 0.11 0.42 >125 
1e 0.091 0.40 >125 
1f 0.099 0.78 >125 
1g 0.044 0.48 >125 
1h 4.28 17.31 >125 
2a 0.141 0.98 >125 
2b 0.117 0.50 >125 
2c 0.126 0.67 >125 
2d 0.186 1.40 >125 
2e 0.240 1.25 >125 
2f 0.112 1.57 >125 
2g 0.132 1.45 >125 
3a 1.63 (1.45) 9.25 >125 




3c 3.45 (3.67) 7.68 >125 
3d 2.04 (2.20) 15.19 >125 
3e 1.13 (1.25) 4.88 >125 
3f 0.711 (-) 2.81 >125 
3g 0.70 (0.95) 2.81 >125 
bortezomib 0.007 0.12 2 
aValue for boronic acid. 
 
Next, cytotoxicities of the two most potent compounds emerging from this work (1b and 1g) 
were assessed against a panel of 8 cell lines (Table 2), including 4 breast cancer cell lines (MDA-
MB-468, MCF7, HS578T and MDAMB231), a colorectal cancer cell line (HCT-116), a Ewing 
sarcoma cell line (WE-68) and two non-malignant cell lines MCF-10A and normal dermal 
fibroblasts (NDF).  
 
Compared to bortezomib, the cytotoxic potency of both compounds 1b and 1g was significantly 
reduced (between 5-10 fold) against all cell lines except for MDA-MB-468. For instance, in the 
breast carcinoma cell line Hs578T, boronic ester 1b was 10-fold less potent compared to 
bortezomib with LD50 values of 0.15 µM and 0.015 µM respectively.  This 10 fold decrease in 
cytotoxic potency for 1b is expected and consistent with its decreased inhibitory potency 
against the β5 activity of the proteasome in in vitro assays (Table 1). As expected, compounds 
1b and 1g did not differ in their relative cytotoxic potencies against all cell lines except MDA-
MB-468.  Unexpectedly, in the MDA-MB-468 breast carcinoma cell line, cytotoxic potencies for 
compound 1b was comparable to bortezomib and significantly higher than 1g. The basis for this 
result is unclear but may be attributed to the specific molecular characteristics of this cell line. 




malignant cell lines. Overall, our results show that bortezomib-ester derivatives, despite having 
bulky P2 moieties, remain functionally active.  
 









1b 0.05 >1.25 0.15 0.16 0.08 0.81 >1.25 0.14 
1g 0.90 1.25 0.31 0.29 0.17 1.25 >1.25 0.41 













































A common motif on the three FDA-approved proteasome inhibitors is the presence of a 
peptidic scaffold with an electrophilic warhead for covalent binding to the catalytic Thr1 
residues of the proteasome. Choosing peptidic backbones for inhibitor synthesis has both pros 
and cons. On the plus side, there is ease of synthesis, cost-effectiveness and derivatization. 
However, a major drawback is their cross-reactivity and drug delivery challenges. As other 
proteases can easily cleave these peptides, frequent dosing becomes necessary.  Protease-
resistant peptides would address many of these limitations. 
 
Here, we have assessed how configuration at P1 and P2 position of bortezomib based inhibitors 
affects affinity, specificity and cytotoxic efficacy. Stereochemistry at P1 proved to be crucial as 
compounds with the natural configuration were 50 fold more active than their epimer 
counterparts. In contrast, the configuration at P2 has less impact on the IC50 values with 
differences of only 1-3 fold and the S2 pocket was able to accommodate bulky aromatic 
residues and long chains, which can be exploited for introducing fluorescent markers for 
experimental purposes. Furthermore, our crystallization studies show that inhibitors 1b and 1c 
bind to non-primed and primed-regions of the S2 pocket. Structural information obtained from 
this study holds significance for future drug design and to improve proteolytic stability. This is 
an ongoing study and we are currently undertaking crystallography studies for compounds 1f, 
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Bortezomib (Selleckchem, Houston, TX, USA), Carfilzomib (Selleckchem, Houston, TX, USA), 
Ixazomib (Selleckchem, Houston, TX, USA) or in-house generated derivatives were dissolved in 
10 mM DMSO and stored at −20 °C. Human cell lines (WE-68, HCT116, MCF7, MDA-MB-468, 
MDA-MB-231, Hs578T, MCF-10A) were purchased from American Type Tissue Culture. Normal 
dermal fibroblasts (established from a normal individual) were a kind gift from A. Prof. Richard 
Sturm (Institutive for Biomolecular Sciences, The University of Queensland, Brisbane, Asutralia). 
WE-68 and MCF7 cell lines were grown in RPMI-1640 media. RD-ES, MDA-MB-468, HCT116, 
MDA-MB-231, Hs578T and primary dermal fibroblast cell lines were grown in Dulbecco’s 
Modified Eagle’s Medium (DMEM). Both RPMI and DMEM media were supplemented with 10% 
FCS, 1% PSG and 10 mM HEPES. MCF-7 cells were supplemented with 1% insulin. MCF10A were 
cultured in DMEM/F12: (1:1) (Invitrogen) with 5% horse serum (Invitrogen), 10 μg/ml insulin, 20 
ng/ml human epidermal growth factor (Sigma-Aldrich, MO, USA), 100 ng/ml cholera toxin, and 
500 ng/ml hydrocortisone (Sigma-Aldrich, MO, USA). All cells were maintained at 37 °C in a 
humidified atmosphere of 5% CO2. 
 
Determination of LD50  
 
Cells were seeded in 96-well microtiter plates at a density of 2×104 cells/well with varying 
concentrations of proteasome inhibitors. Cells were harvested 48 hours post treatment, 




actinomycin-D solution (2 μg/mL) (7AAD, Invitrogen) for 10 minutes at room temperature. 
Viable cells were determined with the use of a FACS Calibur flow cytometer (Becton Dickinson 
Immunocytometry Systems), and analyzed with the use of FLOWJO (Tree Star Inc.) and 
GraphPad Prism (GraphPad Software Inc. version 6).  
 
In Vitro Proteasome Activity Assay  
 
Proteasome CT-L, C-L and T-L activities were determined using hydrolysis of specific short 
peptide substrates conjugated to the fluorescent tag 7-amido-4-methylcoumarin (AMC). 
Purified rabbit 20S proteasome and fluorogenic CT-L substrate (Suc-Leu-Leu-Val-Tyr-AMC) were 
purchased from Boston Biochem (Cambridge, MA, USA). The T-L and C-L fluorogenic substrates 
(Bz-Val-Gly-Arg-AMC and Ac-nLPnLD-AMC) were purchased from Enzo Life Sciences 
(Farmingdale, NY, USA). Purified 20S proteasome (Enzo Life Sciences, Farmingdale, NY, USA) (0-
2 µg) was pre-incubated with the indicated concentrations of inhibitors at 37 °C for 15 minutes 
and subsequently added to the AMC-labelled substrate peptide (50 μM) in assay buffer (20 mM 
Tris-HCl, pH 7.5, 0.5 mM EDTA, and 0.001% SDS (w/v)) for a further 2 hours. Fluorescent 
substrate cleavage by the 20S proteasome was linear during this incubation period. Hydrolysed 
AMC was subsequently detected with the Synergy™ H4 Hybrid Multi-Mode Microplate Reader 
(BioTek, USA) at excitation/emission wavelengths of 390/460 nm. Hydrolysis activity was 
measured as relative fluorescence units allowing IC50  values to be calculated that represented 
half of the maximal inhibitory activity of the proteasome. A minimum of three biological 



























Ewing sarcoma is a highly aggressive solid bone tumour that primarily afflicts children and 
young adults (peak incidence of 15 years) [1, 2]. The genetic change fundamental to the 
pathogenesis of Ewing sarcoma involves a chromosomal translocation between the EWS gene 
located on chromosome 22q12 and a member of the ETS transcription factor family. The 
majority of cases (85% to 90%), are associated with this t(11;22) where the amino terminal of 
the EWS gene is joined to the carboxyl terminus of FLI1 (chromosome 11) [3]. The resulting 
fusion protein is an oncogenic transcription factor that exerts it effect by altering cellular 
functions and signaling pathways leading to growth and proliferation of tumour cells [4, 5]. The 
development of a malignant neoplasm generally requires secondary genetic alterations, most 
frequently in oncogenes or tumour suppressors. P53 is one of the most frequently altered 
proteins in cancers, and this can occur via mutation of the TP53 gene (in 50% of all cancers) or 
overexpression of p53-regulatory proteins that suppress p53 activity e.g. MDM2 and MDM4 [6]. 
However, in Ewing sarcoma, TP53 mutations are rare with the majority of cases expressing a 
functional wild-type p53 [7, 8]. This feature is infrequent in cancer and is suggestive that Ewing 
















Tumour Suppressor p53 
 
 
P53 is a transcription factor that governs major cellular tumour suppression pathways, inducing 
senescence, apoptosis and cell cycle arrest [9]. It has been long known that stabilization of p53 
is pivotal for the cell to respond to cellular stresses (DNA damage, hypoxia etc.) and maintain 
cellular homeostasis. Protein levels of p53 within cells are tightly controlled and kept low 
primarily by its negative regulator MDM2, which binds to the amino terminus of p53, targeting 
it for ubiquitination and subsequent degradation [10]. 
 
Upon cellular or nucleolar stresses and depending on its cellular localization, p53 elicits various 
responses. Nuclear p53 up-regulates RNA polymerase II (Pol II) mediating transcription of cell 
cycle and apoptotic regulators (e.g. p21, BAX, PUMA) [11, 12] , while cytoplasmic p53 induces 
activation of the mitochondrial apoptotic pathway [13]. In the nucleolus, p53 impairs ribosomal 
RNA (rRNA) synthesis by disrupting the binding of the upstream binding factor (UBF) to 
selectivity factor 1 (SL1) which then partially abrogates the assembly of the pre-initiation 
complex at rDNA promoters, thus repressing the transcription by RNA polymerase I (Pol I) [14]. 
With such a crucial role in cellular surveillance in response to stress, it is not surprising that p53 
is often termed ‘the guardian of the genome’, and that mutations in the TP53 gene are 
commonly observed in diverse types of human cancer, making it an promising target for genetic 







History of Ewing sarcoma treatment 
 
Despite decades of research Ewing sarcoma has retained the most unfavorable prognosis of all 
primary musculoskeletal tumours. Prior to the use of multi-drug chemotherapy, surgery alone 
cured less than 20% of patients with Ewing sarcoma, even if the disease was localized [15]. 
However, starting in the 1970s, introduction of chemotherapy as a critical component of  Ewing 
sarcoma treatment has led to a remarkable increase in overall disease free survival, with 
survival rates for patients with localized Ewing sarcoma increasing to 70% [16]. In contrast, 
patients with metastatic Ewing sarcoma have <30% 5-year survival despite advances in 
treatment strategies including dose-intensification, use of multi-drug adjuvant therapy and 
stem cell transplantation. Failure to further manipulate or optimize the current chemotherapy 
treatment to increase overall survival has led to the development of new drugs that can 
specifically target the cancer cells. The idea is to use these targeted therapies in conjunction 
with traditional chemotherapy to achieve greater efficacy, and less toxicity to normal cells. To 
date, many targeted therapies are being explored in pre-clinical and clinical trials for Ewing 
sarcoma with some in advanced clinical stages (Table 1). 
 
On the forefront of Ewing sarcoma targeted therapies are inhibitors of insulin-growth factor- 
receptor (IGF-R) and mammalian target of rampamycin (mTOR), signaling pathways involved in 
cell proliferation and resistance to apoptosis respectively. Patient trials show good tolerance 
and tumour regression, however the major challenges with these inhibitors are their brief 
response periods and rapid development of resistance (reviewed in [17]). Lack of response or 




that these targeted therapies currently face, thus prompting research into other potential 
biological targets and/or improved versions of current drugs. 
 
Table 1. Molecular targets and current development of targeted therapies in Ewing sarcomas in 
advanced stage clinical trials. 
Targets Therapeutic agents Stage References 
IGF1-R inhibitors R1507; SCH 717454 Phase II paed [18, 19] 
mTOR inhibitors Ridaforolimus Phase III ad [20] 
Combination Cixutumumab + temsirolimus Phase II paed 
II ad 
[21] 
Multi-agent inhibitors Imatinib mesylate Phase II paed [22, 23] 
Bone microenvironment Zoeldronic acid Phase III paed/ad [24] 
Angiogenesis inhibitor Bevacizumab Phase I/II paed [25] 
HDAC inhibitors Vorinostat, valproic acid Phase I paed [26, 27] 
HSP90 inhibitors 17-AAG Phase I paed [28] 
Abbreviations: ad, adult patients; HSP, heat shock protein; IGF, insulin-like 











Ribosomal RNA Polymerase as a therapeutic target 
 
The nucleolus is the site of ribosomal synthesis and the assembly of nuclei depends on ongoing 
ribosomal DNA (rDNA) transcription and maturation. It is a dynamic region of the nucleus that is 
disassembled and reformed each cell cycle [29]. The major role for the nucleolus is the 
generation and assembly of the key components of the ribosome, the protein synthesis 
apparatus of the cell (Figure 1). Specifically, the 5.8S, 18S and 28S rRNAs are transcribed by 
ribosomal RNA polymerase (Pol I) as a single 47S rRNA precursor in the nucleolus that is 
subsequently processed and cleaved. These rRNAs, together with the 5S rRNA transcribed by 
Pol III in the nucleoplasm, form the nucleic acid backbone of functional ribosomes. The other 
major components of the ribosome, the Pol II transcribed ribosomal proteins, are transported 
from the cytoplasm into the nucleolus for assembly with the rRNAs (reviewed in [30]). 
 
Though, traditionally viewed as a factory for ribosomal synthesis, 30% of nucleolar proteins do 
not participate in ribosomal biogenesis [31]. It is now clear that the nucleolus regulates a 
myriad of cellular functions, such as cell cycle control, stress response, protein degradation and 
mRNA modification and export suggesting a far greater role in cellular homeostasis than 









Nucleolus in cancer 
 
The relationship between the nucleolus and cancer has been the subject of study for many 
years. Abnormalities in the nucleolar morphology of cancer cells (enlarged and/or increased 
number of nucleoli) were first reported in late 19th century [32]. Since this initial report, a 
series of studies have been performed to clarify whether these nucleolar changes were a 
consequence of the cancerous state or if they might represent a cause of neoplastic 
transformation. In principle, the larger nucleoli associated with tumour cells could be attributed 
to greater levels of protein synthesis, and therefore ribosome biogenesis, required by rapidly 
dividing tumour cells. However, there is increasing evidence that nucleolar defects can be 
causative agents in the onset of cancer. Firstly, it was demonstrated that mammalian cells have 
a surveillance system for monitoring ribosomal biogenesis and nucleolar integrity and that 
disruption of these processes results in cell cycle arrest and programmed cell death at the G1 
and G2 cellular checkpoints [33-35]. Of these, the best understood is the nucleolar stress 
pathway in which insults to the nucleolus lead to the accumulation of p53 [33]. 
 
The second critical observation was that the nucleolar stress pathway in tumour cells could be 
activated in vivo by a selective small molecule inhibitor (CX-5461) of Pol I transcription. This 
approach revealed that dysregulated rDNA transcription is necessary for the transformed 
phenotype induced by oncogenes such as MYC, and that targeting this dysregulated activity 
could be used as a therapeutic strategy to selectively kill malignant cells in vivo [36]. These 




contribution to cellular transformation, and thus represent a novel strategy in the treatment of 
human cancers. 
Dysregulation of Pol I transcription and ribosome biogenesis is universal in cancer. In general, 
this hyperactivation of rDNA transcription can be achieved by altered expression of upstream 
signaling pathways, or by oncogenic and tumour suppressive transcription factors such as p53 
and MYC that interact directly with the rDNA promoter/transcription apparatus (reviewed in 
[37, 38]). These abundant and potent transcription factors regulate all three RNA polymerases, 
suggesting that, in addition to their traditional regulatory role in Pol II transcription, hijacking 
the control of Pol I and Pol III transcription may be essential for malignant transformation 
(reviewed in [36]). In addition to the core Pol I transcription apparatus, numerous other 
nucleolar proteins, some of which may also indirectly affect ribosome biogenesis, are 
modulated in cancer. The most prominent is nucleophosmin 1 (NPM1), which is overexpressed 












Figure 1. Schematic representation of ribosome biogenesis. Multiple coordinated steps are 
involved in ribosome biogenesis. Transcription of ribosomal genes exclusively by the Pol I 
transcriptional machinery in the nucleolus generates the 47S rRNA precursor which is rapidly 
processed into the 18S, 5.8S and 28S rRNAs. These three rRNAs will then assemble together 
with the 5S rRNA transcribed by Pol III, and with the ribosomal proteins transcribed by Pol II to 
form the 60S and 40S ribosomal subunit in the nucleus. These subunitsfurther assemble into 




As yet, there is no clear evidence to support the notion that accelerated rDNA transcription in 
cancer is sufficient to initiate malignant transformation. This is in part due to the fact that rDNA 
transcription is a complex process that is tightly coupled to downstream processes, such as 
rRNA processing, ribosomal assembly, and transport. Therefore, modulation in any single rDNA 
transcription component will likely be counteracted by the rate-limiting step of the 
downstream processes. Although C-myc and oncogenic signaling pathways (PI3K/AKT/mTOR 
and RAS/RAF/ERK) can cause a robust increase in Pol I activity and subsequent acceleration of 
ribosomal synthesis, it is not possible to ascribe this function as causative for malignant 
transformation as these pathways and factors have pleiotropic effects on many aspects of 
malignant transformation in addition to their roles in ribosome biogenesis. 
 
As one bottleneck limiting cancer cell proliferation is the rate of ribosomal synthesis, it is 
possible that tumour cells become ‘addicted’ to accelerated ribosome biogenesis and therefore 
are selectively vulnerable to therapeutics that inhibit rRNA synthesis. It is therefore not 
surprising that numerous anti-cancer drugs mediate their therapeutic effect, at least in part, 
through disrupting ribosome biogenesis. For example, cisplatin, doxorubicin, mitomycin C and 
low concentrations of actinomycin D (<10nM), all inhibit rRNA synthesis at the level of Pol I 
transcription, whereas camptothecin, flavopiridol, and roscovitine modulate early rRNA 
processing steps. In either case, inhibition of Pol I transcription or rRNA processing by these 
drugs leads to nucleolar disruption. In contrast to this, drugs including 5-fluorouracil and 
homoharringtonine, which impair late rRNA processing events, leave the nucleolus intact 




identified in a screen for compounds that intercalate with DNA for use as anticancer agents, 
were recently found to selectively inhibit RNA Pol I by impairing SL-1 promoter binding and 
preinitiation complex assembly [42] . Various ellipticine derivatives have been evaluated in 
Phase I and II clinical trials, but failed further clinical development due to adverse side effects. 
Actinomycin D (FDA approved) which is currently used as a chemotherapeutic drug in Wilms 
and Ewing tumours. Unfortunately, none of these drugs are highly Pol I selective and therefore 
it is not possible to assign the proportion of therapeutic effect mediated via Pol I. Furthermore, 
these drugs are DNA damaging agents that are associated with off-target toxicity. By contrast, a 
new generation of drugs are currently being developed that selectively inhibit Pol I transcription 
for the specific purpose of cancer therapy. 
 
CX-5461: a potent and selective rRNA polymerase inhibitor 
 
CX-3543 (Cycle Pharmaceuticals) was the first chemotherapeutic agent developed that 
selectively targeted Pol I transcription (Pol I) in vivo. This drug selectively disrupts the nucleolin-
rDNA G-quadruplex complex in the nucleolus. Similar to the functions of actinomycin D which 
intercalates into GC-rich duplex DNA, CX-3543 inhibits Pol I transcription at the site of RNA 
elongation and induces apoptosis in cancer cells. CX-3543 was shown to have clinical benefits 
for carcinoid/neuroendocrine tumours and is currently under phase I clinical trials [43]. 
 
CX-5461, is a next generation small molecule inhibitor, which impairs initiation of Pol I 
transcription by disrupting the interaction between Pol I transcription initiation factor SL-1 and 




Pol II or Pol III 44. In vitro studies have revealed that CX-5461 has a high anti-proliferative 
activity against a wide range of human cancer cell lines [45-48], however, the sensitivity 
towards Pol I inhibition varies widely between these cell lines (30 to 1000 fold). Interestingly, 
cell lines derived from p53 wild type hematological malignances were the most sensitive. 
However the precise role of p53 status in conferring sensitivity to CX-5461 is an area of 
contention. CX5461 was shown to selectively kill B-cell lymphoma cells in vivo, but not normal B 
cells, by inducing p53-dependent apoptosis leading to the release of ribosomal proteins which 
bind MDM2, thus abrogating the p53–MDM2 interaction (Figure 2). Several other studies show 
efficacy of CX-5461 in in vivo models of acute myeloid leukemia and prostate cancer [48, 49]. In 
contrast, a study by Wang et al, demonstrated that low nanomolar concentrations of CX-5461 
induce p53-independent autophagy in wild type, mutant and drug-resistant myeloma and 
pancreatic carcinoma cell lines [45] . 
 
This type of non-genotoxic activation of p53 caused by CX- 5461 holds great promise in future 
cancer therapy. Whether selective targeting of ribosome biogenesis can be translated into anti-
cancer treatment for different cancer types remains to be seen. Unfortunately, the majority of 
human cancers have lost wild type p53 functions, but recent results indicate that nucleolar 
stress can also be mediated independently of p53 function by other specific mechanisms, 









Ewing sarcoma is a childhood bone malignancy with alarmingly high mortality rate despite 
aggressive multi-modality treatment regimens. The majority of the Ewing sarcoma cases 
express a functional wild-type p53 suggesting that Ewing sarcoma will be sensitive to p53-based 
targeted therapeutic strategies. 
 
Up-regulated rRNA transcription is a hallmark of cancer cells. To sustain rapid cell growth and 
proliferation, cancer cells become dependent on accelerated ribosome production which is 
controlled by Pol I. Previous studies show that selective inhibition of rRNA transcription by low 






Figure 2. Overview of nucleolar stress related activation of the p53 pathway. Under normal 
conditions (left panel) the ribosomal proteins (RPs) are located within the nucleolus and 
exported to the cytoplasm where they assemble together with rRNA into functional ribosomes. 
MDM2 binds and ubiquitinates p53 which promotes p53 proteasomal degradation. Under 
nucleolar stress conditions (right panel) nucleolar disruption results in the release of RPs into 
the nucleoplasm where they bind MDM2 and abrogate its interaction with p53 leading to p53 
stabilisation and activation of p53 downstream pathways, inducing cell cycle arrest, apoptosis, 






CX-5461, a novel selective small-molecule inhibitor of RNA polymerase (pol) I, induces cell 
death in several human tumour types by both p53-dependent and independent mechanisms. 
However, in vitro results show that hematological cell lines with wild type p53 are the most 
sensitive to CX-5461 mediated cell death, suggesting that cancers with an intact p53 pathway 
will be sensitive to this drug. 
Clinical Significance 
 
Sarcomas represent 20% of malignancies in children and 10% of cancers in young adults. 
Despite aggressive multi-modal treatment regimens, the current mortality rate of 
approximately 50%, is amongst the worst of all cancer types in adolescents and young adults. 
The poor mortality rates have not improved over the past decade, suggesting an urgent need 
for more effective targeted treatment strategies. 
 
RNA Pol I inhibition by CX-5461 is a promising approach for the treatment of Ewing sarcoma. 
Preliminary findings using Ewing sarcoma cell lines demonstrate low nanomolar drug activity 
providing a rationale for further research into CX-5461 as a potential therapeutic agent. Pre-
clinical evaluation of the mechanism of CX5461 induced cellular death in vitro and in mouse 
models is paramount before translation of CX-5461 into the clinic. Furthermore, given that a 
considerable proportion of human cancers (~50%) exhibit mutations of the p53 gene, additional 
experiments are required to unequivocally address the role of p53 status in the sensitivity of 
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This study has evaluated the molecular and cellular responses of cultured Ewing sarcoma cell 
lines following exposure to CX-5461, a recently discovered non-genotoxic specific RNA 
Polymerase I inhibitor. Our findings demonstrate that Ewing sarcoma cell lines are acutely 
sensitive to CX-5461. CX-5461 also displayed synergistic interactions with chemotherapeutic 
Actinomycin D that is currently used in treating Ewing sarcoma. Non-genotoxic cell death via 
CX-5461 provides a singular opportunity to overcome DNA damage associated with current 
treatments.  
 
This chapter is presented as a manuscript in preparation for submission to a journal for 
publication.  
 






Ewing sarcoma is a highly aggressive bone and soft tissue cancer primarily diagnosed in children 
and young adolescents. It affects approximately 200,000 patients worldwide each year and has 
10-20% long term survival in patients with metastatic, relapsed, or recurrent disease1. 
Management of Ewing sarcoma is complicated by the use of genotoxic chemo-and radio- 
therapy that is associated with toxic bystander effects and secondary malignancies. The 
majority of the Ewing sarcoma patients retain functionally intact tumour suppressor p53 and 
downstream signalling pathways, hence exploiting p53-based therapies has been an attractive 
therapeutic approach. Inhibitors targeting MDM2 (e.g. Nutlin), the major negative regulator of 
p53, have demonstrated only modest benefits for patients harbouring wild-type p53. Recent 
sequencing studies demonstrate that Ewing sarcoma possesses one of the lowest mutation 
rates amongst all cancers (0.15 mutations/Mb) 2, 3, with recurrent mutation observed in EWS-
FLI1 (85% cases) and STAG2. Targeted therapies for these proteins are in clinical and pre-clinical 
trials but thus far have no translational benefits. 4-6. The constraints imposed by DNA damaging 
regimen and a combination of lack of recurrent driver mutations for this cancer require an 
alternative approach to evaluate non-genotoxic agents that broadly target cancer cell survival, 
either alone or in combination with traditional chemotherapies.  
 
Dysregulating ribosome biogenesis is one such unexplored approach. Ribosomes are the 
primary protein synthesis apparatus of a cell and directly control cell growth and proliferation. 




18S, 5.8S) transcribed by RNA polymerase I and assemble with ribosomal proteins and 5s rRNA 
transcribed by RNA Pol III and 5S RNA Pol II respectively to form functional ribosome. To 
maintain high proliferation rates, cancer cells need to increase their translational capacity and 
become addicted to high rates of ribosome biogenesis 7-10, which can be exploited 
therapeutically. In fact, many clinically used chemotherapies that interfere with DNA 
metabolism also inhibit ribosome biogenesis11 consequently preventing the transcription of 
rRNA, which leads to ribosomal stress and ultimately p53-dependent cell cycle arrest or 
apoptosis12-14. Actinomycin D, a commonly used chemotherapeutic for the treatment of Ewing 
sarcoma, also inhibits RNA Pol I. However, these multi-modal chemotherapy regimens have 
reached their full capacity now and further improvements to survival can only come from non-
genotoxic approaches. Discovery of small molecule inhibitors that specifically inhibit ribosomal 
biogenesis has gained increased momentum in the last five years, with cell-based screens 
identifying several compounds that have minimal toxicity in non-malignant tissue15, 16.  
 
CX-5461 was the first non-genotoxic and selective inhibitor of ribosomal biogenesis to be 
reported 15. CX-5461 selectively impairs initiation of Pol I transcription by disrupting the 
interaction between Pol I transcription initiation factor SL-1 to the rDNA promoter that leads to 
disruption in ribosome synthesis. CX-5461 elicits its anti-proliferative effects in a wide range of 
cell lines, including leukaemia, lymphoma, osteosarcoma, and prostate cancer cells. CX5461 
was also shown to selectively kill B-cell lymphoma cells in vivo, but not normal B cells, by 
inducing p53-dependent apoptosis17. Currently, CX5461 is undergoing phase I clinical 




(NCT02719977) in patients with advanced/metastatic/recurrent solid tumours. The majority of 
sarcomas harbour wildtype p5318, 19. This study assessed whether selective inhibition of RNA Pol 
I by CX-5461 represents a possible therapeutic approach for Ewing sarcoma both as a mono-




Cell culture and reagents 
CX-5461 and the ATM/ATR inhibitor KU-55933 were purchased from Selleck Chemicals 
(Houston, TX). WE-68 and VH-64 were kindly supplied by F. van Valen (Department of 
Orthopaedic Surgery, Westfälische-Wilhelms-University, Germany). TC-252 and TC-71 cell lines 
were kindly supplied by G. Hamilton (Department of Surgery, University of Vienna, Austria), 
STA-ET1 was sourced from P. Ambros (Children's Cancer Research Institute, St. Anna Children's 
Hospital, Vienna, Austria), and CADO-ES-1 was kindly supplied by J. Sonnemann (Department of 
Pediatric Haematology and Oncology, University Children's Hospital, Jena, Germany). MCF-10A, 
SK-ES-1, RD-ES, HCT116 were purchased from American Type Tissue Culture. YZ5 and pEBS 
were a kind gift from Prof. Kum Kum Khanna (Queensland Institute of Medical Research). Cell 
lines were cultured as previously described 20.  
 
Western blot analysis 
 
Western blot analysis was performed as previously described21. Whole protein lysates (5–20 μg) 




primary antibodies Anti-E2F1 (C20, 1:500, Santa Cruz), p53 DO1 (1:1000, Santa Cruz 
Biotechnology), Phospho-p53 (Ser15) (1:500, Cell Signalling), Phospho-Histone H2A.X (Ser139) 
clone JBW301 (1:500, Millipore) and β-Actin (1:1000, AC-15, Sigma). Chemiluminescent 
detection of protein was achieved using appropriate secondary antibodies conjugated with 
horseradish peroxidase (Amersham) and the enhanced chemiluminescence kit according to the 




Total RNA was extracted from cultured cells using RNeasy mini kits (Qiagen). One microgram of 
total RNA was reverse transcribed using MMLV reverse transcriptase (Life Technologies). qPCR 
was performed using SYBR Green mastermix and run on a CFX96 Bio-Rad real time PCR 
machine. Primer sequences  are listed in the table below. Experiments were repeated three 
times. Results were normalized to GAPDH expression for each sample and plotted as relative to 
the expression of control samples. 
















shRNA, siRNA and transfection 
WE-68 and VH-64 shRNA stable cells were generated using retroviral transduction with 
pRetroSuper (pRS) vectors pRS-p53, which confers puromycin resistance. The pCMV-E2F1-HA 
(#24216) plasmid was purchased from Addgene, USA. Cells were transfected using 




Ewing sarcoma cells were seeded at 1 × 104 cells per well into 96-well plates, and treatments 
were administered. After the indicated time periods of incubation, medium was removed and 
cells were washed twice with PBS. 100 μL of Cell-titre glo (1:1 ration with meduma, Promega) 
was added to each well and the cells were incubated for 10 mins in dark with shaking. 
Luminescence was measured on a LUMIstar Omega Microplate Reader from BMG LABTECH 
(Carlsbad,, CA) with reactions normalised to vehicle control treated cells. 
 
Cell viability assays 
Cells were seeded in 96-well microtiter plates at a density of 2×104 cells/well in the presence of 
CX-5461 and chemotherapy drugs as indicated. For synergy experiments, cells were co-treated 
with indicated concentrations of CX-5461 and chemotherapies. Cells were harvested 48 hours 
post CX-5461 treatment, centrifuged at 1,300 × g, washed in phosphate buffered saline (PBS) 
and stained with 7-amino-actinomycin-D solution (2 μg/mL) (7AAD, Invitrogen) for 10 minutes 




cytometer (Becton Dickinson Immunocytometry Systems), and analyzed with the use of 
FLOWJO (Tree Star Inc.) and GraphPad Prism (GraphPad Software Inc. version 6).  
 
Cell cycle analysis 
 
Cells were harvested, collected by centrifugation, washed with PBS, fixed in cold 70% ethanol, 
and incubated overnight at 4°C. Cell pellets were washed twice with PBS and resuspended in 
PBS containing 25 mg/mL propidium iodide, RNase A, and Triton X-100 for 30 minutes at room 
temperature in the dark immediately before fluorescence-activated cell-sorting (FACS) analysis 
by FACSCalibur flow cytometer (Beckton Dickinson). DNA content was determined with the use 
of a FACS Calibur flow cytometer with cell cycle profiles analysed using MODFIT LT software 
(version 4.1.7). 50,000 cells were counted for DNA content. 
 
Statistical analysis 
Combination index (CI) values were calculated to determine the synergistic effects of CX-5461 
on cell viability in the presence of cytotoxic agents. A CI value of <1, =1 and >1 indicates 
synergistic, additive and antagonistic effects respectively P values were calculated using 









Ewing sarcoma cells are hypersensitive to RNA Pol I inhibition 
 
To investigate the utility of RNA Polymerase I inhibition for the treatment of Ewing sarcoma, 
the cytotoxic effects of CX-5461 (0-5000 nM) were assessed in a panel of nine Ewing sarcoma 
cell lines with varying TP53 mutational status (Table 1). Cytotoxic sensitivity to CX-5461 varied 
widely across the cell lines (LD50 range 3-1176nM). Wild-type TP53 cell lines VH-64 and WE-68 
displayed the greatest sensitivity to CX-5461 with LD50 values of 3.0 nM and 3.4 nM 
respectively. In contrast, the mutant TP53 cell line RD-ES was the most resistant to CX-5461 
(LD50 1120 nM), requiring greater than 300 fold CX5461 to achieve 50% cell death.  However, 
there was no correlation observed between TP53 status and  CX-5461 sensitivity (p = 0.29) 
(supplementary figure 1). 
 
A comparison of CX-5461 cytotoxic sensitivity (LD50s) between Ewing sarcoma and previously 
reported solid cancers revealed Ewing sarcoma to be one of the most sensitive reported to date 
for all solid cancers tested with CX-5461 (supplementary figure 2). More importantly, these LD50 
values mirror those displayed by haematological cell lines (supplementary figure 3) for which 
CX-5461 is in phase I or II clinical trials presently. Importantly, the viability of non-malignant 
breast (MCF-10A) and skin fibroblast (NDF) cell lines remained unaffected at these 








Table 1. CX-5461 exhibits broad anti-cancer potency in a Ewing sarcoma cell panel.  
ES, Ewing sarcoma; NM, Non-malignant; pPNET, peripheral primitive neuroectodermal tumour. 
Data represents mean ± SEM from three independent experiments. Representative dose-
response curves and RNA Pol I inhibition are presented in supplementary figure 4.  
  
Given this acute sensitivity of Ewing sarcoma cells to CX-5461, we next wanted to determine 
whether efficacy of current treatments for Ewing sarcoma could be increased in combination 
with CX-5461. Since current treatment is limited by toxicities, this combination approach 
provides a singular opportunity to both increase treatment efficacy as well as offer protection 
from DNA damage. The ability of CX-5461 to enhance the cytotoxic effects of four standard 








VH-64 ES M/24 Relapse Wildtype t(11;22) 3.0 ± 6.3 
WE-68 ES F/19 Primary Wildtype t(11;22) 3.4 ± 8.7 
SKES1 ES M/18 Primary Cys176Phe t(11;22) 15± 12 
TC71 ES M/22 Primary Truncation t(11;22) 119±59 
STA-ET1 pPNET F/13 Relapse Wildtype t(11;22) 120±63 
TC252 ES Unknown Relapse Wildtype t(11;22) 130±54 
SK-N-MC ES F/14 Primary Null t(11;22) 132±67 
CADO-ES1 ES F/19 Relapse Wildtype t(21;22) 141±97 
RD-ES ES M/19 Primary Arg273Cys t(11;22) 1176±284 
MCF-10A NM  Immort
alized 
  >5000 
NDF Skin 
fibroblasts 




Ewing sarcoma chemotherapeutic agents (vincristine, actinomycin D, doxorubicin or etoposide) 
was assessed in three Ewing sarcoma cell lines (WE-68, SK-ES1 and SK-N-MC). The synergistic, 
additive or antagonist drug interactions were calculated by combination index (CI) approach 
using Chou-Talalay method. CI values were then used to generate a heat map of drug 
interactions.  
 
The combination results varied from additive to antagonistic for all chemotherapy agents 
tested. The most synergistic combination of CX-5461 was observed with Actinomycin D over a 
range of doses in both p53 wild-type WE-68 cells and p53 null SK-N-MC cells but conferred 
additive effect in SKES1 (Figure 1). We suspect similarity of synergy patterns of Actinomycin D 
and RNA polymerase I inhibitor CX-5461 might be due to their overlapping mechanisms of 
action, as previous studies report that Actinomycin D also inhibits ribosomal biosynthesis, albeit 
at low concentrations. A maximum of 40% and 20% increase in cell death was observed in SK-N-
MC and WE-68 respectively, when the two agents were combined (48hr CX-5461 treatment). 
For doxorubicin, etoposide and vincristine, most combination doses with CX-5461 caused 
antagonistic effects in all cell lines tested (supplementary figure 5). Overall, the synergistic 
interaction between CX-5461 and Actinomycin D provides an attractive approach for treating 





Figure 1. CX-5461 synergizes with Actinomycin D in vitro. A. Cells were treated for 48 h with 
the indicated concentrations of CX-5461 in the presence or absence of Actinomycin D (0.625 
ng/ml). Cell viability was measured through 7AAD staining. B. Graphic heat-map representation 
of combination indices calculated for CX-5461 in combination with Actinomycin D using the 






CX-5461 induces cell death and cell  cycle arrest in Ewing sarcoma cell 
lines 
 
Given the disparate sensitivity of cell lines to CX-5461, we initially examined the cellular 
outcome following CX-5461 treatment. Two highly sensitive (WE-68 and VH-64), a moderately 
sensitive (SK-N-MC) and a resistant (RD-ES) cell line were treated with CX-5461 for 24h or 48h 
and analysed for cell-cycle distribution using propidium iodide staining.  
 
Treatment with CX-5461 for  did not alter cell cycle profile of WE-68 and VH-64 compared to 
untreated controls (Figure 2A). However, as expected, these CX-5461 doses significantly 
increased cell death as shown by increase in sub-G1 peak (Figure 2B). In contrast, treatment 
with 200nM CX-5461 caused a significant G2/M arrest in SK-N-MC and RD-ES cell lines. In SK-M-
C, the G2/M population of CX-5461 treated cells was 48% after 48 hr compared to 17% cells in 
in untreated controls(Figure 2A). The most dramatic increase in G2/M cell population was 
observed for the CX-5461 resistant RD-ES cell line which displayed >300% increase in G2/M cell 
cycle arrest after 48h. The increase in G2 phase was found to be associated with a concomitant 
significant decrease in the S-phase populations. These data suggest that CX-5461 elicits 





Figure 2. Anti-proliferative effects of CX-5461 in Ewing sarcoma cell lines. Cells were treated 
with indicated CX-5461 doses for either 24 or 48h and Cell cycle distribution was determined by 
flow cytometry analysis of propidium iodide stained cells for A. G1/S/G2/M population and B. 






CX-5461 induced cell death in Ewing sarcoma cell lines is p53 dependent  
 
A number of lines of evidence suggest that the anti-proliferative activity of CX-5461 is due to its 
ability to activate p53 signalling, an important tumour suppressor pathway that is commonly 
deactivated in >50% of cancers. Although there was no statistical difference between LD50 
values of p53 mutant and p53 wild-type cell lines (supplementary figure 1), two of the most CX-
5461 sensitive cell lines had wild-type p53. Therefore, to determine whether sensitivity to CX-
5461 is driven by p53 function in Ewing sarcoma, we used siRNAs to specifically knock down 
p53 expression in these two cell lines. Significant silencing of p53 protein (>80%) expression 
was confirmed in western blot analysis (supplementary figure 6).  
  
Compared to cells transfected with control siRNA, WE-68 and VH-64 cell silenced for p53 
activity exhibited a modest 15-20% decrease in cell death when exposed to CX-5461 (Figure 
3A). This was not consistent with western blot analysis in which no appreciable increase was 
observed in either p53 or downstream target p21 protein expression except at the highest CX-
5461 dose (Figure 3B). However, treatment with 200nM CX-5461 caused over 15 fold induction 
in p21 mRNA levels (supplementary figure 7).  
 
Given the robust p21 induction and its role in p53 mediated cell cycle induction, we further 
assessed the inhibitory effect of CX-5461 on the cell cycle distribution in WE-68 cells silenced 
for p53 activity. Cell cycle profile of p53shRNA treated WE-68 cells showed that upon 24h 
treatment with 5nM CX-5461, these cells had a significantly higher proportion of G2/M cells 




response to CX-5461 treatment, in Ewing sarcoma cell lines both cell cycle and cell death 
function of p53 are engaged.  
Figure 3. CX-5461 induces anti-proliferative effect through a p53-depedent pathway. 7AAD 
uptake assay to determine the percentage (%) of dead cells of the A. WE-68 and WE-68 
p53shRNA (n = 2) and  VH-64 and VH-64 p53shRNA (n = 2) cell lines treated with CX-5461 as 




analysis of p53, p21, p53(phospho- serine 15) and B-tubulin protein levels in VH-64 and WE-68 
cell lines treated with increasing doses of CX-5461 for 24 h (representative of n = 2). C. Effect of 
CX-5461 on the cell cycle profile after p53 knock-down in WE-68 cells. Top, histograpms of PI 
staining in WE-68 Ewing sarcoma cell line transfected with scrambled shRNA treated with 
vehicle control or 5nM CX-5461 for 48h. Bottom, same as above using WE-68 cells treated with 
TP53 shRNA. 
 
CX-5461 induced ATM/ATR dependent G2/M arrest in resistant Ewing 
sarcoma cell lines  
 
A possible mechanism driving the high CX-5461 sensitivity in sarcoma cells is the ATM/ATR 
pathway. Several previous studies report that in acute lymphoblastic leukaemia cell lines, CX-
5461 treatment causes a non-canonical (non-genotoxic) ATM/ATR dependent G2/M cell cycle 
arrest22, 23 . The compounds KU-55933 and CGK733 have been reported as ATM and ATM/ATR 
dual inhibitors respectively. In WE-68 cells, pre-treatment with ATM or dual ATM/ATR inhibitor 
caused a 25% rescue in cell death caused by CX-5461 (Figure 4A). In contrast, pre-treatment 
with ATM or dual ATM/ATR inhibitor caused a significant 30% and 40% increase in cell death 
upon CX-5461 treatment compared to cells not pre-treated with ATM/ATR inhibitors. We 
expected that this observed increase in cell death was due to abrogation of G2/M arrest caused 
by CX-5461. Indeed, compared to 44.6% of RD-ES cells arrested in G2/M, 1hr pre-treatment 
with dual ATM/ATR inhibitor significantly down-regulated the G2/M arrested population to 
16.4% (Figure 4B). As expected, there were no significant changes in the cell cycle profile of the 
WE-68 cells. Overall, these results suggest that in CX-5461 resistant Ewing sarcoma cell lines, 
treatment with CX-5461 induces a G2/M arrest that can be abrogated with co-treatment with 






Figure 4. CX-5461 induces ATM/ATR driven cell cycle arrest in Ewing sarcoma cells. A. Sarcoma 
cell lines pre-treated with 200nM ATM and ATM/ATR inhibitors for 2 h and subsequently 
incubated in the absence or presence of CX-5461. Cell death was measured using 7AAD staining 
after 48h. B. Cell cycle analysis in WE-68 and RD-ES cells pre-treated with ATM inhibitor or 
ATM/ATR inhibitor for 2h and subsequently treated with CX-5461 (10 nM and 1000 nM for WE-






E2F1 protein levels predict response to CX-5461 
 
Regarding the mechanism by which CX-5461 might induce its anti-tumourigenic effects in the 
absence of p53 function, we focused our attention on the expression of E2F-1, a transcription 
factor that is engaged upon ribosomal stress. E2F1 has been shown to stabilize following rRNA 
transcription inhibition using low levels of actinomycin D. Therefore, we measured the 
expression of E2F-1 protein in the Ewing sarcoma panel exposed to CX-5461 for 16h. Although 
16h exposure to CX-5461 did not modify E2F1 expression compared with untreated cells, basal 
E2F1 protein levels significantly correlated with sensitivity to CX-5461 (Figure 5A and 5B). 
Sensitive cell lines WE-68, TC-71, SK-E-S1 expressed significantly higher levels of E2F1 compared 
to the moderately sensitive SKNMC or resistant RD-ES cell lines. 
 
Next, we assessed the effect of E2F-1 overexpression on the sensitivity to CX-5461. When RD-ES 
were transfected with E2F1 overexpression plasmid pCMV-E2F1-HA, >60% of cells lost viability 
Similar results were obtained from SK-N-MC cell lines overexpressing E2F1 through transfection 






Figure 5. E2F1 protein levels correlate with CX-5461 sensitivity in Ewing sarcoma cell lines. A. 
E2F1 protein expression was determined by western blot analysis, 16h after CX-5461 
treatment. B. Correlation between cytotoxic sensitivity to CX-5461 and E2F1 protein expression 
(quantified using ImageJ program). C. 7AAD cell viability after 48h in RD-ES cells transfected 
















Overall survival for patients with metastatic Ewing sarcoma is less than 30% with multi-agent 
chemotherapy24. Current multi-modal chemo regimens have made a big impact in improving 
Ewing sarcoma survival rates over the past decades, but they have reached their full capacity 
now and further improvements to survival can only come from non-genotoxic approaches. CX-
5461 is a novel non-genotoxic RNA polymerase I inhibitor that has demonstrated its anti-
proliferative effects in a vast panel of hematological and solid tumour cell lines. Encouraging 
results from initial in vitro and in vivo evaluations demonstrated hematological cell lines with 
wild-type p53 to be acutely sensitive to CX-5461, which has led to Phase I/II clinical evaluations 
of CX-5461 in advanced hematological malignancies. Given that approximately 90% of Ewing 
sarcomas retain a functional wild-type p53, we hypothesized that activation of the p53 pathway 
via CX-5461 has potential for Ewing sarcoma treatment.  
 
Here, we show that Ewing sarcoma cell lines are exquisitely sensitive to CX-5461, with a subset 
(WE-68, VH-64 and SKES-1) undergoing cell death at extremely low CX-5461 doses (LD50 
<15nM; 48h). Comparison of LD50 values from previously published studies revealed Ewing 
sarcoma is by far the most responsive solid tumour to CX-5461 that has been tested to date. In 
particular, VH-64 and WE-68 Ewing sarcoma cell lines showed sensitivities lower than any ever 
reported in the literature for solid tumours and parallel some of the most potent responses 
observed in blood cancers. In both VH-64 and WE-68, the anti-tumorigenic response to CX-5461 




sensitivity to CX-5461. Furthermore, cell cycle analysis of WE-68 cells silenced for p53 activity 
showed a significant G2/M arrest compared to scramble controls. Combination drug 
experiments revealed synergistic interaction with Actinomycin D in both wild-type p53 WE-68 
and p53 null SK-N-MC cell lines. Previous studies have reported that at low nM doses 
Actinomycin D causes p53 stabilization and subsequent cell death suggesting that CX-5461 may 
be effective in Ewing sarcoma cases that do not retain functional p53 25.  
 
p53 mutant RD-ES and p53 null SK-N-MC cell lines that were inherently resistant to CX-5461, 
underwent a G2/M arrest. We demonstrate that this G2/M cell cycle arrest is driven via 
checkpoint kinases ATM/ATR in Ewing sarcoma cells. Furthermore, pre-treatment with 
ATM/ATR inhibitor CGK733 abrogates CX-5461 mediated G2/M arrest and results in cell death.  
This observation is consistent with previous studies that show that CX-5461 treatment induces 
an ATM/ATR dependent G2/M cell cycle arrest in both hematological cell and solid cancer cell 
lines in a p53-independent manner 22, 26-28.  
 
The fact that CX-5461 was able to induce cell death in mutant p53 cell lines (SK-ES-1 and TC-71) 
implies the involvement of p53-independent mechanisms. Apart from inducing p53-dependent 
signaling, ribosomal stress is also known to induce p53-independent signaling through E2F1 
(reviewed in29). Indeed, our results strongly indicate that cell line sensitivity to CX-5461 was 
reflected in E2F1 protein expression in Ewing sarcoma cell panel.  This is in line with a previous 
study that shows that in response to low doses of Actinomyic D, p53 deficient neuroblastoma 




that CHK1 and CHK2 promote E2F1 stabilization and activity after ribosomal stress in a p73-
dependent manner as a backup when p53 is defective to ensure that damaged cells can 
undergo cell death 30. Role of E2F1 in CX-5461 mediated cell death is also consistent with the 
observation that autophagy is the mechanism of CX-5461 mediated cell death in solid cancers 
(ref). It is likely that cellular outcome following CX-5461 treatment is determined by a complex 
interplay and cross-talk between E2F1- ATM/ATR and E2F1-p53 determine cellular outcome 
and warrants further experimentation.  
 
In conclusion, we show that Ewing sarcoma cell lines are exquisitely sensitive to CX-5461. 
Amongst all cancers screened to date, Ewing sarcoma are by far the most responsive solid 
tumour. Sensitivity to CX-5461 is driven by both p53 dependent and p53-independent 
mechanisms, and likely through the E2F1 pathway. Furthermore, combination of CX-5461 with 
chemotherapeutic Actinomycin D produces synergistic interaction and causes potent cell death. 
Taken together, our study provides encouraging pre-clinical results for the application of CX-
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Figure 2. Relative LD50 of all solid tumour cell lines published. Ewing sarcoma cell lines (in red) 
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Figure 5. CX-5461 combination charts and heat map with various chemotherapies. Combination 
indices show that combination with most chemotherapies (Doxorubicin, Vincristine, and 
Etoposide) were either antagonistic or additive in all three cell lines for most concentrations 
tested. One exception was the comibation with Nutlin (a p53 activatior) in WE-68 cell line, 




























Figure 7. mRNA expression levels of p21 in cell lines treated with 200nM CX-5461. Error bars 







































XI-006 induces potent p53-independent apoptosis in Ewing sarcoma 
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This study has evaluated the molecular and cellular responses of cultured Ewing sarcoma cell 
lines following exposure to XI-006, a MDM2 inhibitor. Treatment with XI-006 results in potent 
p53-independent apoptosis at non-DNA damaging concentrations in Ewing sarcoma cell lines.  
Notably, strong synergy was observed with olaparib, a PARP inhibitor that is gaining significant 
interest for the treatment of solid cancers and thus represents a novel therapeutic intervention 
for the treatment of Ewing sarcoma.  
 
This research has been published in Scientific Reports. (Dec, 2016) and this chapter is the 
published version of the manuscript.  
 















There is an imperious need for the development of novel therapeutics for the treatment of 
Ewing sarcoma, the second most prevalent solid bone tumour observed in children and young 
adolescents. Recently, a 4-nitrobenzofuroxan derivative, XI-006 (NSC207895) was shown to 
diminish MDM4 promoter activity in breast cancer cell lines. As amplification of MDM4 is 
frequently observed in sarcomas, this study examined the therapeutic potential of XI-006 for 
the treatment of Ewing and osteosarcoma. XI-006 treatment of Ewing and osteosarcoma cell 
lines (n = 11) resulted in rapid and potent apoptosis at low micro-molar concentrations 
specifically in Ewing sarcoma cell lines (48 hr IC50 0.099–1.61 μM). Unexpectedly, apoptotic 
response was not dependent on MDM4 mRNA/protein levels or TP53 status. Alkaline/neutral 
comet and γH2AX immunofluorescence assays revealed that the cytotoxic effects of XI-006 
could not be attributed to the induction of DNA damage. RNA expression analysis revealed that 
the mechanism of action of XI-006 could be accredited to the inhibition of cell division and cycle 
regulators such as KIF20A and GPSM2. Finally, potent synergy between XI-006 and olaparib 
(PARP inhibitor) were observed due to the down-regulation of Mre11. Our findings suggest that 












Sarcomas are a group of rare malignancies that affect approximately 200,000 individuals 
worldwide each year1. Exemplifying the heterogeneous nature of this malignancy type, 
approximately 50 distinct histological subtypes of sarcoma have been identified to date, ranging 
from indolent to highly invasive and metastatic2. The introduction of cytotoxic 
chemotherapeutic agents such as doxorubicin in the 1960’s for chemo-sensitive subtypes was a 
paradigm shift in oncology practice, however current multi-agent chemotherapeutic regimens 
are associated with significant cumulative and late toxicities. With the exception of 
gastrointestinal stromal tumours (GIST), limited progress in the management of sarcomas has 
been achieved over the past few decades years. For this reason, the advent of novel and 
targeted therapeutics with favourable efficacy and toxicity profiles are eagerly awaited, 
especially for those 20–40% of patients with non-responding, unresectable or metastatic 
disease. 
 
Cancer is a multifaceted process that can arise due to the activation of proto-oncogenes and/or 
inactivation of tumour suppressor genes. The development of novel anti-cancer agents, 
specifically those focused on targeting oncogene addiction has undergone a dramatic 
renaissance over the past decade. One particular oncogene which has gained significant 
interest is MDM4 (Mouse Double Minute 4), a structural homologue of MDM2, thought to 
promote tumourigenesis via its ability to inhibit the tumour suppressor function of TP533. In 
keeping with this hypothesis, amplification and/or overexpression of MDM4 has been 




retinoblastoma (65%)5, head and neck squamous carcinoma (50%)6 , breast (19%)3 and 
sarcoma (17%)7,8. In particular, MDM4 copy number gain was documented in 54% of 
conventional, intramedullary, high-grade osteosarcomas and 33% of parosteal osteosarcomas9. 
Furthermore, amplification of MDM4 defined as >3 fold was shown to be a distinctive attribute 
of Ewing, synovial and osteosarcomas, with amplification observed in 50%, 44% and 35% of 
tumour samples respectively8. Prevailing evidence suggests that MDM4 primarily represses the 
transcriptional activity of p53 by binding its trans-activation domain. However, although 
displaying no intrinsic E3 ubiquitin ligase activity, MDM4 can also regulate p53 stability by 
promoting MDM2-mediated degradation10,11. 
 
Owing to the prevalence of MDM4 genomic amplification/mRNA overexpression in human 
cancers, several strategies aimed at inhibiting the oncogenic activity of MDM4 have been 
explored. Although a selective MDM4 small-molecule inhibitor does not currently exist, the first 
reported p53-MDM4 antagonist, SJ-172550, did exhibit cytotoxicity in retinoblastoma cells12. 
However, the thiol reactivity of SJ-172550 precludes its chemical scaffold from further 
development13. Recently, a peptide antagonist of the p53-MDM4 interaction, designated SAH-
p53-8 has been developed. This stapled peptide possesses substantially improved 
pharmacokinetic profiles compared to non-stapled peptide counterparts, and has nano-molar 
binding affinity to the N-terminal p53-binding pocket of both MDM2 and MDM414. However, 
the bioavailability of stapled peptides and their potential as therapeutic agents has been 
questioned. Small molecules are considered more desirable for cancer therapy as their cellular 




pinocytosis, which is less effective15. Indeed, this is highlighted by the fact that high 
concentrations of SAH-p53-8 (15–30 μM) were required to induce significant cytotoxicity in 
melanoma cells in vitro, uptake was attenuated in the presence of serum, and complete 
regression of xenograft tumours was not achieved4,16. Given that aberrant transcription of 
MDM4 can be attributed to its overexpression in cancer17, Wang and colleagues employed a 
high-throughput drug screening strategy to identify small molecules that could mitigate MDM4 
promoter activity. A 4-nitrobenzofuroxan derivative, designated XI-006 (NSC207895) was 
identified and was shown to repress MDM4 promoter activity resulting in decreased MDM4 
mRNA and protein expression and cell viability in MDM4 amplified breast cancer cell lines18. 
To our knowledge, no studies have hitherto directly addressed whether repression of MDM4 
activity can represent a novel therapeutic strategy for the treatment of sarcomas. In particular, 
as MDM4 amplification is a characteristic of both Ewing and osteosarcoma, this study has 
examined the biological effects of XI-006 both as a single agent and in combination with 
standard chemotherapeutic agents and olaparib (PARP inhibitor) in a comprehensive panel of 
Ewing and osteosarcoma cell lines in vitro. Specifically, treatment of Ewing sarcoma cell lines 
resulted in potent apoptosis that was remarkably not dependent on MDM4 mRNA or protein 











MDM4 protein is overexpressed in sarcomas 
 
The majority of studies that have evaluated sarcoma MDM4 expression levels have done so 
through quantification of mRNA. As MDM4 mRNA expression was recently shown not to 
correlate with protein expression in freshly isolated human melanomas4, these previous 
studies may have grossly underestimated the frequency of MDM4 protein expression in 
sarcomas. Indeed, MDM4 mRNA overexpression was not observed in our previous cohort of 24 
sarcoma tissues19. As such, MDM4 protein expression in a cohort of 36 sarcoma samples of 
varying histopathology was determined through immunohistochemical analysis (IHC). Although 
MDM4 expression was very low to undetectable (<10% MDM4 positive cells) in 24/36 (66.7%) 
of tumour samples, strong positive staining was observed in 12/36 (33.3%) cases (Fig. 1a, Table 
1). Grade III staining (>51% positive MDM4 cells) was only observed in one de-differentiated 
liposarcoma (Tumour SE74). Interestingly, well/de-differentiated liposarcomas and 
myxofibrosarcomas exhibited significantly higher levels of MDM4 protein expression compared 











Figure 1: MDM4 protein is overexpressed in sarcomas 
a) Representative images of sarcoma MDM4 immunohistochemical staining. MDM4 grading 
determined from the average number of MDM4 positive cells from four fields of view, Grade 0 
(<10% positive cells), Grade I (11–25% positive cells), Grade II (26–50% positive cells), Grade III 
(>51% positive cells) Scale bar=100uM. (b) Correlation between sarcoma pathology and 
percentage positive MDM4 cells determined from immunohistochemical analysis. Asterisk 
denotes statistical significance in MDM4 expression (****P < 0.0001). (c) Lack of correlation 
between MDM4 SNP34091 genotype (AA, AC, CC) and percentage positive MDM4 cells 















SE74* M De-differentiated 
liposarcoma 
51.8 ± 2.3 3 A/A 
SE73 M Well-differentiated 
liposarcoma 
36.2 ± 5.4 2 A/A 
SE10* M Well-differentiated 
liposarcoma 
30.2 ± 1.8 2 A/C 
SE18* M Myxofibrosacroma 28.8 ± 2.5 2 C/C 
SE31 F Undifferentiated 
pleomorphic sarcoma 
23.8 ± 5.1 1 A/A 
SE13* F Myxofibrosacroma 23.6 ± 3.7 1 A/C 
SE15* F Myxofibrosacroma 18.3 ± 1.7 1 A/A 
SE1 M Myxofibrosacroma 17.7 ± 2.0 1 C/C 
SE27* F Radiation induced sarcoma 16.5 ± 1.9 1 A/A 
SE61* M Well-differentiated 
liposarcoma 
15.4 ± 2.6 1 A/A 
SE7* M Pleomorphic liposarcoma 12.9 ± 2.8 1 A/C 
SE24* M Leiomyosarcoma 10.7 ± 4.0 1 A/C 
SE35* M Myxoid liposarcoma 6.1 ± 1.5 0 A/C 
SE72* M Undifferentiated 
pleomorphic sarcoma 
5.8 ± 2.3 0 A/A 
SE39* M De-differentiated 
liposarcoma 




SE54 M Well-differentiated 
liposarcoma 
3.5 ± 1.0 0 C/C 
SE58* F Myxofibrosacroma 3.2 ± 1.4 0 A/A 
SE100 M Chondrosarcoma 2.6 ± 0.6 0 A/C 
SE43* F Undifferentiated 
pleomorphic sarcoma 
2.5 ± 1.3 0 A/A 
SE108 F Undifferentiated 
pleomorphic sarcoma 
2.4 ± 2.0 0 C/C 
SE66 F Leiomyosarcoma 1.9 ± 1.0 0 A/C 
SE115 F Leiomyosarcoma 1.7 ± 1.0 0 A/A 
SE105 M Synovial Sarcoma 1.5 ± 0.8 0 A/A 
SE69* M Undifferentiated 
pleomorphic sarcoma 
0.7 ± 0.7 0 A/C 
SE79* F Undifferentiated 
pleomorphic sarcoma 
0.6 ± 0.0 0 C/C 
SE51* F Osteosarcoma 0.5 ± 0.5 0 A/A 
SE52* F Leiomyosarcoma 0.4 ± 0.2 0 A/C 
SE41* M Ewing sarcoma 0.3 ± 0.2 0 A/C 
SE104 M Undifferentiated 
pleomorphic sarcoma 
0.3 ± 0.3 0 A/C 
SE88 M Osteosarcoma 0.3 ± 0.2 0 A/A 
SE86 F Undifferentiated 
pleomorphic sarcoma 
0.3 ± 0.2 0 A/A 
SE3 F Undifferentiated 
pleomorphic sarcoma 
0.2 ± 0.2 0 C/C 
SE83 M Leiomyosarcoma 0.2 ± 0.2 0 A/C 
SE47* M Angiosarcoma 0.2 ± 0.2 0 A/A 




SE45 M Leiomyosarcoma 0.0 ± 0.0 0 A/A 
MDM4 IHC Grade 0 (<10% positive cells), Grade I (11–25% positive cells), Grade II (26–50% 
positive cells), Grade III (>51% positive cells). * Denotes sarcoma samples previously described 
in Pishas et al., 2014. 
 
Recently, Wynendaele and colleagues reported that presence of a single nucleotide 
polymorphism (SNP34091, rs4245739) located 32 nucleotides downstream of the stop codon in 
the 3’UTR of MDM4 was associated with statistically significant increased MDM4 protein 
expression in high-grade ovarian carcinomas20. This A>C transversion was reported to create a 
putative illegitimate target site for hsa-miR-191, which only recognised the 3’UTR of the 
MDM4-C allele resulting in decreased MDM4 mRNA and protein expression. To determine 
whether SNP34091 regulates MDM4 protein expression in sarcomas, the 3’UTR of MDM4 was 
sequenced. Genotypes were as follows, 17 (47.2%) were homozygous for the wild-type allele 
(A/A), 12 (33.3%) were heterozygous (A/C) and 7 (19.4%) were homozygous for SNP34091 (C/C) 
(Table 1). Presence of the C allele was not significantly associated with decreased MDM4 
protein expression within our sarcoma cohort (AA vs AC: P = 0.521) (AA vs CC: P = 0.624) (Fig. 
1c). 
XI-006 induces potent apoptosis in Ewing sarcoma cell lines. 
 
As amplification of MDM4 is frequently observed in Ewing and osteosarcomas8, the anti-
tumour activity of XI-006 was evaluated in a panel of eleven Ewing and osteosarcoma cell lines. 




degree of apoptosis determined after 24 and 48 hrs of treatment through 7AAD staining and 
flow cytometry. A pronounced reduction in cell viability was observed specifically in Ewing 
sarcoma cell lines at low micro-molar concentrations (Table 2, Fig. 2a). Following treatment, 
concentrations of XI-006 required to induce 50% apoptosis (IC50) in Ewing sarcoma cell lines 
ranged from 0.376–2.46 μM and 0.099–1.61 μM, 24 and 48 hr treatment respectively. In 
contrast, osteosarcoma cell lines required significantly higher levels of XI-006 (P = 0.008) to 
achieve an IC50, range of 3.60–>10 μM and 2.14–5.41 μM, 24 and 48 hr treatment respectively 
(Fig. 2b). Importantly, the viability of normal human fibroblasts (IMR90) remained unaffected at 
these low micro-molar concentrations, IC50 of 8.35 μM and 6.80 μM (24 and 48 hr treatment 
respectively) (Table 2). Colony formation assays were performed to investigate the long term 
effect of XI-006 on cellular proliferation. Following 10 days of XI-006 treatment, no colonies 
were observed at any XI-006 concentration exceeding 0.03 μM in TC252 and RD-ES Ewing 
sarcoma cell lines, and 0.11 μM in U20S and SJSA osteosarcoma cell lines (Supplementary Fig. 
S1a,b). In contrast, numerous colonies were observed at the maximum XI-006 concentration 
tested (3 μM) in IMR90 fibroblasts (Supplementary Fig. S1c), highlighting the tumour specific 


















 (nM, 24 hr) 
XI-006 IC50 
 (nM, 48 hr) 
STA-ET-1 ES Wild-type 1.68 ± 0.03 376.3 ± 26.9 98.9 ± 19.5 
TC252 ES Wild-type 2.74 ± 0.04 390.2 ± 106.6 115.6 ± 6.6 
SK-N-MC ES Truncation 0.61 ± 0.00 472.3 ± 176.4 121.8 ± 31.7 
SK-ES-1 ES Cys176Phe 0.70 ± 0.01 442.4 ± 57.5 236.0 ± 15.0 
RD-ES ES Arg273Cys 0.32 ± 0.00 638.9 ± 142.4 299.7 ± 68.5 
TC71 ES Truncation 0.40 ± 0.02 567.9 ± 150.8 396.1 ± 78.8 
WE-68 ES Wild-type 1.09 ± 0.04 2089.3 ± 20.4 1475.7 ± 222.6 
VH-64 ES Wild-type 1.07 ± 0.01 2456.4 ± 315.1 1613.1 ± 274.4 
Saos-2 OS Null 0.17 ± 0.00 3600.2 ± 525.7 2143.0 ± 34.9 
SJSA OS Wild-type 0.15 ± 0.01 6257.1 ± 366.5 3690.5 ± 270.2 
U20S OS Wild-type 1.94 ± 0.04 >10 000 5416.8 ± 255.7 
IMR90 LFB Wild-type — 8348.0 ± 231.0 6802.1 ± 696.5 
ES: Ewing sarcoma, OS: Osteosarcoma, LFB: Lung fibroblast 
IC50: Concentration of XI-006 required to induce 50% apoptosis (mean ± STDEV from two 
independent experiments).MDM4 mRNA expression determined through real-time qPCR 






Figure 2: MDM4 mRNA and protein levels do not confer XI-006 sensitivity 
(a) XI-006 apoptotic dose response curves of all sarcoma cell lines following 48 hrs of XI-006 
treatment. Dashed and red lines denote osteosarcoma and mutant TP53/null cell lines 




reactions. (b) Correlation between XI-006 apoptotic 48 hr IC50 values determined from 7AAD 
staining and sarcoma pathology. (c) STA-ET-1, TC252, WE-68 and U20S cells were treated with 
XI-006 (0, 2.5 and 5 μM) for the indicated times with mRNA expression levels of MDM4 
determined through real-time qPCR analysis. Data represents mean expression (fold 
change) ± SE from triplicate reactions. (d) TC252, WE-68 and U20S cell lines were treated for 
4 hrs with the indicated concentrations of XI-006. MDM4, p53, and phosphorylated p53 (serine 
15) protein levels were detected through western blot analysis. β−Actin was used a loading 
control. (e) Lack of correlation between XI-006 apoptotic 48 hr IC50 values and basal MDM4 
mRNA expression levels. ♦• Denotes Ewing sarcoma and osteosarcoma cell lines respectively. 
(f) Western blot analysis of basal MDM4 protein levels of the cell line cohort. Cell lines ranked 
in order of XI-006 sensitivity. MCF-7 (MDM4 amplified breast cancer cell line) was used as a 
positive control. Luciferase assay of (g) MDM4 and (h) p21 promoter activity from U20S cells 
treated with XI-006 for 6 hrs. Data represents mean ± SE from 3 independent experiments. 
Asterisk denotes statistical significance (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). 
 
To examine the cellular outcome following XI-006 treatment, cell lines were treated with XI-006 
for 48 hrs, with cell cycle distribution determined through propidium iodide (PI) staining 
(Supplementary Fig. S2). In the Ewing sarcoma cell lines TC252 and RD-ES, XI-006 induced a 
dose-dependent decrease in the number of G1-phase cells, and accumulation of cells in SubG1. 
In contrast, XI-006 effectively arrested cell cycle progression in osteosarcoma cell lines (U20S, 
Saos-2), depleting the G1 compartment to 18.6–19.9% and increasing the G2 compartment to 




MDM4 mRNA and protein levels do not confer sensitivity to XI-006 
 
As XI-006 was shown to decrease MDM4 expression in breast cancer cell lines18, we 
investigated the effects of XI-006 on both MDM4 mRNA and protein levels in cell lines with 
varying MDM4 genomic21, mRNA and protein expression levels (Table 2, Fig. 2f). A maximum 
61.2% reduction in MDM4 mRNA expression was observed in U20S cells (2.5 μM, 4 hrs) 
following XI-006 treatment; however U20S cells were the least sensitive cell line to XI-006 (Fig. 
2c). Although XI-006 did not attenuate MDM4 mRNA levels in the sensitive Ewing sarcoma cell 
line TC252, a 23.1% reduction was observed in WE-68 cells (0.5 μM, 12 hrs), the least sensitive 
Ewing sarcoma cell line. Consistent with these findings, a dose-dependent reduction in MDM4 
protein levels following XI-006 treatment was only observed in U20S and WE-68 cells, but not 
TC252 cells (Fig. 2d). We next determined whether basal MDM4 mRNA and protein levels in our 
cohort of cell lines confers sensitivity to XI-006. Unexpectedly, no correlation between MDM4 
mRNA or protein levels and XI-006 sensitivity was observed (R2 = 0.0005) (Table 2, Fig. 2e,f). To 
confirm whether XI-006 can repress MDM4 promoter activity, luciferase assays of U20S cells 
treated with escalating concentrations of XI-006 for 6 hrs were performed. A significant 
decrease in MDM4 promoter activity was only observed at 4 μM (P = 0.05), equating to a 30.5% 
reduction in activity (Fig. 2g). No effect on p21 promoter activity was observed at this dose 
(P = 0.491) (Fig. 2h). As X1-006 had no effect on MDM4 promoter activity or mRNA/protein 
levels at concentrations required to induce 50% apoptosis in the most sensitive Ewing sarcoma 
cell lines (<0.5 μM), this suggest that the ability of XI-006 to impart apoptosis occurs 





XI-006 cytotoxicity occurs independently of TP53 
 
We next examined whether XI-006 can induce expression of TP53 target genes implicated in 
apoptosis (BAX, PUMA), cell cycle arrest (CDKN1A) and p53 regulation (MDM2). Wild-type TP53 
Ewing (TC252, STA-ET-1, WE-68) and osteosarcoma (U20S, SJSA) cell lines were treated with XI-
006 (0.5, 2.5 μM), with target gene expression assessed through real-time qPCR assays 
(Supplementary Fig. S3a). XI-006 dramatically increased mRNA expression levels of all TP53 
target genes in Ewing sarcoma cell lines in a dose and time dependent manner. A maximum 63 
fold increase in BBC3 levels was observed in STA-ET-1 cells (2.5 μM, 4 hrs). In contrast, 
induction of these target genes was significantly lower in all osteosarcoma cell lines, in 
particular BAX and CDKN1A, where no induction was observed for all time points and XI-006 
concentrations. 
To determine whether induction of p53 target genes specifically in Ewing sarcoma cells could 
be attributed to activation and stabilisation of p53, p53 protein levels following XI-006 
treatment were examined. Activation and stabilisation of p53 protein levels was only observed 
in TC252 and WE-68 Ewing sarcoma cell lines but not U20S cells following 4 hrs of XI-006 
treatment (Fig. 2d). Furthermore, phosphorylation of p53 at serine 15 which is synonymous 
with ATM dependent activation of the DNA damage pathway22 was observed at XI-006 
concentrations exceeding 0.5 μM. Although XI-006 induced expression of TP53 target genes, 
the cytotoxic effects of XI-006 were shown to be TP53 independent, as XI-006 sensitivity was 
not correlated with TP53 status (P = 0.190) (Supplementary Fig. S3b). Indeed, the least sensitive 
Ewing (WE-68, VH-64) and osteosarcoma (U20S, SJSA) cell lines harboured wild-type p53 (Table 




isogenic cell lines were treated with XI-006 (0–10 μM) (Supplementary Fig. S3c). No significant 
difference in both XI-006 IC50 
 values (24 hr: P = 0.230, 48 hr: P = 0.505) or relative viability at any concentration tested was 
observed, endorsing the p53-independent cytotoxic effects of XI-006. 
 
Low micro-molar concentrations of XI-006 do not induce DNA damage 
 
Previous reports proposed that XI-006 activates the DNA damage response pathway leading to 
a delay in cell cycle progression23. As XI-006 cytotoxicity occurs independently of MDM4, we 
sought to address whether XI-006 drives apoptosis through DNA damage. Clustering of 
phosphorylated H2AX moieties (γH2AX foci) at the site of double-strand breaks (DSBs) is one of 
the earliest events indicative of DNA damage24. Indeed a dose dependent increase in γH2AX 
foci was detected through immunofluorescence analysis following 4 hrs of XI-006 treatment in 
TC252 and U20S cells (Fig. 3a). At 4 μM 64.7–79.3% of cells (TC252 and U20S respectively) 
displayed >5 positive γH2AX foci. However at low doses required to induce apoptosis in the 
most sensitive Ewing sarcoma cell lines (0.5 μM), positive γH2AX foci were only detected in 9.9–
17.4% of cells (Fig. 3b). In agreement with these findings XI-006 induced γH2AX foci formation 
was correlated with H2AX phosphorylation (Fig. 3c). Neutral comet assays were also employed 
to determine whether low dose XI-006 (0.075, 0.150, 0.300 μM) induces DSB’s following long 
term exposure (20 hrs) n TC252 and RD-ES cells (Fig. 3d). No significant difference in comet tail 
length was observed in comparison to vehicle control treated cells at any XI-006 concentration 





Figure 3: XI-006 does not induce double-strand break DNA damage at low micro-molar 
concentrations. (a) Representative images of γH2AX foci formation (immunofluorescence) from 
TC252 and U20S cells treated with the indicated concentrations of XI-006 for 4 hrs. Cells were 




cells treated as in (a) (mean ± STDEV from duplicate wells). (c) Western blot analysis of γH2AX 
protein levels in TC252 cells treated as in (a). β-Actin was used as the loading control. (d) 
Representative images of neutral comet assays from TC252 and RDES cells treated with low 
dose XI-006 (0.075, 0.150, 0.300 μM) for 20 hrs. (e) Quantification of tail length from cells 
treated as in (d), mean ± SE. 
 
The serine/threonine protein kinase ATM (ataxia telangiectasia mutated) is critical for sensing 
and co-ordinating repair of DNA DSBs. To further confirm that the cytotoxic effects of XI-006 
was not due to DNA damage at low concentrations, Ewing cells (TC252, RD-ES and WE-68) were 
pre-treated with the ATM inhibitor KU-55933, before the addition of XI-006 (0.02–5 μM). A 
significant reduction in both ATM and ATR mRNA expression (82.0% and 87.5% respectively) 
was observed following monotherapy KU-55933 treatment (5 μM) (Supplementary Fig. S4a,b). 
No significant difference in XI-006 apoptotic IC50 values (24 and 48 hr treatment) was observed 
following ATM inhibition across all cell lines tested (Supplementary Fig. S4c). 
 
Previous chemogenomic profiling studies suggested that XI-006 imparts its cytotoxic effect 
through the activation of the DNA-damage-response pathway. Phosphorylation of the N-
terminal domain of EWS-FLI1, the hallmark gene fusion of Ewing sarcoma, at Thr25 has been 
reported in response to mitogen or DNA alkylating agent induced DNA damage26. This post-
translational modification was found to be catalysed by p38α/p38β mitogen-activated protein 
kinases (MAPKs). As all Ewing sarcoma cell lines utilised in this study harbour the EWS-FLI1 




were pre-treated with the p38α/p38β MAPK inhibitor BIRB 796 (0.1, 1 and 10 μM) before the 
addition of XI-006 (0–2.5 μM) for 24 and 48 hrs. BIRB 796 was previously shown to inhibit 
p38α/p38β MAPKs specifically at 0.1 μM, p38y/p38δ MAPKs at 1 μM and completely suppress 
the activation and activity of all JNKs at 10 μM26 in Ewing cell lines. Treatment with BIRB 796 
had no effect on XI-006 induced cytotoxicity (24 and 48 hrs), as a significant reduction in 
apoptosis (>30%) was not observed at any BIRB 796 concentration (Supplementary Fig. S5). 
 
Finally, alkaline comet assays were employed to investigate whether XI-006 induces single-
strand break DNA damage. Following 4 hrs of XI-006 treatment, a significant increase in comet 
tail and length was only observed at concentrations exceeding 2 μM (Fig. 4). Collectively these 
results suggest that XI-006 concentrations (<0.5 μM) required to induce apoptosis in sensitive 














Figure 4: XI-006 does not induce single-strand break DNA damage at low micro-molar 
concentrations. a) Representative images of alkaline comet assays from TC252 and U20S cells 
treated with XI-006 (1, 2, 4 μM) for 4 hrs. Etoposide (ETO) was used as a positive control (b) 
Quantification of tail length and tail moment from cells treated as in (a) mean ± SE. 
XI-006 synergises with olaparib, actinomycin D, doxorubicin and etoposide 
 
As conventional single-agent cancer therapy increases the likelihood of the emergence of 
resistant cancer cell clones, combination therapies are required to achieve maximal therapeutic 
response. As such, the ability of XI-006 to enhance the cytotoxic effects of four standard Ewing 
sarcoma chemotherapeutic agents (vincristine, actinomycin D, doxorubicin or etoposide) was 




Modest synergistic combination indexes (CI < 1) were observed in 4/5 cell lines for actinomycin 
and doxorubicin and 3/5 cell lines tested for etoposide (CI range 0.753–0.989) over multiple 
chemotherapeutic doses (Supplementary Table S2, Supplementary Fig. S6). Although 
antagonistic CI values were obtained between XI-006 and vincristine (inhibitor of microtubule 
assembly), a strong correlation (R2  = 0.722) was observed between XI-006 and vincristine IC50 
 values in all Ewing sarcoma cell lines, suggesting that these two agents may have a similar 
mechanism of action (Supplementary Fig. S7). 
 
The EWS-FLI fusion protein has been shown to drive expression of PARP1 (poly-ADP-ribose 
polymerase), which subsequently further promotes transcriptional activation by EWS-FLI27. The 
primary function of PARP is to sense and mediate repair of DNA single strand breaks (SSB). 
Therefore we determined if XI-006 can synergise with olaparib (PARP inhibitor) in EWS-FLI 
positive Ewing sarcoma cell lines. TC252, RD-ES and WE-68 cells were pre-treated with olaparib 
prior to addition of XI-006 (0–5 μM). Potent synergy between these two agents was observed in 
all cell lines tested and across multiple XI-006 concentrations, 24 and 48 hrs post XI-006 
treatment. A maximum 51.9% increase in apoptosis was observed in RD-ES cells when these 
two agents were combined (48 hr XI-006 treatment) (Fig. 5a). Olaparib did not abrogate the 
cytotoxic effects of XI-006 at any concentration tested, suggesting that XI-006 does not induce 







Figure 5: Inhibition of PARP potentiates the cytotoxic effects of XI-006 
a) TC252, RD-ES and WE-68 were pre-treated with olaparib (0.5 or 1 μM) or vehicle control 
(DMSO) for 2 hrs, prior to the addition of XI-006 (0–5 μM). Cell viability was determined 
through 7AAD staining (24 and 48 hrs post XI-006 treatment) and analysed by flow cytometry. 




denotes significant increase in apoptosis compared to XI-006 alone (*15–30%, **31–45%, 
***>46% increase). (b) STA-ET-1, RDES, WE-68 and U20S cells were treated with XI-006 (0.5, 
1.25, 2.5 μM) for 4 and 8 hrs. mRNA expression levels of Mre11 were determined through real-
time qPCR analysis. Data represents mean expression (fold change) ± SE from triplicate 
reactions. (c) RD-ES cells were pre-treated with Olaparib for 2 hrs prior to the addition of XI-006 
(0.5, 1, 2 μM) for an additional 4 hrs. Mre11 mRNA expression levels determined as in (b). 
Asterisk denotes statistical significant reduction in expression compared to either vehicle 
control (b) or XI-006 treatment alone (c) (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). 
 
In addition to repair of SSB, PARP detects stalled replication forks and attracts Mre11 (meiotic 
recombination 11) for end processing to facilitate replication restart and recombination 
repair28. As XI-006 was previously shown to induce a significant delay in replication23, Mre11 
mRNA expression levels following XI-006 treatment was assessed. A decrease in Mre11 mRNA 
expression was observed across all cell lines tested, with a maximum 50.1% reduction observed 
in STA-ET-1 cells (8 hr treatment) (Fig. 5b, Supplementary Fig. S8). As PARP mediates the 
recruitment Mre11 to stalled replication forks, Mre11 expression in RD-ES pre-treated with 
olaparib (1 μM) before the addition of XI-006 was assessed. Olaparib treatment alone resulted 
in a significant 25% decrease in Mre11 mRNA expression (Fig. 5c). Co-treatment with XI-006 
(0.5 and 1 μM) further repressed Mre11 mRNA expression levels, maximum 50.4% reduction 
compared to XI-006 treatment alone observed. Together, these findings indicate that in the 
absence of DNA damage low micro-molar concentrations of XI-006 can potentiate the cytotoxic 




HEG1, FLOT1, UTRN and EDIL3 are differentially expressed in Ewing and osteosarcoma cells 
following XI-006 treatment. 
 
mRNA sequencing of XI-006 treated and untreated cell lines was employed to identify genes 
responsible for XI-006 cytotoxicity. Across all Ewing and osteosarcoma cell lines eleven genes 
were found to be either significantly (P < 0.05, Bonferroni correction) repressed (KIF20A, IDH1, 
SCD, GPSM2, EIF2AK4, HIBCH) or induced (STK19, DNAJC24, MTG2, FAM175B, CYB5D1) 
following non DNA-damaging XI-006 treatment (0.5 μM) (Table 3). Real-time qPCR analyses 
confirmed that KIF20A which is required for normal cleavage furrow ingression and cytokinesis 
during cell division29 and IDH1 (cytosolic NADP dependent enzyme) were repressed on average 
by 51.2% and 41.3% respectively across all cell lines following XI-006 treatment (Supplementary 
Fig. S9). 
 
We next sought to identify genes that were differentially expressed between Ewing and 
osteosarcoma cell lines following XI-006 treatment. Four genes (UTRN, HEG1, FLOT1, EDIL3) 
were identified and validated through real-time qPCR analysis (Table 3, Supplementary Fig. 
S10). Of particular interest UTRN which mediates several mitochondria dependent apoptosis 
pathways, was found to be significantly up-regulated in Ewing cell lines (average 22.7% 
increase) which undergo apoptosis following XI-006 treatment, and repressed in osteosarcoma 






Table 3: Genes identified from RNA expression profiling of Ewing and osteosarcoma cell lines treated with XI-006. 
 
Genes significantly induced or repressed following XI-006 across all sarcoma cell lines 
Accession 
Number 
Gene Location Full Name % Change   P value 
NM_005733 KIF20A 5q31 Kinesin family member 20A −44.49   0.0214 
NM_005063 SCD 10q24.31 Stearoyl-CoA desaturase (delta-9-
desaturase) 
−38.01   0.0076 
NM_005896 IDH1 2q33.3 Isocitrate dehydrogenase 1 (NADP+), 
soluble 
−37.14   0.0040 
NM_013296 GPSM2 1p13.3 G-protein signalling modulator −33.34   0.0401 
NM_001013703 EIF2AK4 15q15.1 Eukaryotic translation initiation factor 
2 alpha kinase 
−24.35   0.0034 
NM_014362 HIBCH 2q32.2 3-hydroxyisobutyryl-CoA hydrolase −16.66   0.0134 
NM_004197 STK19 6p21.3 Serine/threonine kinase 19 31.43   0.0433 
NM_181706 DNAJC24 11p13 DnaJ (Hsp40) homolog, superfamily C, 
member 24 
25.99   0.0181 
NM_015666 MTG2 20q13.33 Mitochondrial ribosome-associated 
GTPase 2 
25.18   0.0040 
NM_032182 FAM175B 10q26.13 Family with sequence similarity 175, 
member B 
24.37   0.0459 
NM_144607 CYB5D1 17p13.1 Cytochrome b5 domain containing 1 20.32   0.0311 









Genes differentially expressed in Ewing and osteosarcoma cell lines following XI-006 treatment 
Accession 
Number 





NM_020733 HEG1 3q21.2 Heart development protein with EGF-
like domains 1 
4.77 −73.76 0.00001 
NM_005803 FLOT1 6p21.3 Flotillin −5.44 −98.73 0.0007 
NM_007124 UTRN 6q24 Utrophin 2.65 −53.96 0.0128 
NM_005711 EDIL3 5q14 EGF-like repeats and discoidin I-like 
domains 3 










Despite the use of aggressive multi-modal therapeutic strategies, five year survival rates for 
relapsed Ewing sarcoma patients is <30% and in such cases no standard therapy currently exists 
for second line treatment. Despite the emerging role of MDM4 (structural homologue of 
MDM2) in the pathogenesis, maintenance, and chemo-resistance of human cancer, there are 
currently no selective MDM4 antagonists undergoing clinical trial evaluation. As MDM4 gene 
amplification is a characteristic of both Ewing and osteosarcoma8, this study assessed the 
therapeutic potential of XI-006, a small molecule thought to attenuate MDM4 promoter 
activity, for the treatment of sarcoma. Indeed, MDM4 IHC analysis of our sarcoma cohort 
detected MDM4 protein expression (>10 positive cells) in 33.3% (12/36) of cases and was highly 
prevalent in well/de-differentiated liposarcomas and myxofibrosarcomas (Fig. 1). 
 
Low micro-molar concentrations of XI-006 induced rapid apoptosis specifically in Ewing 
sarcoma cell lines (IC50 0.099–1.61 μM) in the absence of both observable DNA damage and 
effect on MDM4 expression levels (Table 1, Fig. 2). Cell line sensitivity to XI-006 was not 
correlated with MDM4 mRNA or protein levels, and reduction of MDM4 mRNA and protein 
levels were only observed in the least sensitive Ewing sarcoma and osteosarcoma cell lines at 
high XI-006 concentrations (>1 μM) that also induced DNA damage (Figs 3 and 4). It is known 
that DNA damage induces ATM/Chk2 dependent phosphorylation of several MDM4 C-terminal 
residues (S342, S367, S403), resulting in degradation of MDM4 and activation of p5325. Indeed, 




following treatment with double-strand break inducing concentrations of XI-006 (>0.5 μM). As 
only a maximum 30.5% reduction in MDM4 promoter activity was observed following 4 μM XI-
006 treatment (Fig. 2), our findings suggest that XI-006 cytotoxicity in Ewing sarcoma cell lines 
cannot be attributed to repression of MDM4 activity. 
 
The introduction of systemic chemotherapy in the 1960’s greatly improved survival rates for 
patients with localised Ewing sarcoma30, hence it is imperative that XI-006 can synergise with 
current chemotherapeutic protocols as well as novel agents. In addition to synergising with 
doxorubicin, etoposide and actinomycin D (CI range 0.753–0.989), a maximum 51.9% increase 
in apoptosis was observed when XI-006 was combined with the PARP inhibitor olaparib (Fig. 5). 
PARP-1 is a member of the base excision repair pathway that sensors and modulates the spatial 
and temporal organization of single-strand break repair31. Inhibition of PARP-1, results in the 
accumulation of persistent single-strand breaks which are converted to lethal double-strand 
breaks upon replication. Since the 1990’s it has been known that Ewing sarcomas express high 
levels of PARP-132, and the premise of PARP inhibition as a therapeutic avenue for the 
treatment of Ewing sarcoma has been furthered strengthened by several key studies. Firstly, 
large-scale drug screening (130 compounds) in >600 human cancer cell lines identified a highly 
significant association between EWS-FLI1, the hallmark translocation of Ewing sarcoma, and 
sensitivity to the olaparib. Indeed, FLI1 expression levels in Ewing sarcoma cell lines were highly 
correlated with olaparib sensitivity33. This study was complemented by Brenner and 
colleagues, who demonstrated that the EWS-FLI1 fusion acted in a positive feedback loop to 




Furthermore, DNA damage induced by expression of EWS-FLI1 was potentiated by PARP1 
inhibition in vitro. As PARP1 inhibitors have exhibited promising activity in early clinical trials34, 
phase I/II trials of PARP inhibitors (olaparib and BMN-673) are currently undergoing 
investigations in adults with recurrent and metastatic Ewing sarcoma (NCT01583543), and 
patients with locally advanced or metastatic solid tumours (NCT02049593). 
 
Previous chemogenomic profiling studies suggested that XI-006 (referred to as NSC-207895) 
activates the DNA-damage-response pathway through an indirect mechanism leading to a 
significant delay in replication and cell cycle progression23. Replication stress, defined as the 
slowing or stalling of replication fork progression and/or DNA synthesis, has severe implications 
for genome stability and cell survival35. Several studies have implicated that PARP binds to and 
is activated at stalled replication forks that contain small gaps (<4 nucleotides) or short ssDNA 
regions, and mediates the recruitment of Mre1128. Mre11 is a key component of the MRN 
(Mre11-Rad50-Nbs1) complex, which is vital for double-strand break (DSB) recognition, 
replication fork stabilization, ATM/ATR activation and the initiation of end resection required 
for replication restart and homologous recombination (HR)36. Inhibition or loss of PARP impairs 
Mre11 localisation to stalled forks, RPA and RAD51 foci formation, HR and replication restart. 
Indeed numerous studies have shown that due to impaired HR DNA repair, loss of Mre11 
expression sensitizes breast37, colorectal38,39, endometrial40, and haematological cancers41 
to PARP-inhibitors. In the absence of DNA damage, our findings demonstrate that low dose XI-
006 rapidly down regulates the expression of Mre11 (Fig. 5) and this repression in further 




findings provide a strong rationale for further investigations into the combinatorial approach of 
PARP inhibitors with XI-006. 
 
To elucidate the genes specifically responsible for Ewing sarcoma apoptotic XI-006 sensitivity, 
mRNA sequencing was employed and identified four genes significantly differentially expressed 
between Ewing and osteosarcoma cell lines following XI-006 treatment (Table 3). Of particular 
relevance, UTRN (Utrophin) was significantly up-regulated in Ewing sarcoma cell lines but 
repressed in osteosarcoma cell lines (P = 0.025). The GTPase UTRN also known as Drip1, 
mediates outer mitochondrial membrane fission and is essential for the normal progression of 
several mitochondria dependent apoptosis pathways42. Upon induction of apoptosis, UTRN is 
recruited from the cytosol to the mitochondrial outer membrane, where it colocalizes with Bax 
at fission sites and mediates the release of apoptotic regulatory proteins including cytochrome 
c prior to caspase activation43,44. The expression of FLOT1 (flotillin) was also significantly 
repressed in osteosarcoma cell lines (P = 0.044) compared to Ewing. The flotillin family of 
proteins have been implicated in numerous cellular processes such as actin-cytoskeleton 
reorganization, endocytosis, adhesion and transduction of cellular signals45. Knockdown of 
FLOT1 has been shown to significantly impair cell proliferation and tumourigenicity of breast 
and esophageal squamous cell carcinoma cells in vitro and in vivo through the Akt/FOXO3a 
pathways46,47. Indeed, silencing of FLOT1 induced G1-S-phase arrest of breast cancer cells due 
to up-regulated expression of the CDK inhibitors p21Cip1 and p27Kip1. Following XI-006 
treatment, both UTRN and FLOT1 were strongly repressed in osteosarcoma cell lines (31.9% 




the basis of the finding that XI-006 induces apoptosis in Ewing sarcoma cell lines but cell cycle 
arrest in osteosarcoma cell lines (Supplementary Fig. S2).  
 
Expression profiling also revealed that following XI-006 treatment, eleven genes were globally 
repressed or induced across all Ewing and osteosarcoma cell lines. Three of these genes which 
were downregulated, KIF20A, IDH1 and GPSM2 (44.49%, 37.14% and 33.34% reduction 
respectively), have been implicated in cell proliferation. KIF20A belongs to the family of kinesin 
microtubule-dependent motor proteins, which are required for bipolar spindle assembly, 
chromosome alignment, chromosome segregation, and cytokinesis48. Similarly GPSM2 is 
required for spindle cell orientation towards the interphase long-axis49. Several studies have 
demonstrated the essential role of KIF20A in cytokinesis and maintenance of cell viability. 
Microinjection of anti-KIF20A antibody was shown to induce multi-nucleation in Hela cells50 
and knockdown of endogenous KIF20A expression markedly attenuated the growth of 
pancreatic and gastric cancer cells51,52. As sensitivity to XI-006 was strongly correlated with 
vincristine sensitivity (R2 = 0.722) (Supplementary Fig. S7), a widely used chemotherapeutic 
that inhibits microtubule assembly and induces tubulin self-association into coiled spiral 
aggregates53, this supports that the mechanism of action of XI-006 at low, micro-molar 
concentrations (<0.5 μM) can be attributed to inhibition of cell division and cycle regulators and 
not DNA damage. 
 
In summary, our findings demonstrate that XI-006 is a promising new potential therapeutic for 




damaging concentrations specifically in Ewing sarcoma cell lines. Notably, strong synergy was 
observed with olaparib, a PARP inhibitor that is gaining significant interest for the treatment of 
solid cancers. As such, our preclinical findings warrant further pharmacokinetic and 
























Cell lines and reagents 
Ewing sarcoma cell lines were cultured as previously described21 and supplied by G. Hamilton 
(University of Vienna, Austria) (TC252, TC71), F. van Valen (Westfälische-Wilhelms-University, 
Germany) (WE-68, VH-64), P. Ambros (St. Anna Children’s Hospital, Austria) (STA-ET-1) and V. 
Russo (Murdoch Children’s Research Institute, Australia) (SK-N-MC). SK-ES-1, RD-ES cell lines 
were purchased from American Type Tissue Culture. Osteosarcoma cells (SJSA, U20S and Soas-
2) were supplied by A. Evdokiou (University of Adelaide, Australia). 
XI-006 and BIRB 796 were purchased from Merck Millipore, KU-55933 and olaparib (AZD2281) 
were purchased from Selleck. Vincristine sulfate (Hospira), doxorubicin HCI (Pfizer), actinomycin 
D/Cosmegen (Lundbeck) and etoposide (Royal Adelaide Hospital, Australia) were supplied by 
M.P Brown (Centre for Cancer Biology, Australia). 
Sarcoma tissue cohort 
Chemotherapy/radiotherapy naïve tumour specimens were collected from thirty-six patients 
with sarcoma (22 males, 14 females) undergoing surgical resection/core biopsy at three clinical 
institutions; Royal Adelaide Hospital (RAH), Calvary Wakefield Hospital, and St Andrew’s 
Hospital between 2010 and 2013. Patient consent was obtained for accrual of surgically excised 
tissue. Study was approved by the Royal Adelaide Hospital Human Ethics Committee (RAH 
Protocol #100505). The different morphological subtypes were represented by nine 
undifferentiated pleormorphic sarcomas, eight liposarcomas (four well-differentiated, two de-




two osteosarcomas, two synovial and one Ewing sarcoma, angiosarcoma, chondrosarcoma and 
radiation induced sarcoma. Twenty patients were previously described19. All methods were 
carried out in accordance with National Health and Medical Research (NHMRC) approved 
guidelines. 
Immunohistochemistry 
MDM4 immunohistochemical protocol was adapted from54. Briefly, FFPE (4 μm thickness) 
were deparaffinised by serial immersion in a xylene-to-ethanol solvent gradient. After citrate 
buffer (0.001 mol/L, pH 6.0) antigen retrieval, slides were quenched in 3% hydrogen peroxide 
for 5 mins to eliminate endogenous peroxidase activity. Sections were blocked with normal 
goat serum (30 mins) and immuno-labelled with rabbit HdmX/MDM4 (1:250, IHC-00108, Bethyl 
Laboratories) overnight at 4 °C. Digital images were acquired using a Nanozoomer Digital 
Pathology Scanner, at x40 magnification. To determine the percentage of positive MDM4 cells, 
a minimum of 80 cells per field of view (four) were assessed. 
MDM4 SNP34091 genotype analysis 
DNA from sarcoma tissues was isolated using the DNeasy Blood and Tissue Kit (Qiagen) 
according to the manufacturer’s instructions. The 3’UTR region of MDM4 was amplified using 
the following primer pair55 forward: 5′ACGGGCCATCTTGTCACTTGTT 3′ and reverse: 
5′ACCTGACTGCT GCATAAAGTAATCCAT 3′, to amplify a 355 base pair (bp) product. PCR was 
performed using 100 ng of genomic DNA and FastStart Taq DNA Polymerase (Roche) using the 
following parameters, enzyme activation 95 °C 3 mins, followed by 45 cycles of denaturation at 




final extension at 72 °C 10 mins. Reactions were processed on an ABI Hitachi 3730 DNA 
analyser. 
Apoptosis and Cell cycle analysis 
For viability assays, cell were seeded in 96-well micro-titer plates at a density of 3 × 104  
cells/well and treated with XI-006 alone or in combination with chemotherapeutics agents. For 
inhibitor studies, cells were pre-treated with olaparib, KU-55933 or BIRB 796 for 2 hrs prior to 
the addition of XI-006. Following treatment for 24 and/or 48 hrs, cells were centrifuged at 
2500 rpm for 5 mins, washed in phosphate buffered saline (PBS) and stained with 7-amino-
actinomycin-D solution (7AAD, 2 mg/mL, Invitrogen) for 10 mins at room temperature. 
For cell cycle analysis, XI-006 and vehicle control treated cells were permeabilized with cold 
70% ethanol overnight, and stained with a solution containing 50 μg/ml propidium iodide (PI, 
Sigma Aldrich), 0.05% Triton-X and 100 μg/ml RNase A at 37 °C for 40 mins. Cell viability and 
DNA content was determined through the use of a FACS Calibur flow cytometer (Becton-
Dickinson Immunocytometry Systems) with cell cycle profiles and viability analyzed using 
FLOWJO software (V7.6.5). 
Luciferase Assay 
U20S cells (3.2 × 104) were seeded overnight in 24-well plates (triplicate wells per treatment) 
and transfected with 200 ng of pCM-luci-MDM4 or p21-pro-Luc reporter constructs and 25 ng 
of pRL-TK plasmid (Promega) using Lipofectamine LTX (Invitrogen) according to the 
manufacturers’ instructions. pCM-Luci-MDM4 was kindly supplied by C. Yan (GRU Cancer 
Center). Cells were treated with vehicle control or XI-006 for 6 hrs with Dual-luciferase reporter 




Real-time qPCR analysis 
Total RNA was extracted using RNeasy mini kit (Qiagen), using on-column RNase-free DNase 
digestion according to the manufacturer’s instructions. cDNA was synthesized by reverse 
transcribing 600 ng of total RNA using random primers (Promega) and Moloney murine 
leukemia virus reverse transcriptase (H_; Promega). Real-time qPCR reactions were performed 
using iTaq Universal Sybr Green Supermix (BIORAD) and processed on a CFX Real-Time PCR 
detection system (BIORAD). Cycling parameters were as follows: 95 °C for 3 mins, followed by 
45 cycles of denaturation at 95 °C for 10 secs, annealing at 59–63 °C for 15 secs, and extension 
at 72 °C for 30 secs. Relative target mRNA expression was determined using the ΔCT method 
from triplicate reactions, with the levels of gene expression normalized to the relative average 
Ct value of Peptidylprolyl Isomerase-G (PPIG). Primer sequences and annealing temperatures 
are listed in Supplementary Table S1. 
Western blot 
Western blot analysis was performed as previously described21. Whole protein lysates (5–
20 μg) were resolved using SDS PAGE electrophoresis, and probed overnight at 4 °C with the 
following primary antibodies MDM4 (1:500; A300-287A, Bethyl Laboratories), p53 DO1 (1:1000, 
Santa Cruz Biotechnology), Phospho-p53 (Ser15) (1:500, Cell Signalling), Phospho-Histone H2A.X 
(Ser139) clone JBW301 (1:500, Millipore) and β-Actin (1:1000, AC-15, Sigma). 
Immunofluorescence 
TC252 and U20S cells (1.5 × 104  cells per 6 well chamber) were seeded on microscopes slides 
and treated with XI-006 (0.5, 1, 2 and 4 μM) or vehicle control (DMSO) for 4 hrs. Cells were fixed 




serum with 0.3% Triton-X 100 (Sigma-Aldrich). Slides were washed in PBS (3 × 5 min), then 
incubated with 1 μg/ml biotinylated mouse anti-human anti-phospho-histone H2AX (ser139) 
(JBW301, Millipore) overnight at 4 °C. After further washing, samples were incubated with 
5 μg/ml streptavidin-Alexa Fluor 488 (Life Technologies) followed by counterstaining with 
1 μg/ml DAPI. Slides were examined using an Olympus IX71 microscope (x40 magnification) 
with CellSens Standard (v1.6) software. Images were analysed using ImageJ (v1.45) (National 
Institute of Health). 
Comet Assay 
Neutral and alkaline comet assays were performed with the Trevigen CometAssay kit according 
to the manufacturer’s protocol. Briefly, 3.5 × 105  cells were plated in 6 well plates and treated 
with XI-006 or vehicle control for 4 or 20 hrs. Lysed cells were subjected to electrophoresis for 
40 mins at 30 V (300 mA) at 4 °C. Cells were stained with 2.5 μg/ml PI for 15 mins and visualised 
with an Olympus IX71 microscope (x20 magnification) with CellSens Standard (v1.6) software. 
Tail length and moment were assessed using AutoComet software (TriTek) from a minimum of 
60 cells. 
mRNA sequencing 
Ewing and osteosarcoma cell lines (n = 11) were treated with XI-006 (0.5 μM) or vehicle control 
for 4 hrs. One μg of RNA was used for polyA selection and library construction with NEBNext 
UltraT RNA Library Prep Kits for Illumina sequencing, according to the manufacturer’s 
instructions (E7530 Version 2). The mRNA library size was validated with the Agilent 
BioAnalyzer on High Sensitivity chips, with yield determined with a Life Technologies Qubit 2.0 




HiSeq 2500 flowcell (1 × 50 bp reads) at the Australian Cancer Research Foundation Cancer 
Genomics Facility (Adelaide, Australia). Reads were trimmed for the NEB single end adapter 
“AGATCGGAAGAGCACACGTCTGAACTCCAG TCAC” with Cutadapt v1.3, requiring a minimum 
overlap of 5, allowing a 20% error rate and discarding trimmed sequences shorter than 18 
bases. Reads were mapped to the UCSC hg19 genome and GTF annotations with Tophat 2.0.9 
using default parameters. Gene counts were performed with HTSeq-count v0.6.1p1 using 
gene_id as the GTF feature ID. 
Statistics 
Combination Index (CI) values were used to determine synergy between XI-006 and cytotoxic 
agents. A CI value of <1, =1 and >1 indicates synergistic, additive and antagonistic effects 
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Supplementary Table S1: Primer sequences utilised in this study.  
  
Target  
Primer sequence 5’ to 3’    
Annealing  
Temperature  









ATR  CTGATGCGTGATCAGCGAGA  ACGGCAGTCCTGTCACTCTA  65˚C  
EDIL3  GAACCAACTTCAGCAGGTCCC  TAAATTCGCCTGGGCACTCA  61˚C  
FLOT1  ACTGGCATTGCCCAGGTAAA  AGGGCAATGTGGGCAATCTC  63˚C  
HEG1  TCCCAGAGTGGCAACTTAGC  ATCTCCGAGGTTCCACT  61˚C  
IDH1  TTGGCTGCTTGCATTAAAGGTT  GTTTGGCCTGAGCTAGTTTGA  61˚C  
KIF20A  CTACAAGCACCCAAGGACTCT  AGATGGAGAAGCGAATGTTT  61˚C  
MDM2  TCTACAGGGACGCCATCGA  CTGATCCAACCAATCACCTGAA  61˚C  
MDM4  TCTCGCTCTCGCACAGGATCACA  AACCACCAAGGCAGGCCAGCTA  61˚C  
Mre11  TGCCCAGGAAAATGAAGTGGA  CAGGCCGATCACCCATACAA  61˚C  
p21 (CDKN1A)  TGGACCTGGAGACTCTCAGGGTCG  TTAGGGCTTCCTCTTGGAGAAGATC  61˚C  
PARP-1  AGCGAGAGCATCCCCAAGG  TCAAACATGGGCGACTGCAC  61˚C  
PPIG  CAGATGCAGCTAGCAAACCGTTTG  CTCTTCAGTAGCACTTTCGGAATCAGAGG  61˚C  























Supplementary Figure 1: XI-006 reduces cellular proliferation specifically in cancer cell lines 
(a) Ewing (TC252, RD-ES) and osteosarcoma (U20S and SJSA) cell lines were seeded (3x103 
cells/well) in 6-well plates in the presence or absence of XI-006 (0.03, 0.11, 0.33, 1, 3µM). Cells 
were fixed in methanol (5mins) and stained with giemsa (Sigma) (50 mins) 10 days post seeding. 
(b) Quantification of colonies from cells treated as in (a). Data represents mean ± STDEV from 
two independent experiments. (c) Representative image of IMR90 cells (normal human 




































Supplementary Figure 2. XI-006 induces apoptosis specifically in Ewing sarcoma cells.Ewing (TC252, RD-ES) and osteosarcoma (U20S, 
Soas-2) cells were treated with XI-006 (1μM, 3 μM) or vehicle control for 48hrs. Cells were fixed, stained with propidium iodide, and 
analyzed by flow cytometry for DNA content. Numbers inserted in graphs indicate percentage of cells at different stages of the cell 










Supplementary Figure 3: XI-006 induces expression of p53 target genes specifically in Ewing sarcoma cell lines (a ) Wild-type Ewing 
(STA-ET-1, TC252,WE -68) and osteosarcoma (U20S, SJSA) cell lines were treated with XI-006 (0, 2.5 and 5μM) for the indicated 
times. mRNA expression levels of TP53 target genes (BBC3, CDKN1A, MDM2, BAX) was determined through real-time (qPCR) 
analysis. Data represents mean expression (fold change) ± SE from triplicate reactions. Asterisk denotes statistical significance in 
target gene expression (Ewing versus osteosarcoma cell lines) (*P<0.05, **P<0.01, ***P<0.001, **** P<0.0001). (b) Lack of 
correlation between XI-006 apoptotic 48hr IC50 values and TP53 status (wild-type versus mutant/null). ♦●Denotes Ewing sarcoma 
and osteosarcoma cell lines respectively. (c) Relative viability of TP53 wild-type (+/+) and null (-/-) HCT116 isogenic cell lines 
following treatment with XI-006 for 24 and 48hrs. Data represents mean ± STDEV from duplicate reactions. Viability determined 
























Supplementary Figure 4: Inhibition of ATM does not suppress XI- 006 cytotoxicity. Real-time qPCR analysis of (a) ATM and (b) ATR 
mRNA expression following treatment with the ATM inhibitor KU-55933 (5μM) for 6hrs. Data represents mean expression (fold 
change) ± SE from triplicate reactions. Asterisk denotes statistically difference compared to vehicle control treated cells (*P<0.05, 
****P<0.0001). (c) TC252, RDES and WE-68 were pretreated with KU-55933 (5μM) or vehicle control (DMSO) for 2hrs, prior to the 
addition of XI-006 (0-5μM). Cell viability was determined through 7AAD staining (24 and 48hrs post XI-006 treatment) and analysed 









Supplementary Figure 5: Inhibition of p38 MAPKs has no effect on XI -006 sensitivity. TC252 and RD-ES cells were pre-treated with 
BIRB 796 (0.1μM, 1 μM and 10μM) or vehicle control (DMSO) for 2hrs, prior to the addition of XI-006 (0-2.5μM). Percentage cell 
death was determined through 7AAD staining (24 and 48hrs post XI-006 treatment) and analysed by flow cytometry. Data 

























Supplementary Figure.  6: XI-006 synergises with etoposide, doxorubicin, and actinomycin D 
but not vincristine STA-ET-1, TC252, RD-ES, SK-N-MC and WE-68 cells were treated with the 
chemotherapeutic agents vincristine (VIN), actinomycin D (ActD), doxorubicin (DOX) and 
Etoposide (ETO) alone or in the presence of XI-006 (indicated concentrations) for 48hrs. Cell 
viability was determined through 7AAD staining and analysed by flow cytometry. Data 
represents average percentage cell death ± STDEV from duplicate reactions. Asterisk denotes a 
Combination Index (CI) of <1, indicating synergy.   
  
XI-006 IC50 (nM) XI-006 IC50 (nM) 
  
XI-006 IC50(nM)                   XI-006 IC50 (nM) 
Supplementary Figure 7:. XI-006 sensitivity correlates with vincristine sensitivity in 
Ewing sarcoma cell lines.Correlation between XI-006  IC50 values and chemotherapeutic 
(vincristine, actinomycin D, doxorubicin, etoposide) IC50 values. All Ewing sarcoma cell 
lines (n=8) were treated with chemotherapeutic agents or XI -006 for 48hrs. Cell viability 
was determined through 7AAD staining and analysed by flow cytometry. Data represents 
mean apoptotic IC50 values (duplicate wells).  







R 2 = 0.722 
XI-006 vs Vincritstine  






XI-006 vs Etoposide  
R 2 = 0.522  





R 2 = 0.187 
XI-006 vs Actinomycin D  





R 2 = 0.019  





Supplementary Figure 8: Lowmicro-molar doses of XI-006 reduces Mre11 mRNA expression. 
Mre11 mRNA expression levels were determined through real-time qPCR analysis from STA-ET-
1 and U20S cells treated with XI-006 (0.1, 0.2, 0.3 and 0.4µM) or vehicle control for 6hrs. Data 
represents mean expression (fold change) ± SE from triplicate reactions. Asterisk denotes 




Supplementary Figure 9: KIF20A and IDH1 are repressed following XI-006 treatment. Real-time 
qPCR analysis of KIF20A and IDH1 expression levels following 4hr XI-006 (0.5µM) or vehicle 
control treatment. Data represents mean ± SE from triplicate reactions. Asterisk denotes 
statistical significance compared to vehicle control (*P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001). 
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Supplementary Figure  10: EDIL3, UTRN, HEG1 and FLOT1 expression levels following XI-006 
treatment. Real-time qPCR analysis of EDIL3, UTRN, HEG1 and FLOT1 expression levels 
following 4hr XI-006 treatment (0.5µM). Data represents mean ± SE from triplicate reactions. 
(*) denotes statistical significance in expression compared to vehicle control (*P<0.05, 
**P<0.01, ***P<0.001). (#) denotes significant difference in % change in expression, Ewing 


















Over the past decade, deeper understanding of molecular mechanisms underlying cancer 
progression have led to development of new compounds that target specific pathways involved 
in tumorigenesis. Incorporation of these targeted therapies alongside chemotherapies has 
drastically improved patient survival in many cancers. However, for basal-like (triple-negative) 
breast cancers and metastatic sarcomas, the survival rates are less than 30%. Although research 
continues to reveal critical targetable pathways, there are currently no targeted treatments 
available for these cancers. This research is intended to highlight the potential for exploiting 
two relatively unexplored molecular targets, ribosomal RNA Polymerase I and the proteasome, 
for the treatment of Ewing sarcoma and breast carcinomas, respectively. These findings will 
provide the basis for future clinical studies and have the potential to provide new therapies for 
patients. 
 
Basal-like (triple negative) breast cancers accounts for 15-20% of all breast cancers and have 
the poorest survival amongst breast cancer subgroups. The current lack of targeted therapy for 
this subgroup stems from the fact that there are no recognized targets. Here, we have 
investigated whether the proteasome has utility as a therapeutic target in the treatment of 
breast cancers. Although breast cancers patients did not respond to bortezomib in the limited 
early clinical trials, these studies did not assess proteasome levels/activity. Detailed 
characterization of the proteasome in breast cancers utilizing the TCGA RNA sequencing data 
from breast cancer patients revealed that the basal-like and HER2+ breast cancer subgroups 




proteasome expression is classically associated with cells of the immune lineage. As multiple 
myeloma cells that express high levels of immuno-proteasome are extremely sensitive to 
proteasome inhibitor based therapy, we hypothesized that breast cancer cell lines with high 
levels of immuno-proteasome will likely respond to bortezomib. Indeed, cytotoxic sensitivity of 
breast cancer cell lines to the proteasome inhibitor bortezomib was significantly correlated with 
immuno-proteasome expression. A limited number of studies have shown immuno-proteasome 
overexpression in solid cancer tissues, but to the best of our knowledge this is the first report 
that characterizes proteasome expression and evaluates proteasome inhibitory effects in the 
breast cancer subgroups in detail. In addition, we provide an overarching hypothesis that 
encapsulates cross-talk between immuno-proteasomes, immune surveillance and superior 
prognosis in breast cancer patients. Overall, our results provide convincing preliminary 
evidence for the utility of immuno-proteasomes both as a prognostic and predictive biomarker 
for proteasome inhibitor based therapy for the targeted treatment of basal-like and HER2+ 
breast cancers. 
 
The limited use of proteasome inhibitors for the treatment of cancers has been attributed to 
their dose-limiting toxicities and instability. Since the late 1990s, bortezomib has been assessed 
in several clinical trials in various solid cancers both as monotherapy and in combination with 
chemotherapies. Unfortunately, almost invariably patients did not respond and further 
research into proteasome inhibitor drug-development and assessment in solid cancer 
treatment was abandoned. Instead, the major focus for drug-design veered into developing 




specifically for multiple myeloma treatment. However, like bortezomib, these second 
generation proteasome inhibitors share similar structural characteristics and were marred by 
dose-limiting toxicities and drug delivery issues. Here, we have conceptualized and developed 
second-generation proteasome inhibitors by modifying peptide backbones using non-natural 
peptides and by attaching photo-switches for specific activation.  Overall, in vitro analyses of 
some of these new compounds revealed significantly less toxicities and better efficacies 
compared to benchmark drugs.  
 
In second part of the thesis we investigated the utility of activating p53 signaling using two 
different approaches for the treatment of Ewing sarcoma. Overall survival for patients with 
metastatic Ewing sarcoma is less than 30% with multi-agent chemotherapy. Activation of the 
p53 pathway has been a primary focus for Ewing sarcoma treatment as approximately 90% of 
Ewing sarcomas retain a functional wild-type p53. CX-5461 is a novel non-genotoxic RNA 
polymerase I inhibitor that has demonstrated its anti-proliferative effects in a vast panel of 
hematological and solid tumour cell lines. Encouraging results from initial in vitro and in vivo 
evaluations demonstrated hematological cell lines with wild-type p53 to be acutely sensitive to 
CX-5461, which led to Phase I/II clinical evaluations of CX-5461 in advanced hematological 
malignancies. Here, we show that Ewing sarcoma is by far the most responsive solid tumour to 
CX-5461 that has been tested to date. In particular, two of the Ewing sarcoma cell lines show 
sensitivities lower than any ever reported in the literature for solid tumours and parallel some 
of the most potent responses observed in blood cancers. While some Ewing sarcoma cell lines 




was p53 dependent. In our second approach to exploit p53 signaling for Ewing sarcoma 
treatment, we found that while XI-006 caused rapid apoptosis in cancer cell lines, its effect was 
independent of p53 activation. However, in addition to being non-genotoxic, both CX-5461 and 
XI-006 were synergistic in combinations with chemotherapies, highlighting tremendous 
therapeutic potential that warrants further pre-clinical studies. 
 
There are currently 77 FDA approved anti-cancer targeted therapies and few hundred more in 
clinical trials. However, these targeted therapies are effective only in limited number of 
cancers, and within those cancers for only a proportion of patients. It is now becoming 
increasingly clear that cancer is a highly heterogeneous disease and that moving forward it is 
crucial to identify those patients who will respond to these targeted therapies. In this regard, 
this research provides excellent leads and highlights how immuno-proteasome expression can 
serve as a biomarker for stratifying patients who will respond to proteasome inhibitor based 
therapy in breast cancer and perhaps, in other solid cancers. 
 
                                                        
 
